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Summary 
 
In advanced lung cancer, careful selection of systemic anticancer therapy (SACT) 
is of vital importance. Companion biomarkers can optimise treatment selection, 
such as with the use of EGFR tyrosine kinase inhibitors (EGFR TKi) in patients 
with EGFRmut+ve adenocarcinoma of the lung. There is increasing interest in 
mutation detection and monitoring, in circulating cell free tumour DNA (ctDNA). 
This thesis reports that Next Generation Sequencing (NGS) with software 
VarScan with Annovar, can detect mutations at a 10-fold lower alternate allele 
frequency compared to alternative software available through Ion Torrent, but 
with a greater number of low level ‘false positive’ genetic variants. Droplet 
digital PCR (ddPCR) is more sensitive than NGS, successfully detecting mutations 
as low as 0.1% alternate allele frequency. 
Lung cancer mutations were successfully detected in small, formalin-fixed, 
paraffin embedded (FFPE) tumour tissue samples, and ctDNA, from lung cancer 
patients, using the same NGS technique, with a commercially available, targeted 
50 gene cancer hotspot panel. Results are compared to a custom 22-gene panel. 
The kinetics of mutation levels in serial ctDNA samples is reported in a case 
series. In EGFRmut+ve lung adenocarcinoma patients treated with EGFR TKi, 
decreases in levels of mutant EGFR in ctDNA were observed. Levels remained 
undetectable during periods of disease control/stability, and increases in mutant 
EGFR in ctDNA were seen several weeks before the diagnosis of clinical or 
radiological disease progression. NGS of ctDNA during disease progression 
revealed novel genetic mutations that were not detected in the original tumour 
biopsy, and may inform subsequent treatment options. 
Similar ctDNA kinetics was seen in advanced SCLC patients treated with SACT. 
The level of mutated ctDNA, at diagnosis may be an independent prognostic 
biomarker, using a cut-off of 44.3% alternate allele frequency. SCLC patients who 
experienced a greater absolute decrease in mutant ctDNA had a poorer 
prognosis. 
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Abstract 
 
Lung cancer is the leading cause of cancer related death. Most patients present 
with advanced, or metastatic, small cell lung cancer (SCLC) or non-small cell lung 
cancer (NSCLC). Careful selection of optimal anticancer therapy is therefore key 
in minimising the adverse consequences of palliative treatment. Systemic anti-
cancer therapy (SACT) remains the mainstay of management of advanced lung 
cancer. The presence of specific mutations in lung tumours can help to predict 
response to some SACTs, for example, the use of targeted EGFR tyrosine kinase 
inhibitors (EGFR TKi), in patients with EGFRmut+ve adenocarcinoma of the lung. 
These same mutations can often be detected in peripheral blood, as circulating 
cell free tumour DNA (ctDNA).  However, mutations may occur at very low level, 
against a background of genomic or ‘wild-type’ DNA (expressed as an alternate 
allele frequency), requiring sensitive technologies, such as Next Generation 
Sequencing (NGS) and droplet digital PCR (ddPCR), for reliable detection. 
For downstream analysis of ctDNA in samples from lung cancer patients in this 
thesis, limits of detection of NGS and ddPCR,, are explored using reference 
standard DNA. The Ion Proton NGS platform with VarScan and Annovar 
bioinformatics tool detected mutations at a 10-fold lower alternate allele 
frequency, but with a greater number of low level ‘false positive’ genetic variants, 
compared to the Ion Torrent Variant Caller software. Droplet digital PCR was 
more sensitive than NGS, successfully detecting mutations as low as 0.1% 
alternate allele frequency. Mutation detection by ddPCR was limited, however, 
by the amount of available DNA for the assay.  
Using the same NGS approach, it is possible to detect mutations in small FFPE 
tumour tissue samples from patients with adenocarcinoma of the lung, 
squamous cell carcinoma of the lung and SCLC. The commercially available 50 
gene cancer hotspot panel was more robust in detecting EGFR mutations in lung 
cancer tumour samples compared to a custom 22-gene panel which includes 
extra genes of clinical relevance to NSCLC. A novel EGFR exon 19 deletion 
sequence variant has been detected. 
 xii 
EGFR mutations were detected in ctDNA by NGS and ddPCR, even at low level, in 
patients with EGFRmut+ve adenocarcinoma of the lung. Quantitative changes in 
mutant EGFR in ctDNA, were monitored in the same patients, in real-time, during 
treatment with oral EGFR TKi. Decreases were observed and related to 
radiological responses to treatment. Levels remained undetectable during 
periods of disease control, or stability, but increases in mutant EGFR in ctDNA 
were seen several weeks before the diagnosis of clinical or radiological disease 
progression. Mutations detected by NGS during disease progression included 
detecting genetic mutations that were not detected in the original tumour 
biopsy. Detection of acquired mutations in ctDNA, that convey therapeutic 
resistance (such as EGFR c.2369C>T p.T790M resistance to EGFR TKi), provide a 
basis for decision-making in the use of newer SACT, such as osimertinib. 
Similar ctDNA kinetics were seen in advanced SCLC patients treated with SACT. 
SCLC patients who experienced a greater absolute decrease in mutant ctDNA had 
a poorer overall survival. It is feasible that the level of mutated ctDNA, at 
diagnosis may be an independent prognostic biomarker, using a cut-off of 44.3% 
alternate allele frequency. This needs validation in a larger, prospective cohort of 
patients. Using ctDNA as a prognostic biomarker, may be particularly clinically 
useful for advanced SCLC patients, to help stratify them to different therapeutic 
options, to maximize therapeutic benefits, and to avoid potentially unnecessary 
treatment toxicities. 
Data presented in this thesis demonstrate that NGS and ddPCR can successfully 
detect mutations in small FFPE tumour tissue samples, and ctDNA samples, and 
these can act as biomarkers in lung cancer. Changes in ctDNA level are dynamic, 
and can be used as a monitoring biomarker in ongoing response to therapy, as 
well as detecting disease relapse. Earlier signals of disease progression may 
facilitate an earlier change in the patient’s clinical management plan, which could 
offer potential benefits for the patient’s quality of life, during the late stages of 
their cancer journey. This thesis demonstrates that it is feasible to apply ctDNA 
mutation detection, and ctDNA kinetics, to specific clinical situations. This may 
help clinicians and patients make better-informed choices, about optimising the 
management of lung cancer, and improving patient outcomes. This should form 
the basis of future clinical studies. 
 1 
1 Introduction 
 
1.1 Incidence 
 
Lung cancer is currently the second most common cancer diagnosed in the UK. In 
2010, there were 42,000 new cases of lung cancer diagnosed in the UK. Lung 
cancer remains the most common cause of cancer death in the UK, with 34,859 
deaths in 2010, at a rate of 38.6 per 100,000 population(1). Currently, there is 
less than a 10% overall 5-year survival associated with lung cancer(2). Up to 9 
out of 10 cases of lung cancer are significantly associated with a history of 
tobacco smoking(3). 
 
1.2 Histological Sub-types of Lung Cancer 
 
Lung cancers have traditionally been classified according to their histological 
subtype. The latest World Health Organisation (WHO) update (2015) for 
histological classification of lung tumours has been widely accepted(4). The main 
histological subtypes of lung cancer include small cell lung cancer (SCLC) 
(approximately 25% of cases) and non-small cell lung cancer (NSCLC) 
(approximately 75% of cases). NSCLC is further divided into squamous and non-
squamous cell carcinoma sub-types, including adenocarcinoma and large cell 
carcinoma. Traditionally, classifying lung cancers into these histological sub-
types has been important in prognostication, and to direct appropriate 
therapeutic approaches to their treatment. For example, small cell lung cancer, 
usually associated with a history of heavy smoking, is usually a much more 
aggressive form of lung cancer, and is associated with a worse prognosis. 
1.3 Presentation and Survival 
 
The peak incidence of lung cancer is in the 65 – 89 years age group, and the 
majority of cases of lung cancer are diagnosed with stage IIIB (locally advanced) 
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or IV (metastatic) disease(2). These stages of lung cancer are associated with 
worse survival than earlier stages of disease(5). 
1.4 Treatment of Lung Cancer 
The aim of most aspects of the clinical management of cancer is to detect and 
diagnose cancer early enough (ideally stages I and II) to enable radical or 
curative therapy, most often involving surgery and/or chemo-radiotherapy. This 
is provided the patient is fit enough to tolerate these treatments. However, for 
patients with lung cancer who present with stage III (locally advanced) or stage 
IV (metastatic) disease, the currently available anticancer treatments can only 
offer a period of disease control, rather than cure. Complicating issues are that 
many patients with lung cancer are either too unwell to tolerate standard 
palliative systemic anti-cancer therapies, or have other medical problems which 
preclude them(6). Despite improvements in chemotherapy regimens and 
radiotherapy techniques for patients with lung cancer, these treatments can still 
be associated with significant toxicities that have an adverse impact upon 
patients’ quality of life. This is especially so if the patients are elderly, or have 
concurrent medical co-morbidities. Therefore, one very important therapeutic 
goal in cancer therapy is to optimise efficacy whilst minimising the toxicities that 
may detract from the patient’s quality of life. 
1.5 Radical Treatment for Lung Cancer 
 
Curative treatment for lung cancer includes surgical resection of part of a lobe of 
a lung (wedge resection), a whole lobe (lobectomy), or whole lung 
(pneumonectomy). If surgical resection is not possible, then radical radiotherapy 
can be considered(7),(8). There have been some clinical studies examining the 
role of adjuvant chemotherapy, and radiotherapy, following surgical resection of 
lung cancer. Adjuvant chemotherapy may offer an absolute reduction in 5 year 
mortality in the order of 5%(9). 
 
 3 
1.6 Treatment of advanced NSCLC 
1.6.1 First Line Chemotherapy for NSCLC 
 
In 2008, the NSCLC Collaborative Group reported an improvement in 1 year 
survival from 5% to 15%, for lung cancer patients with locally advanced, or 
metastatic disease, treated with chemotherapy and best supportive care, 
compared to best supportive care alone(10). 
 
Small-molecule cytotoxic chemotherapy agents commonly used in routine 
clinical practice include platinum agents that disrupt DNA synthesis and repair 
(cisplatin and carboplatin), thymidylate synthase inhibitors that impair DNA 
synthesis (pemetrexed), tubulin inhibitors such as vinca alkaloids (vinorelbine), 
and nucleoside analogues such as gemcitabine. In general, they work by 
interfering with DNA synthesis and cellular proliferation. In treating a cancer 
patient with these chemotherapy drugs, cancer cells are preferentially affected, 
owing to their higher rate of cellular proliferation, thus rendering them more 
susceptible to the effects of these drugs. These agents can affect non-cancer cells 
of the body, causing many of the toxicities associated with these therapies. 
Common toxicities of these agents include fatigue, nausea and vomiting, 
diarrhoea or constipation, neutropenia that can result in severe infection/sepsis, 
hospitalisation and death. 
 
It has been reported (Schiller et al, 2002) that platinum-based doublet 
chemotherapy regimens offer the best disease control and improvements in 
overall survival in patients with incurable NSCLC and SCLC. There is no 
significant difference between the different agents combined with cisplatin or 
carboplatin chemotherapies, and response rates were reported in the order of 
19%, with median survival of 7.9 months (7.3 – 8.5 months)(11). Survival rates 
with cytotoxic chemotherapy in NSCLC have not improved significantly since 
1995(10). Scagliotti et al (2008) reported an improvement in survival from 10.9 
months to 12.6 months, in patients with advanced stage adenocarcinoma of the 
lung, when treated with cisplatin/pemetrexed chemotherapy, compared to 
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cisplatin/gemcitabine chemotherapy. A similar survival benefit was also 
observed in patients with large cell carcinoma of the lung(12). Due to treatment 
toxicities, lung cancer patients can usually tolerate no more than 4-6 cycles of 
chemotherapy. After this, the potential risks of continuing chemotherapy can 
outweigh the clinical benefits, and so a course of first line chemotherapy is 
usually discontinued at this point. 
 
1.6.2 Maintenance Chemotherapy 
 
Maintenance chemotherapy is the term given to chemotherapy used as an 
ongoing treatment strategy, immediately after a course of first line 
chemotherapy has brought about a clinical response or stable disease. The 
PARAMOUNT clinical trial examined the role of maintenance pemetrexed 
chemotherapy, following initial therapy with cisplatin and pemetrexed 
chemotherapy. Maintenance pemetrexed was associated with a 22% reduction in 
the risk of death at median follow-up of 24.3 months(13). This has been adopted 
in routine clinical practice, provided the patient can tolerate on-going 
chemotherapy. 
 
1.6.3 Second Line Chemotherapy 
 
For patients who tolerate first line palliative chemotherapy, but whose cancer 
then progresses, second line chemotherapy may be appropriate. An example is 
the use of second-line, single-agent docetaxel, in previously treated, advanced 
stage, NSCLC. However, only modest improvements in survival, in the order of a 
few months, have been observed in clinical studies(14). 
1.6.4 Immunotherapy in advanced non-small cell lung cancer 
A mechanism by which lung cancer cells evade the immune system is by the 
expression of cell surface ligand, called programmed death ligand 1 (PD-L1), 
which inhibits the anti-tumour function of programmed death receptor 1 (PD-1) 
positive cytotoxic T-cells. Monoclonal antibodies that target PD-1 or PD-L1, and 
promote immune related tumour cell death, have been developed as systemic 
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anti-cancer therapy (SACT) in patients with advanced lung cancer. Examples 
include pembrolizumab (Keytruda®, Merck), nivolumab (Opdivo®, Bristol 
Myers Squibb) and atezolizumab (Tecentriq®, Roche). Levels of PD-L1 
expression can be determined by immunohistochemistry of FFPE tumour tissue, 
and this is expressed as a percentage of nucleated tumour cells that are ‘positive’ 
for the PD-L1 stain, compared to nucleated tumour cells that are ‘negative’.  
There is debate as to the value of PD-L1 expression levels as a predictive 
biomarker of response to therapy(15). 
The KEYNOTE-010 clinical study revealed that previously treated, advanced 
NSCLC patients, with PD-L1 expression on >1% of nucleated tumour cells, have a 
significantly superior median overall survival (12.7 months, compared with 10.4 
months for patients treated with docetaxel chemotherapy)(16). In the first line 
setting clinical study KEYNOTE-024, patients with PD-L1 expressed on >50% of 
nucleated tumour cells, who were treated with pembrolizumab, experienced a 
significantly greater median progression free survival (10.3 months) and overall 
survival at 6 months (80.2%), compared to standard first line palliative 
chemotherapy (median progression free survival of 6.0 months and overall 
survival of 72.9% at 6 months)(17). Both KEYNOTE-010 and KEYNOTE-024 
report fewer significant toxicities associated with pembrolizumab, compared to 
chemotherapy. 
Pembrolizumab is now in routine clinical use in the first line palliative setting, 
for patients with advanced NSCLC expressing PD-L1 >50%, or as a second or 
greater line therapy, for patients with advanced NSCLC expressing PD-L1 
>1%(18),(19). 
1.7 Small Cell Lung Cancer 
 
Small Cell Lung Cancer (SCLC) is a particularly aggressive form of lung cancer, 
significantly associated with a history of heavy smoking. There were 
approximately 11300 new cases of SCLC in the UK in 2013. This equates to 
approximately 30 new diagnoses a day.(20)  
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Prognosis associated with SCLC is poor, and is linked to the stage at diagnosis. 
Historically, SCLC was described as limited stage i.e. disease contained within the 
thorax, and extensive stage i.e. disease that has spread outside the thorax. 
However, as therapeutic strategies become more refined, the TNM classification 
and staging system is increasingly used for SCLC.  Only about 30% of patients are 
diagnosed with limited, or earlier stage of SCLC, and, even with treatment of less 
advanced disease, 2 year survival rate is only 25%, due to high recurrence rates. 
The majority of SCLC patients (up to 70%) present with metastatic disease (stage 
IV), and here treatment is even less successful, with 5-year survival less than 
5%.(21) Median overall survival rates for metastatic SCLC have been estimated 
at 9 months from diagnosis.(22)  
 
1.7.1 Radical treatment for Small Cell Lung Cancer 
 
Nearly one-third of patients will be diagnosed with early stage SCLC, and radical 
treatments are in the form of surgical lung resection or concurrent radical 
chemo-radiotherapy(7). However, there is a high relapse rate, and for the 
majority of patients with relapsed or metastatic disease, treatment aims are 
disease control and prolonged survival. 
 
1.7.2 Treatment for Advanced Small Cell Lung Cancer 
 
As with advanced stage NSCLC, the mainstay of treatment for patients with 
advanced stage SCLC is palliative SACT. This most commonly entails use of a 
platinum compound, usually cisplatin or carboplatin, often in combination with 
the topoisomerase inhibitor, etoposide.  
 
50 – 85% of patients with incurable SCLC experience quite dramatic initial 
responses to chemotherapy, but time to disease relapse is often only of the order 
of a few months, and relapsed disease is often much more chemotherapy-
resistant(22). Survival in relapsed SCLC is poor, with estimated median overall 
survival of 4 months.(23) Furthermore, patients with relapsed SCLC tend to have 
a poor performance status. It has been estimated that second-line palliative 
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chemotherapy is a clinically appropriate option for only 42% of these patients, 
while the remainder receive best supportive care.(24, 25) This highlights the 
importance of trying to select patients who are going to receive a clinical benefit 
from second-line therapies, when clinically appropriate. Therefore, there is 
currently an unmet clinical need to develop novel therapeutic approaches, with 
companion biomarkers, for patients with advanced stage SCLC. 
1.7.3 Brain Metastases in Small Cell Lung Cancer 
 
Up to 30% of SCLC patients, will develop brain metastases, during progression of 
their cancer, resulting in marked deterioration in quality of life.(26) 
 
Patients with early or intermediate stage disease, for example stage III, who 
respond to palliative chemotherapy, can subsequently receive prophylactic 
cranial irradiation (PCI), to reduce the incidence of developing cerebral 
metastatic disease, but this is associated with its own toxicities. In the study by 
Slotman, et al (2007), most eligible patients with stage III and IV SCLC, were 
offered PCI. The authors report that from the time of randomization, patients 
treated with PCI had a lower risk of developing symptomatic brain metastases, 
and a lower cumulative risk of developing brain metastases at one year (14.6% v 
40.4%, treated v untreated groups). Also, for patients treated with PCI, the 
median disease free survival increased from 12 to 14.7 weeks, median overall 
survival increased from 5.4 to 6.7 months, and the one-year survival increased 
from 13.3% to 27.1%(27). 
 
Potential toxicities of PCI include hair loss, headache, nausea and vomiting and 
profound fatigue. Patients treated with PCI can also experience hyper-
somnolence syndrome, 6-8 weeks following completion of radiotherapy. Patients 
who were well enough to complete the questionnaire reported treatment 
toxicity, though it was not thought to be clinically significant, compared to their 
global health status(27). Despite these concerns over toxicity, PCI is now offered 
routinely to patients with metastatic, or extensive stage SCLC who respond to 
chemotherapy. 
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1.8 Pathogenesis of Lung Cancer 
The pathogenesis of a cancer is thought to be due to the accumulation of cellular 
damage, at the genetic level, which conveys the characteristics of a tumour cell, 
namely uncontrolled growth, proliferation and metastatic potential(28). Tobacco 
smoking is the most common cause of acquired cellular genetic damage in the 
aetiology of lung cancer(29). Different types of genetic abnormality include point 
mutations, small and large deletions and/or insertions, gene translocations, gene 
copy number gain, loss of heterozygosity and gross chromosomal abnormalities, 
including translocations. 
 
In principle, drugs that selectively target an aberrant, oncogenic molecular 
pathway, will selectively kill cancer cells, with reduced toxicity to other, healthy 
cells. These are called targeted therapies(30). 
 
Since the 1990’s, abnormalities in the Epidermal Growth Factor Receptor (EGFR) 
intra-cellular signaling pathway has been associated with lung cancer. In 
particular gain-of-function mutations have been identified in the tyrosine kinase 
genes in that pathway, including EGFR, KRAS, NRAS, BRAF, MEK1(MAP2K1)(31). A 
more recent on-line database, my-cancer-genome, identifies additional 
oncogenic driver mutations in lung cancer, namely AKT1, ALK, DDR2, FGFR, 
HER2, MET, PIK3CA, RET and ROS1. Mutations in these genes can be found in all 
histological sub-types of NSCLC, thought lung cancer patients who have never 
smoked and are of adenocarcinoma sub-type have higher incidences of EGFR, 
HER2, ALK, RET and ROS1 mutations(32). 
 
Figure 1-1shows the frequency of major driver mutations found in 
adenocarcinoma of the lung. Novel anti-cancer agents, targeted against several of 
the gene products of these driver mutations, are now in routine clinical use, or in 
various phases of clinical development. 
 9 
 
Figure 1-1 Frequency of Major Driver Mutations in Signalling Molecules in Lung Adenocarcinomas. 
Adapted from Cheng et al (2012)(30) 
1.8.1  Clinically Relevant Genetic Changes in Lung Cancer 
 
Table 1-1 summaries the up-to-date frequency, and availability of targeted 
therapies in NSCLC. The more commonly occurring genetic abberations are delt 
with individually below.
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Table 1-1 Clinically relavent genetic abberations in NSCLC. Adapted from my-cancer-genome(32), 
last updated 28 March 2016. 
Gene Genetic Alteration Frequency in 
NSCLC (%) 
Availability of 
Targeted Therapy 
AKT1 Mutation 1 In clinical 
development 
ALK Rearrangement 3 – 7 Drugs approved in 
NSCLC 
BRAF Mutation 1 – 3 Drugs approved in 
other cancer 
DDR2 Mutation ~ 4 Drugs approved in 
other cancer 
EGFR Mutation 10 – 35 Drugs approved in 
NSCLC 
FGFR1 Amplification 20 In clinical 
development 
HER2 Mutation 2 – 4 Drugs approved in 
other cancer 
KRAS Mutation 15 – 25 In clinical 
development 
MEK1 Mutation 1 Drugs approved in 
other cancer 
MET Amplification 2 – 4 Drug approved in 
NSCLC, but 
another molecular 
sub-type 
NRAS Mutation 1 In clinical 
development 
PIK3CA Mutation 1 – 3 In clinical 
development 
PTEN Mutation 4 – 8 In clinical 
development 
RET Rearrangement 1 Drugs approved in 
other cancer 
ROS1 Rearrangement 1 Drugs approved in 
NSCLC 
 
1.8.1.1 Epidermal Growth Factor Receptor (EFGR) Tyrosine Kinase Inhibitors (TKi) 
 
Small molecule tyrosine kinase inhibitors have been developed which 
specifically target the tyrosine kinase domain of the cell surface receptor protein, 
Epidermal Growth Factor Receptor (EGFR). They work by blocking aberrant 
catalytic activity of the intracellular tyrosine kinase domain of EGFR, and 
subsequent downstream cellular growth and proliferation signals, including the 
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MAPkinase pathway. The first EFGR TKi developed was gefitinib (Iressa®, 
AstraZeneca), approved for clinical use in 2004. However, initial clinical trials 
involving EGFR tyrosine kinase inhibitors proved inconsistent. The ISEL study 
compared gefitinib with active supportive care, which demonstrated no 
statistically significant improvement in survival. However, a sub-group analysis 
revealed a significant survival benefit with gefitinib, in patients who have never 
smoked and were of Asian ethnicity(33). 
 
A seminal publication, in 2004, noted that approximately 10% of the patients in 
these sub-groups had a rapid and often dramatic clinical response to 
gefitinib(34). Several mutations in the Epidermal Growth Factor Receptor 
(EGFR) gene have since been shown to be associated with the sensitivity of the 
tumours to EGFR tyrosine kinase inhibitors (EGFR TKi), gefitinib and erlotinib. It 
is estimated that between 7 -15% of patients with non-small cell lung cancer 
harbour a somatic ‘driver’ mutation in the EGFR gene(35). EGFR mutations are 
more strongly associated with lung cancers of the adenocarcinoma histological 
sub-type, and in patients who were never-smokers, female, and of Asian 
ethnicity(33). The clinical response to oral EGFR TKi also depends on the type of 
EGFR mutation detected, whereby some mutations act as a positive predictive 
biomarker of response to certain oral EGFR TKi (so called ‘sensitising 
mutations’) most commonly EGFR c.2573T>G, p.L858R, whilst others have 
proved a predictive biomarker for resistance (so called ‘resistance mutations’), 
most commonly EGFR c.2369C>T, p.T790M (34). These are illustrated in figure 
1-2. 
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Figure 1-2 Gefitinib- and erlotinib- sensitizing mutations of EGFR in NSCLC. Adapted from Sharma et 
al (2007)(36) 
1.8.2 Clinical Data for EGFR TKi use 
 
The EURTAC clinical trial has demonstrated that the oral EGFR TKi, erlotinib can 
increase progression free survival, compared with cytotoxic chemotherapy (9.7 
versus 5.2 months), in patients with locally advanced and metastatic 
adenocarcinoma that harbour sensitising EGFR mutations. Conversely, patients 
with EGFR ‘wild-type’ tumours do not gain a clinical benefit from EGFR TKi (37, 
38). Consequently, erlotinib is approved in the UK and elsewhere, either as first 
line therapy for patients with locally advanced or metastatic NSCLC harbouring 
EGFR mutations(39), or second line as an alternative to docetaxel 
chemotherapy(40). 
 
In the IPASS clinical trial, patients with adenocarcinoma of the lung were 
allocated to the EGFR tyrosine kinase inhibitor, gefitinib, or chemotherapy 
(carboplatin and paclitaxel), and analysis was performed on patients with lung 
tumours that harboured EGFR mutations. This demonstrated a 3-month 
improvement in median progression free survival (from 7 months to 10 months) 
in EGFRmut+ve patients treated with gefitinib(37). In the UK, gefitinib has been 
approved since 2010, for the first line treatment in patients with locally 
advanced or metastatic NSCLC whose tumours harbour EGFR mutations(41). 
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The BR21 clinical study utilized EGFR TKi, erlotinib (Tarceva®, Roche), as a 
second line palliative therapy for patients with NSCLC(42). This demonstrated a 
modest improvement in overall survival for erlotinib, compared with placebo. In 
this study, patients were not selected to receive erlotinib based on their tumour 
EGFR mutation status.  
 
Compared to erlotinib and gefitinib, afatinib is a second generation, irreversible 
EGFR TKi. It has been used in the LUX-Lung 3 clinical trial, which randomised 
EGFR mutant-positive lung cancer patients (with EGFR sensitizing mutations 
L858R or exon 19 deletions) to afatinib or chemotherapy (cisplatin and 
pemetrexed). Median progression free survival for the afatinib group was 13.6 
months, and 6.9 months in the chemotherapy group (HR 0.47 (0.34-0.65) 
p<0.0001)(43). 
 
1.8.3 EGFR Testing 
 
Based on this clinical data, it is therefore extremely important to be able to offer 
a routine test for EGFR mutational analysis of tumour DNA from lung cancer 
patients, at diagnosis. This is to ensure distinguish between patients with 
EGFRmut+ve adenocarcinoma of the lung, who are most likely to benefit from EGFR 
TKi therapy, and patients with EGFRwild-type adenocarcinoma of the lung, who are 
unlikely to obtain a clinical benefit, but may experience unnecessary toxicity. 
This is an example of patient ‘stratification’. 
 
1.9 Therapeutic Resistance to EGFR tyrosine Kinase inhibitors 
 
Almost invariably, patients with locally advanced or metastatic, EGFRmut+ve 
adenocarcinoma of the lung will eventually develop resistance to continuous 
EGFR TKi therapy, and the cancer will progress. Molecular mechanisms of 
resistance to EGFR TKi have been characterised. Approximately 50% of 
molecular resistance mechanisms involve the EGFR gene, specifically via EGFR 
gene amplification, or via a secondary mutation within the EGFR tyrosine kinase 
domain, that may convey resistance to EGFR TKi. The most common type of 
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resistance-conferring mutation of this nature is the EGFR c.2369C>T, p.T790M. 
The remaining 50% of resistance mechanisms involve other genes such as 
mutations within PIK3CA, and gene amplifications including HER2 and MET(44). 
 
Precise identification of molecular mechanism of resistance to therapy are 
becoming increasingly important for patients with metastatic EGFRmut+ve 
adenocarcinoma of the lung, as subsequent therapeutic options become available 
for these patients. For example, there has been the development of a ‘third 
generation’ of EGFR TKi (osimertinib, Tagrisso® - previously AZD9291, 
AstraZeneca), that has shown to be effective against both the original sensitising 
EGFR mutation and the secondary EGFR c.2369C>T, p.T790M resistance 
mutation(45). 
 
1.9.1 ALK and ROS1 Translocated Lung Cancer 
1.9.1.1 EML4-ALK Translocation 
 
In 2007, an additional oncogenic mechanism was discovered in NSCLC, in the 
form of echinoderm microtubule associate protein like 4 – anaplastic lymphoma 
kinase (EML4-ALK) genetic translocation(46). NSCLC patients harbouring these 
ALK translocations have been reported in up to 5% of lung cancer cases, and 
tend to be most prevalent in younger patients, with adenocarcinoma histological 
sub-type, with a light- or never-smoking history(47). 
 
1.9.2 ALK Inhibitors 
 
Clinical trials have randomised patients with ALK translocation positive lung 
cancer, between the ALK inhibitor, crizotinib (Pfizer), and chemotherapy, in the 
first line setting (Profile1014(48)), and in the  second line setting, between 
crizotinib and docetaxel or pemetrexed chemotherapy (Profile1007(49)). 
Profile1014 observed an increased median progression free survival from 7.0 
months (chemotherapy group) to 10.9 months for ALK positive patients treated 
with crizotinib. However, an overall survival advantage with crizotinib was not 
demonstrated, possibly due to cross-over of patients between arms, whereby 
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patients who developed progression of their cancer after chemotherapy, were 
then treated with crizotinib, and vice versa.  
 
Like patients with EGFRmut+ve adenocarcinoma cancer, patients who have an ALK-
translocation positive lung cancer may develop resistance to ALK inhibition 
therapy, due the development of a secondary mutation within the tyrosine 
kinase domain of ALK, in 50% of cases(50). 
1.10 Other Clinically-Relevant Genetic Changes in NSCLC 
KRAS 
Lung cancer with mutated KRAS has been known to be a poor prognostic factor 
since 1990. They tend to occur in Caucasian patients with a history of smoking. 
(51). Mutations in KRAS and EGFR tend to be mutually exclusive as they exist in 
the same intracellular signaling pathway(52, 53). It is generally thought that 
EGFR TKi are not effective in KRAS mutant lung tumours, but Miller et al 
demonstrated some mild tumour shrinkage with erlotinib (not significant by 
RECIST criteria). More targeted therapies are in clinical development (Table 1-
2).  
 
HER2 
The most commonly occurring mutation in HER2 in lung cancer are Exon 20 
insertions, and tend to occur in female, non-smoker patients(54). These tumours 
are sensitive to HER2 targeted therapies in-vivo and in-vitro(55, 56). Generally, 
HER2 mutated lung cancers are resistant to EGFR TKi therapy, but increases in 
HER2 gene copy number may convey sensitivity to gefitinib therapy(57). 
Targeted HER2 therapies are approved for the clinical use in HER2 amplified 
breast cancers and gastro-oesophageal adenocarcinomas(58, 59). Further 
clinical studies in lung cancer are underway (Table 1-2). 
 
BRAF 
It has been proven in a mouse model that lung cancers containing mutant BRAF 
c.1799T>A, p.V600E, may be sensitive to treatment with a down-stream MEK 
inhibitors, such as CI-1040(60). A clinical benefit of BRAF and MEK inhibitors 
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has been observed in clinical studies involving BRAF mutated lung cancer. These 
are summarized in Table 1-2. 
 
PIK3CA 
Mutations in this gene can be observed in up to a third of cases of colon, liver and 
breast cancer, but only 1-4% of lung cancer cases. So far, mutations in PIK3CA 
have not been shown to be mutually exclusive with other mutations, and further 
research is required to determine whether PIK3CA mutational status predicts 
tumour response to EGFR TKi therapy(61). 
 
FGFR 
Fibroblast Growth Factor Receptor (FGFR) is a cell surface tyrosine kinase 
receptor, and mutations in lung cancer have been found in upto 2% of cases of 
NSCLC, and include activating point mutations and gene fusions(62). Pan-FGFR 
inhibitors and FGFR antibodies are being developed in pre-clinical research, and 
there has been some evidence that these agents demonstrate anticancer activity 
in a few patients with mutant FGFR bladder cancer (63), but clinical data for the 
efficacy of anti-FGFR therapy in FGFR mutant NSCLC is currently lacking. 
 
MET 
Another cell surface tyrosine kinase receptor – MNNG-HOS transforming gene 
(MET), can also be amplified, or mutated in NSCLC, specifically via an exon 14 
skipping mutation, leading to the enhanced signaling through the MET receptor 
pathway(64). The exon 14 skipping mutation has been reported in 3-4% of cases 
of adenocarcinoma of the lung(65). There are numerous case reports in the 
literature that suggest that patients with MET mutant adenocarcinoma of the 
lung may get a clinical benefit from MET inhibition therapy, for example 
Crizotinib (66). 
 
RET gene fusionsFusions of this gene are thought to occur in approximately 1% 
of cases of adenocarcinoma of the lung (67). A phase 2 study using a multi-
targeted kinase inhibitor – cabozantinib, only reported 3 cases of RET fusion 
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positive patients (68), so further clinical data is required to determine whether 
this is an effective treatment strategy for these patients.
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Table 1-2 Clinically Relevant Genetic Changes in NSCLC and Potential Therapeutic Agents (other than EGFR mutations and ALK translocations). PFS = Progression Free 
Survival. 
Genetic abberation Clinical Implication Agent Clinical Study Clinical Outcome Reference 
KRAS mutation 
Mutant KRAS conveys poorer 
prognosis and relative resistance to 
chemotherapy 
Selumetinib (MEK 
inhibitor) – downstream 
of KRAS 
Phase II & Phase III 
(SELECT-1) for Docetaxel 
+/- selumetinib for KRAS 
mutant NSCLC 
Addition of selumetinib to 
docetaxel did not improve 
PFS 
(69) 
MET gene amplification 
Target for MET Tyrosine Kinase 
Inhibitors 
Tivantinib 
(ARQ197)(Arqule Inc) 
Marquee Clinical Trial – 
Erlotinib +/- Tivantinib as 
2nd or 3rd line therapy in 
NSCLC 
Improved PFS and OS in 
patients with increased 
MET expression 
(confirmed by IHC) 
(70) 
BRAF mutation Target for BRAF inhibitors 
Vemurafenib and 
debrafenib 
Phase II Basket Clinical 
Trial – treating BRAF 
mutant NSCLC with 
vemurafenib 
RR 42% 
Median PFS 7.3 months 
One year PFS 23% 
(71) 
EURAF – retrospective 
study of BRAF mut+ve 
NSCLC patients treated 
with BRAF inhibitors 
RR – 50% 
Median PFS 5 months 
(72) 
BRAFmut+ve NSCLC 
treated with combination 
therapy dabrafenib and 
trametinib (MEK inhibitor) 
RR >60% (72) 
DDR2 Target for DDR2 inhibition therapy DDR2 inhibitors 
Phase II clinical study 
dasatinib v chemotherapy 
Lower RR with dasatinib 
compared with 
chemotherapy and 
increase in pleural 
effusion rates 
(73) 
RET gene fusions Multi-targeted kinase inhibitor Cabozantinib Phase II 
3 patients experience 
partial response 
(68) 
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1.10.1 Next Generation Sequencing in Lung Cancer 
A key contributor to our understanding of the molecular abnormalities of lung 
and other cancers has been next generation sequencing (NGS), also known as 
massively parallel genetic sequencing. This allows the analysis of the genetic 
sequence of the whole genome, whole exome, or targeted panels of genes, from a 
single sample of tumour DNA. This significantly reduces the cost, time and DNA 
requirement, to achieve the same degree of genetic sequencing, compared with 
more conventional techniques such as Sanger sequencing(74). The Cancer 
Genome Atlas (TCGA) pan-cancer analysis project, uses NGS to profile and 
analyse large numbers of human tumours, generating vast databases of genetic 
information which help inform cancer pathogenesis, and identify molecular 
targets for anticancer therapy or causes of resistance to anticancer 
therapies(75). 
 
1.10.2 Tumour Clonal Evolution 
 
NGS has made a major contribution to the understanding of the theory of tumour 
clonal evolution(76). This theory proposes that, as tumours evolve, they 
accumulate acquired genetic mutations, and different sub-clones of tumour cells 
develop. It may be that different tumour sub-clones convey different tumour 
characteristics, such as the ability to metastasise, or convey resistance to anti-
cancer therapies. 
 
1.10.3 Intra-patient Heterogeneity 
 
Within each patient, different tumour sub-clones, characterised by the presence 
of different somatic mutations, may be observed both within the primary 
tumour, and between metastatic tumours(77). Some genetic aberrations are 
common to all sub-clones in an individual patient’s disease.  These are thought to 
have originated earlier in tumourigenesis, and are common to all sub-clones, are 
called ‘trunk’ mutations. Mutations that occur later in tumour evolution, and that 
may be unique to particular tumour sub-clones, are so called ‘branch 
mutations’(78). 
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1.10.4 Inter-patient Tumour Heterogeneity 
 
Patients with seemingly the same histological sub-type of lung cancer, may 
exhibit very different outcomes, both in terms of their response to treatment and 
their prognosis.  This may reflect observations, from tumour sequencing data, 
that different tumours, with identical microscopic appearances, harbour 
different oncogenic somatic mutations(79),(80). 
 
A landmark study, TRACERx, published in 2017 (by the Swanton group) aimed to 
prospectively characterize intra-tumour heterogeneity and determine the clonal 
nature of key driver events and the evolutionary process in early NSCLC. This 
was achieved by whole-exome-sequencing of 100 early stage, resected NSCLC 
tumours, from a total of 327 different tumoral regions. Driver mutations 
involving EGFR, MET, BRAF and TP53, almost always occur early in tumour 
evolution, and are common to all tumour sub-clones. At least 75% of driver 
mutations that occur later in tumour evolution, that are unique to certain tumour 
sub-clones, involve PIK3CA, NF1, genes involved in chromatin modification and 
DNA damage response and repair. Ongoing dynamic chromosome instability and 
genomic doubling were features associated with intra-tumour heterogeneity and 
parallel evolution of driver somatic increases in gene copy number including 
CDK4, FOXA1 and BCL11A. Particularly, intra-tumour heterogeneity mediated via 
chromosomal instability was associated with an increased risk of recurrence of 
resected NSLC and death(81). 
 
1.10.5 Molecular Resistance 
 
Unfortunately, even lung cancer patients who experience a dramatic initial 
clinical response to systemic treatment, will eventually develop resistance to 
treatment and/or progression of their disease. It is thought that clonal evolution 
in the presence of an anti-cancer agent, leads to the development of one or more 
tumour sub-clonal populations that are resistant to that particular anti-cancer 
therapy. These resistant sub-clones may be present prior to therapy (innate 
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resistance), or may emerge during the course of treatment and/or clinical 
follow-up (acquired resistance). 
 
1.10.6 Molecular landscape of Small Cell Lung Cancer 
 
As in NSCLC, a large number of acquired somatic mutations are observed in small 
cell lung cancers, often due to the mutagenic effects of tobacco smoke, in patients 
with a heavy smoking history. One study of NGS in a small cell lung cancer cell 
line (NCI-H209) identified 22,910 somatic substitutions, including 134 contained 
within coding exons.(82) 
 
Inactivation of TP53 or RB1 occurs in over 90% of cases of SCLC.(83) This is 
confirmed in a recent comprehensive genomic profiling of 110 cases of small cell 
lung cancer.(84) George et al (2015) describe bi-allelic inactivation of TP53 and 
Rb1, sometimes by complex rearrangements. Unlike in NSCLC, few cases of SCLC 
have been associated with mutations in kinase genes e.g. KRAS, EGFR and PTEN. 
Inactivating mutations in the NOTCH family of genes were seen in 25% of cases 
of SCLC.(84) 
 
1.11 Epigenetic Alteration in Small Cell Lung Cancer 
Other molecular mechanisms can indirectly affect cancer gene expression 
(epigenetic changes). These are a hallmark of SCLC. These can be secondary to 
genetic alterations in genes that are involved in transcriptional regulation (e.g. 
abnormalities in the transcriptional regulator CHD7 and chromatin 
modification(82). A massive genetic insult, followed by remodelling of 
chromosome structure (chromothripsis) is alternate mechanism of Rb1 
deregulation (when Rb1 was wild-type). This results in an overexpression of 
cyclin D1.(84) The SOX transcription factor family of genes has also been 
implicated in SCLC, with amplification of SOX2 occurring in approximately 27% 
of cases. Supporting evidence comes from the observation that proliferation of 
SOX2-amplified SCLC cell lines could be achieved, using anti-SOX2 shRNA. 
MYCL1 is also a transcription factor, and RLF-MYCL1 fusion transcripts have also 
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been observed in SCLC cell lines, that have demonstrated reduced proliferation 
when MYCL1 is subsequently silenced.(85) 
 
Similarly to NSCLC, there are newer therapies, in various stages of clinical 
development, which are more specifically targeted to the aberrant, mutational 
processes implicated in SCLC pathogenesis. These are summarised in table 1-2.
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Table 1-3 Summary of targeted therapeutic strategies in Small Cell Lung Cancer (reviewed in Santarpia et al 2016)(86) 
Therapeutic Target Potential Predictive Biomarker Potential Therapeutic Strategy 
Receptor Tyrosine Kinases 
Pre-treatment phosphor-ERK level Low levels may convey sensitivity to IGF-R1 inhibitor 
FGFR1 amplification Sensitivity to FGFR inhibitors 
FGF/FGFR1 member molecular aberrations Sensitivity to FGFR inhibitors 
Activating mutations in c-MET Sensitivity to small molecule MET inhibitors and MET monoclonal antibodies, or 
synergy of these with Top1 inhibitor 
PI3K/AKT/mTOR pathway 
PI3K/AKT pathway activation and low BCL-2 expression Sensitivity to mTOR inhibitors. Overcome chemo-resistance with mTOR 
inhibitors 
MYC and eIF4E overexpression MYC-eIF4E inhibitors may convey sensitivity to mTOR inhibitors 
PIK3CA mutation or amplification, AKT or PTEN mutation Phase II trial using AKT inhibitor 
Targeting apoptosis 
Overexpression BCL-2 BCL-2 antisense oligonucleotide enhance efficacy of cis/etop chemo 
Overexpression BIM Synergy of mTOR and BCL-2 inhibitors 
Hh pathway 
To be established Small Molecule Inhibitors of Hh signalling pathway or anti-IGF-1R monoclonal 
antibodies. Potential synergy with chemotherapy 
DNA damage/repair 
Overexpression of PARP1. Elevated baseline expression levels of multiple 
DNA repair proteins ("DNA repair score") 
PARP inhibitors. Potential of PARP inhibitors to enhance chemotherapy and 
radiotherapy efficacy. Potential to combine PARP inhibitors/ WEE1 inhibitors. 
MYC 
Increased expression of enhancer associated transcription factor genes eg. 
MYC or SOX2 
Sensitivity to CDK7 inhibitors 
Aurora kinase  MYC overexpression Sensitivity to AURKA inhibitors 
HDAC To be established Sensitivitiy to HDAC inhibitors and potentiate effect of chemotherapy 
Hsp90 
Increased expression of RIP1 Sensitivity to Hsp90 inhibitors and potential use in combination with 
chemotherapies that up-regualte RIP1 
Anti-angiogenesis 
To be established Sensitivity to mono-clonal antibodies against VEGF and other anti-
VEGF/VEGFRs agents 
PD-L1 
PD-L1 expression, Mutational load and higher burden of candidate 
neoantigens, molecular smoking marker and DNA repair pathway 
mutations 
Immune checkpoint inhibitors against CTLA-4 and PD-1/PD-L1 
TP53 Mutation, overexpression of GD3 Vaccines 
Neuro-endocrine marker 
inhibitors Increased expression of NCAM1, CD56 Anti-body drug conjugate - anti CD56-DM1 
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1.12 Biomarkers  
 
It is important to be able to monitor the success of lung cancer treatment and, 
with an increasing list of effective drugs from which to choose, prospectively 
predict response to each, so that we achieve the primary aim of ‘precision 
medicine’ -  “the right treatment for the right patient at the right time”.  It is 
therefore imperative that new and better predictive biomarkers of response are 
developed, comparable to EGFR mutations in EGFRmut+ve adenocarcinoma, for 
each of the new targeted agents, as they are developed. 
 
A biomarker can be defined as a “Characteristic, objectively measured and 
evaluated, indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention.” (US National Institute of 
Health Biomarkers Definition Working Group). Biomarkers can be anything that 
signal the presence of a biological process, including cancer. There are several 
potential uses of cancer biomarkers, for example to help in cancer screening, 
cancer diagnosis, inform prognosis, predict response to treatment, determine 
minimal residual disease, or detect disease relapse or progression. Although 
‘biomarker’ is a popular, recent terminology, in fact such molecules have been 
used for decades, for example, serum Alpha-fetoprotein (AFP), human Chorionic 
Gonadotrophin (hCG) and Lactate dehydrogenase (LDH) in germ cell tumours. 
Further examples of blood-borne biomarkers, in routine clinical practice include 
Prostate Specific Antigen (PSA) in prostate cancer, Chorionic Embryonic Antigen 
(CEA) in colorectal cancers and Ca125 in Ovarian cancer(87). 
1.12.1 Biomarkers in lung cancer 
Until recently, the main biomarkers used in routine clinical practice for patients 
with lung cancer are imaging, rather than molecular, biomarkers - abnormal 
radiological appearances, detected by chest radiograph or CT scan. Monitoring of 
therapeutic response to anticancer therapies includes clinical assessment, and 
interval radiology comparing serial radiological appearances to base-line scans. 
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There are currently no validated biomarkers for predicting response to palliative 
chemotherapy, monitoring periods of disease control, or detecting disease 
relapse and prognosis in patients with lung cancer. 
 
1.12.2 Predictive Biomarkers to Targeted therapies in lung cancer 
 
Specific mutations within certain genes can act as ‘predictive biomarkers’ of 
response of lung tumours to targeted therapies, such as EGFR mutations for 
EGFR TKi therapy, as above. The USA’s National Comprehensive Cancer Network 
(NCCN) currently recommends molecular mutational analysis of the genes EGFR, 
BRAF, ERBB2, and MET, and for gene rearrangement analysis for ALK, ROS1 and 
RET, and MET gene amplification analysis, in patients with metastatic non-small 
cell lung cancer, to guide the use or avoidance of potential targeted 
therapies(88). The most commonly accepted method of detecting these 
mutations is by genetic analysis of tumour DNA, extracted from tumour tissue, 
usually obtained as a result of an invasive biopsy, or surgical resection. Recently, 
the value of mutational analysis of alternative sources of tumour DNA, such as 
circulating cell free tumour DNA (ctDNA), has also started to become clearer.  
Clinically relevant analysis of these sources of DNA for genetic abnormalities has 
been dependent on major technological advances, particularly in nucleic acid 
sequencing. 
1.13 Relevant Genetic Technologies for Cancer Mutation Detection 
1.13.1 Sanger Sequencing 
 
Sanger sequencing allows in-vitro DNA replication of a target DNA sequence, 
using short DNA primer sequences and selective incorporation of fluorescently-
labelled, chain-terminating dideoxynucleotides (ddNTP), by DNA-directed DNA 
polymerase. A different fluorophore is used to represent each of the 4 ddNTPs. 
The resulting DNA strands of different lengths and fluorophore labels, are 
separated by size using the principle of chromatography, and genetic sequence 
data is generated by fluorescence detectors. This technique can be used to assess 
the genetic sequence of single genes from any given DNA sample. It requires a 
relatively large amount of input DNA, which is not always available from small 
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lung cancer tissue samples. Hence, while this technique can be used for single 
gene analysis in tumour tissue samples, it is not able to detect low-level genetic 
mutations, such as those seen in ctDNA samples. 
1.13.2 Pyrosequencing 
 
Pyrosequencing is a quantitative, real-time DNA sequence analysis performed on 
biotinylated PCR products. It involves four key enzymes; DNA polymerase, ATP 
sulfurase, firefly luciferase and apyrase. Iterative incorporation of nucleotides by 
DNA polymerase causes an equivalent release of inorganic pyrophosphate. This 
by-product of DNA elongation is utilised by luciferase, to produce equimolar 
quantities of ATP and light. The release of light is detected and recorded. Apyrase 
degrades any ATP and unincorporated nucleotides before the cycle of 
incorporating the next nucleotide starts again. Resulting sequence data files are 
visualized and analysed using software, to detect the presence of a mutation. 
1.13.3 COLD-PCR 
 
Co-amplification at Lower Denaturation temperature PCR (COLD-PCR) is a 
modified PCR technology that reduces the signal to ‘wild-type’ ratio. For samples 
containing a mix of mutant and wild-type DNA strands, a critical denaturation 
temperature is used, allowing a mutant: wild-type heteroduplex to form.  This 
heteroduplex preferentially denatures at lower denaturation temperatures, 
relative to a wild-type: wild-type duplex. This allows the preferential 
amplification of DNA strands containing a mutant sequence. When used prior to 
pyrosequencing, the limit of detection is lowered 100 fold, which is particularly 
more useful for detecting a low level of mutant alleles in a background of wild-
type DNA(89). 
1.13.4 Next Generation Sequencing (NGS) 
 
NGS generates genetic sequence data for a whole genome, whole exome, multiple 
genes, or genetic regions simultaneously, from a single tumour DNA sample, 
rather than performing multiple, sequential, single-gene analyses. This is 
particularly advantageous when there is a limited amount of DNA from small 
tumour tissue samples, as is commonly the case with lung cancer samples. Figure 
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1-3 gives an overview of the principle of amplification based, next generation 
sequencing. 
 
 
Figure 1-3 Principles of amplification based next generation sequencing (NGS). 
NGS works by utilizing a ‘pool’ of DNA primers that amplify multiple, specific 
genetic regions, in a single PCR reaction. The resulting ‘amplified’ genetic regions 
are called amplicons. Multiple ‘overlapping’ amplicons are ‘sequenced’, and 
analysed using bioinformatics software tools, to generate sequence data for 
whole genes.  Subsequently, multiple genes from a single DNA sample can be 
screened for genetic sequence changes, including pathogenic mutations. 
1.13.5 Droplet Digital PCR 
The droplet digital PCR process is summarized in Figure 1-4 below. 
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Figure 1-4 Droplet Digital PCR (BioRad technology). 1. Initial emulsion PCR mixture is dispersed into 
approx.. 20000 droplets, each containing an average one copy of DNA (mutant or wild-type), 
primers, mutant probe and wild-type probe. 2. PCR of droplet. 3. Each droplet is ‘read’ individually 
and classified as positive or negative. Positive droplets further divided into mutant or wild-type. 
Adapted from http://www.bioradiations.com/digital-pcr-at-the-next-level-users-find-many-
applications-for-the-qx100-droplet-digital-pcr-system/ (accessed 11 Feb 2018). 
 
Droplet digital polymerase chain reaction (ddPCR) is a quantitative PCR method. 
DNA primers and fluorescently labelled DNA probes are designed against a 
specific DNA mutation sequence and their corresponding wild-type DNA 
sequence. The PCR reaction is dispersed into 20,000 individual reaction droplets, 
and utilising Poisson distribution statistics, the emulsion PCR of the droplets 
occurs with an average of 1.2 copies of DNA per droplet. Depending on whether 
the copy of DNA in each droplet is mutant or wild-type, the corresponding 
fluorescent probe will be incorporated, so that each droplet can then be 
individually detected as ‘mutant’ or ‘wild-type’ on a droplet reading machine. 
This gives a digital, and subsequently very accurate DNA quantitation, and ratio 
of mutant allele compared to a background of wild-type alleles (alternate allele 
frequency (AAF)), with Poisson error statistics. Droplet digital PCR  has a much 
lower limit of mutant allele detection than NGS - the sensitivity of this platform 
has been reported to detect alleles as rare as 0.01% frequency(90). However, 
unlike NGS, which can provide sequence data of multiple genes from one DNA 
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sample, ddPCR is based around hybridization of sequence-specific probes, and 
thus can only detect the presence of specific genetic sequences, depending on 
which probes are used. 
1.14 Detecting EGFR Mutations and ALK translocations in lung cancer 
samples 
 
There are many different accepted methods, in widespread clinical-diagnostic 
use, to detect somatic EGFR mutations. These include Sanger sequencing and 
pyrosequencing of DNA extracted from formalin fixed, paraffin embedded 
(FFPE) lung tumour tissue(91). The current accepted standard to detect ALK 
translocation is by fluorescence in-site hybridization (FISH) analysis of the FFPE 
tumour tissue, using a break-away probe(92) 
1.15 NGS in Lung Cancer 
1.15.1 Targeted NGS Gene Panel for lung cancer 
 
There exist different platforms on which to perform NGS. Therefore, when 
choosing an appropriate NGS strategy for lung cancer DNA analysis, important 
factors to be considered include the quantitative DNA requirement of the NGS 
reaction and the choice of genes to be included by any targeted panel. 
1.15.2 DNA Requirement 
 
The DNA requirement for NGS can range, from as little as 10ng DNA per sample 
(with platforms such as Ion Torrent, Ion Proton NGS platform (LifeTech)) to 30-
50ng per sample (with NGS platforms such as Illumina). 
1.15.3 Gene Panels 
 
Despite the NCCN current recommendation (section 1.12.2), there is no 
consensus NGS platform, or gene panel, for the analysis of lung cancer. 
Commercial gene panels are available.  For example, a targeted 50 gene cancer 
hotspot panel (ThermoFischer Scientific), focuses on specific regions within 50 
oncogenic or tumour suppressor genes that are known to be hotspots for 
pathogenic mutations, many of which are commonly observed in lung cancer. 
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However, to investigate genetic regions of interest to lung cancer which are not 
contained within commercially available panels, there is the option to design 
‘custom’ gene panels for use in NGS.  
1.16 Sources of Lung Cancer Tissue 
 
The most common source of tumour tissue from patients with advanced or 
metastatic lung cancer is tumour tissue obtained from an invasive, percutaneous 
or trans-bronchial biopsy. Sometimes, tumour cells can be obtained from 
cytology of malignant pleural fluid, or from an endoscopic bronchial ultrasound 
(EBUS) guided fine needle aspiration of a malignant lymph node. All of these 
invasive procedures are associated with complications, and patients often find 
them uncomfortable and sometimes intolerable.(93)  
 
A diagnostic difficulty is presented by the fact that these biopsy procedures are 
only possible in 80% of patients with advanced lung cancer. Furthermore, even 
where they are possible, in some cases the biopsies only contain very small 
amounts of tumour tissue.  Multiple analyses need to be performed on these 
small samples, including diagnostic histopathological examination and 
immunohistochemistry, which often exhaust the tissue sample, prior to any 
genetic molecular analyses, such as NGS64. As a result, and as exemplified by 
EGFR mutational analysis, the ability to detect the presence, or confirm the 
absence, of cancer mutations, using more conventional genetic technologies, can 
depend on the tumour tissue sampling method. For examples, image-guided 
percutaneous transthoracic core-needle biopsies have a 31.8% mutation test 
failure rate, and bone samples from core biopsies, especially after decalcification 
have up to 40% mutation test failure rate(94). Therefore, methods of molecular 
analysis that require only small amounts of DNA are desirable.  Alternatively, 
alternative sources of tumour cells and tumour DNA for mutational analysis need 
to be explored, such as circulating tumour cells (CTCs) and circulating cell free 
tumour DNA (ctDNA). 
1.17 Circulating Tumour Cells (CTCs) 
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Individual tumour cells can be identified, isolated and enriched from the 
peripheral circulation in patients with cancer. Many technologies, including the 
CELLSEARCH® platform, and Parsortix (Angle Plc.) platform, have been 
developed to identify, isolate and enrich CTCs, on the basis of cell surface protein 
expression.  
There is a relative abundance of CTCs in small cell lung cancer, and these 
decrease in number when a patient is exposed to carboplatin/etoposide 
chemotherapy(95). In non-small cell lung cancer, 32% of stage IV patients are 
positive for CTCs (defined as >2 absolute count) at baseline(96). 
It is possible to extract DNA for molecular genetic analysis from CTCs. However, 
these technologies are expensive and not readily available, certainly compared to 
technologies used for ctDNA extraction and analysis, below. 
Advantages of CTC analysis include the discovery of concurrent genetic 
mutations that co-exist within the same cell, rather than ctDNA, which 
represents a pool of DNA from all tumour cells that shed DNA into the 
circulation.  It is also possible to extract DNA or mRNA from the same cell. 
Current limitations of CTC research are that it appears less cost effective than 
ctDNA research, and is more technically challenging.  
1.18 Circulating Cell Free Tumour DNA (ctDNA) 
 
The idea of circulating cell-free DNA (cfDNA) has been developed since it became 
known that free foetal DNA can be identified within the maternal circulation(97). 
Similarly, it is now known that cancers also shed DNA into the blood circulation.  
This sub-fraction of cfDNA is known as circulating tumour DNA (ctDNA).  There 
are several hypotheses about the mechanism of DNA shedding.  One is that 
ctDNA is shed from dead or dying tumour cells(98). The amount of ctDNA in the 
circulation is proportional to tumour burden(99), for example in patients with 
lymphoma(100). 
 
There are between 1,800 and 13,000 fragments of cfDNA per millilitre of plasma, 
of which it is estimated that between 0.4 and 11% can be ctDNA. The fraction, or 
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percentage, of a genetic mutation within ctDNA, compared to the background of 
‘wild-type’ or genomic DNA, is known as the alternate allele frequency (AAF), or 
variant allele frequency (VAF). 
 
Total cell free DNA, and hence ctDNA, yields from plasma tend to be low, in the 
order of 0.5 – 1.5 ng/μl in elution volumes of 20 – 50 μl. Despite the low cfDNA 
and ctDNA concentrations, however, it is possible to perform molecular 
characterisation, following amplification with polymerase chain reaction (PCR) 
based technologies(101). 
1.19 Clinical Uses of ctDNA 
 
It is relatively simple to obtain ctDNA samples for analysis, via a minimally 
invasive, peripheral circulating blood draw, requiring only a few millilitres of 
blood.  Serial samples can be obtained, sequentially and in ‘real time’, as the 
patient undergoes various anti-cancer therapies, enabling monitoring of disease 
relapse, or progression.  These sequential ‘liquid biopsies’ are a more acceptable 
alternative to repeat, invasive tissue biopsy for patients, especially if the patient 
is unwell. 
 
CtDNA analysis has been used as a biomarker to help monitor response to 
treatment, detect minimal residual disease (MRD), detect relapse and predict 
prognosis(102).  Dawson et al (2013) monitored ctDNA in 30 patients with 
metastatic breast cancer, and compared it with the biomarker Ca15-3, a 
commonly used biomarker in breast cancer. The authors concluded that 
monitoring somatic mutations in ctDNA is an informative, sensitive and specific 
biomarker(103). Brenton and Rosenfield (2016) identified somatic TP53 
mutations in FFPE tumour tissue samples from patients with ovarian cancer. 
These TP53 mutations were then monitored quantitatively in serial plasma 
samples using ddPCR, and comparisons made with circulating Ca-125 biomarker 
levels. Copy number of TP53 mutations in cell free DNA correlated with changes 
in Ca-125. There could potentially be a greater prognostic value compared with 
Ca-125(104). 
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Analysis of ctDNA can provide insight into the genetic evolution of cancer as it 
progresses, as well as understanding molecular mechanisms of resistance to 
various anti-cancer therapies(105). This is exemplified by Diaz et al (2012), who 
detected emergent KRAS mutations in ctDNA in 28 ‘KRAS wild-type’ colorectal 
cancer patients during the development of clinical resistance to anti-EGFR 
therapy (e.g. panitumumab or cetuximab)(106). 
  
1.20 CtDNA in Lung Cancer 
1.20.1 CtDNA Analysis of EGFR at Diagnosis 
 
Clinicians are now able to prescribe EGFR TKi, such as gefitinib, based on 
detection of the EGFR mutations described above, in ctDNA from a lung cancer 
patient, rather than from samples taken from the tumour itself. It has been 
reported that there is a high concordance, in detecting EGFR mutations in ctDNA, 
compared with FFPE tumour tissue analysis, in patients with locally advanced, or 
metastatic EGFRmut+ve adenocarcinoma of the lung16. Therefore, EGFR mutational 
analysis of ctDNA is an acceptable alternative for EGFR mutational analysis of 
tumour tissue, especially for patients who do not have sufficient tumour tissue 
for molecular analysis, or where the DNA from tumour issue is not of sufficient 
quality or quantity. 
1.21 CtDNA Analysis of EGFR mutations during Disease 
Progression/Resistance to Therapy 
 
One study used a hybridization capture, NGS technology called Cancer 
Personalized Profiling by deep Sequencing (CAPP-Seq) to characterise 
therapeutic resistance mechanisms in ctDNA in 43 NSCLC patients treated with a 
3rd generation EGFR TKi, rociletinib. Acquired mutations were simultaneously 
detected in MET, EGFR (including a novel p.L798I mutation), PIK3CA, ERBB2, 
KRAS and RB1 genes (107). 
 
The most commonly-observed mechanism of resistance to therapy in EGFRmut+ve 
adenocarcinoma of the lung is the T790M resistance mutation.  This is detectable 
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in ctDNA, in patients who develop acquired resistance to first line EGFR 
TKi(108). For such patients, the EGFR TKi osimertinib, mentioned previously, 
can be given, with response rates as high as 67% reported in early phase clinical 
trials. This is where the T790M mutation is detected by analysis of tumour tissue 
obtained by invasive biopsy(45). 
 
Previously, EGFR T790M detection has been described in a few case studies. Two 
case studies investigated mutational abundance in serial ctDNA samples in 
osimertinib-treated patients, using ddPCR. In both patients, circulating 
mutational load became undetectable within 1 month of treatment, and the 
original sensitising mutations became detectable again when the patients 
developed therapeutic resistance to osimertinib, as confirmed by standard 
radiology. However, levels of circulating EGFR c.2369C>T p.T790M were only 
detectable in one of these osimertinib-treated patients on radiological 
progression, and the therapeutic resistance mechanism was confirmed to be 
MET amplification on repeat tumour biopsy. The authors suggested that 
monitoring levels of the original EGFR TKi sensitizing mutation, rather than 
T790M, may facilitate more reliable detection of disease progression, in this 
disease setting(109). 
 
1.22 Recommended ctDNA Sample Processing 
 
The validity of genetic testing techniques will be limited by the quantity and 
quality of ctDNA employed, and so it is crucial that great care is taken in various 
aspects of sample handling and processing. Specialised blood collection tubes 
have been developed, CellSave (Janssen Diagnostics) and Streck tubes (Streck), 
which contain a preservative that binds to cells, and prevents shedding of DNA 
into the plasma, thereby reducing degradation of cfDNA, including ctDNA. These 
blood collection tubes have been shown to reduce genomic DNA shedding into 
the plasma, up to 4 days after collection, and thus reducing the relative amount 
of tumour-derived DNA(110). 
 
 35 
The ECMC Cell-free DNA Consensus Meeting (2014) recommended a double-spin 
protocol, whereby two more gentle centrifugation steps are employed, the first 
to remove the majority of cellular material without excessive cell lysis, and the 
second, of the plasma, to remove any remaining cellular material(111). 
1.23 Technical Limitations for ctDNA analysis 
 
A key current issue in assessing ctDNA in ‘liquid biopsies’ is the ability of various 
molecular techniques to identify somatic mutations at low AAF. Given that 
cancer mutations in ctDNA can exist at low alternate AAF (previously published 
range 0.1 – 5%)(112), it is important to utilise molecular testing techniques that 
increase the changes of detecting a mutation (true-positive), while minimizing 
the chances of a false-negative and false-positive test results. It is also important 
to remember that the amount of cfDNA is limited, and whether this affects the 
ability to detect mutations at low AAF. 
 
With regard to NGS, many genetic sequence changes are observed in NGS data, at 
low level frequency (1-2% alternate allele frequencies)(113). It is recognised 
that many of these changes are sequencing artefacts, resulting from the NGS 
sequencing process. This gives rise to a potential false-positive test result for the 
presence of cancer mutations. Different NGS techniques and bioinformatics 
software tools have been developed in an attempt to enhance true-positive 
results, and reduce false negative results. 
 
In order to test the lower limit of variant detection using NGS, Lanman et al 
(2015) ‘spiked’ cfDNA with a panel of 10 known mutations at a level of 0.1% 
variant allele frequency, i.e. one copy of DNA containing a mutation, per 1000 
copies of wild-type DNA. They then performed NGS on the Illumina NGS 
platform. They discovered a high level of background false positives, with 
alternate allele frequencies 0.05 – 5%(114). 
 
Incorporating unique short DNA sequences, or ‘barcodes’, to ctDNA molecules, 
prior to NGS, can increase the true positivity rate, as is the case with tagged 
amplicon deep sequencing (TamSeq), an NGS method that can detect mutant 
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alleles as low as 2% with sensitivity and specificity of >97% (115). Another NGS 
method to improve low-level mutation detection, is Cancer Personalised 
Profiling by deep Sequencing (CAPP-Seq), which utilises DNA probes for specific 
cancer mutations, followed by a hybridisation-capture NGS technique. It can 
detect one mutant DNA strand in a background of 10,000 wild-type DNA 
molecules. Using this technique, the authors report an ultrasensitive ability to 
detect ctDNA in 100% of patients with stage II-IV NSCLC, and in 50% of patients 
with stage I. They report a 96% specificity for mutant allele fractions down to 
0.02% alternate allele frequency(116). However, within this publication there 
was still the issue of false positive, or ‘background’ sequence noise, from which it 
is hard to differentiate the true positive genetic sequence changes. Therefore this 
group developed integrated digital error suppression (iDES). This is an in-silico 
elimination of highly stereotypical background artefacts and a molecular 
barcoding strategy to identify ctDNA molecules. The authors report that CAPP-
Seq, in combination with iDES, can further increase the ability to detect low level 
ctDNA. In particular, when applied to patients with NSCLC, they achieved 90% 
sensitivity and 96% specificity in detecting EGFR mutations(117). TamSeq and 
CAPP-Seq are not yet widely available for routine use in the clinic setting. 
1.24 Thesis Overview 
 
This thesis will focus on the use of ctDNA as a biomarker in advanced lung cancer 
(NSCLC and SCLC). This thesis will specifically address ctDNA as a circulating 
biomarker to inform prognosis, and to predict and monitor response to therapy, 
as well as predict therapeutic resistance. The ultimate aim is to contribute to the 
improvement of the ability to select lung cancer patients most likely to respond 
to both conventional therapies, as well as to enhance the management of 
patients treated with a more molecularly targeted approach. 
1.25 Thesis Aims 
 
The aims of this thesis are: 
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o To assess whether ddPCR and/or NGS are sufficiently sensitive to 
detect mutations in tumour DNA, occurring at low alternate allele 
frequency, and therefore their suitability for use with ctDNA analyses. 
o To determine whether carefully-selected NGS platform and gene 
panels are able to detect somatic mutations in FFPE tumour tissue and 
ctDNA samples, from patients with locally advanced or metastatic lung 
cancer. 
o To assess the potential utility of EGFR mutation detection in ctDNA as 
a surrogate predictive biomarker of response/resistance to EGFR TKi 
treatment in EGFRmut+ve NSCLC cancer patients. 
o To assess the utility of sequential ctDNA sampling as a surrogate 
biomarker of early disease relapse in patients with EGFRmut+ve lung 
cancer. 
o To assess the potential clinical utility of ctDNA as a potential 
predictive, and prognostic surrogate biomarker in SCLC. 
o To investigate the potential of ctDNA to supplement/supplant the use 
of existing methods of mutation detection, in routine lung cancer 
clinical practice, thereby facilitating earlier clinical decision-making. 
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2 Methods and Materials 
 
2.1 Project governance, patients and clinical data collection 
 
A research protocol, patient information sheet and patient consent sheets were 
written to specifically recruit patients to this research project, which is 
sponsored by Cardiff University (Section 7 Appendix – Patient Information Sheet, 
Section 8 – Patient Consent Sheet). Patients were invited to give written, 
informed consent to participate in this research, and for access to FFPE tumour 
blocks from their original diagnostic biopsy, access to the clinical case notes, and 
to provide serial blood samples during various anti-cancer therapies. 
 
National ethics approval was gained (Edgbaston, IRAS 149571), and local 
research and development approvals provided by Cardiff and Vale University 
Health Board, Velindre NHS Trust, and Aneurin Bevan University Health Board, 
to allow patient identification, recruitment and research related procedures 
across these sites. Patients could also consent to this research project via the 
Wales Cancer Bank (WCB). 
 
At total of 29 patients were recruited: 11 patients had locally advanced or 
metastatic, EGFR mutation-positive (EGFRmut+ve) adenocarcinoma of the lung; 10 
patients had locally advanced or metastatic small cell lung cancer; and 8 patients 
had NSCLC - 5 patients with adenocarcinoma of unknown EGFR mutation status 
and 3 patients with squamous cell carcinoma. 
 
Consented patients were given a unique, anonymous research identifier, against 
which clinical samples and data were recorded, so that no patient identifiable 
information was included in any of the research sample processing, data analysis 
or presentation. 
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2.2 DNA Extraction 
2.2.1 FFPE Tumour DNA extraction 
 
For each consented patient, FFPE tumour tissue slides were obtained from the 
patient’s diagnostic biopsy, with a matched H&E slide, with the tumour area 
ringed and the percentage of nucleated tumour cells denoted on the slide. This 
was performed by the local histopathology department. Tumour tissue was 
subsequently macro-dissected and DNA extracted using the EZ1 (Qiagen) 
according to the manufacturer’s protocol, and stored at 4°C. 
2.2.2 DNA Quantification 
 
Final concentrations of extracted DNA samples were determined by fluorometric 
quantitation. Using the Qubit® dsDNA HS (High Sensitivity) Assay Kit 
(ThermoFisher Scientific, UK), 2μl of sample was mixed with a fluorescent dye 
and buffer mix, that fluoresces once intercalated into double stranded DNA 
molecules. Fluorescence of each sample is measured using Qubit® Fluorometer 
2.0, and the concentration of DNA is directly proportional to the amount of 
fluorescence signal. The concentration detection range for this assay is 0.2 – 100 
ng of DNA of double stranded DNA. 
 
2.3 Collection and processing of ctDNA samples 
 
Up to 2x 10mls peripheral venous blood, were collected in appropriate clinical 
environments, such as hospital out-patients department, into CellSave blood 
collection tubes (Janssen Diagnostics), at selected time-points during the 
patient’s anti-cancer therapy. Where possible, CellSave blood samples were 
taken at the same time as a routine clinical blood test, in order to minimize the 
number of blood draws. 
 
Blood samples in CellSave tubes were centrifuged at 1000g for 10 mins at 4°C 
using a double spin protocol, to minimize cell lysis and reducing any extra 
genomic DNA entering the plasma compartment, according to CRUK protocol, 
and in accordance with the ECMC cell free consensus opinion(111).  The 
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supernatant was used for ctDNA analysis and the ’buffy coat’ used for genomic 
DNA extraction, as below. 
 
The supernatant (plasma) was transferred into 2 ml Eppendorf tubes and 
centrifuged at 2000g for a further 10 mins. The second supernatant was then 
stored at -80°C in 1 ml aliquots. 
 
2.3.1 Cell Free DNA extraction 
 
Frozen plasma aliquots were thawed to room temperature, and extracted using 
the QiaAmp circulating nucleic acid extraction kit (Qiagen) according to the 
manufacturer’s protocol. This involves a proteinase-K digestion step, to liberate 
any plasma protein-bound nucleic acids. Samples are then mixed with the Buffer 
ACL (a Qiagen proprietary buffer containing guanidine thiocyanate and 
trometamil), to optimize DNA binding to a silica membrane, contained within a 
column attached to a vacuum manifold. The bound DNA was washed using 
ethanol. Bound cell free DNA was eluted into a final volume of 40μl of AVE 
elution buffer (a Qiagen proprietary buffer of 0.04% sodium azide in RNase free 
water). Eluted DNA samples are placed on ice, ready to be quantified, using 
fluorometic analysis with the Qubit system described above. 
 
2.3.2 Genomic DNA extraction 
 
After the first centrifugation, the ‘Buffy coat’ from each blood sample was 
transferred to fresh Eppendorf tubes and stored at -80°C. Genomic DNA was 
extracted from 300μl of thawed buffy coat. This was performed by lysing white 
blood cells contained within the buffy coat, liberating nucleic DNA Lysed samples 
were placed into a Maxwell® RSC Instrument (Promega UK) where nucleic acids 
are captured using paramagnetic MagneSil® particles which are then washed in 
a series of ethanol washes, and nucleic acids are then eluted according to the 
Maxwell protocol. Resulting DNA concentrations were determined using 
fluorometric quantitation with the Qubit 2.0, as above. 
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2.4 Next Generation Sequencing – Principles 
 
The principles in amplification based next generation sequencing are illustrated 
in Figure 1-3 (see Introduction chapter). The amplification based, Ion Torrent - 
Ion Proton platform for NGS (Ion Ampliseq™) was chosen for this project 
(LifeTechnologies part of ThermoFisher Scientfic, UK). Steps involved in this 
process are library preparation, template preparation, DNA sequencing and data 
analysis. 
2.4.1 Library Preparation 
 
This is the process whereby the sample DNA is mixed with a combination of 
short, single stranded DNA primers, and DNA polymerase, in a polymerase chain 
reaction, to amplify the DNA sequences of interest. This polymerase chain 
reaction step can be multiplexed, so that one DNA sample can be mixed with a 
‘pool’ of primers, to amplify several ‘target’ genetic regions, simultaneously. 
Depending on the number of ‘target’ regions that need to be amplified, the initial 
PCR of the sample may need to be divided across more than one primer pool, 
which are later combined. Amplified segments of DNA are called amplicons, and 
further short strands of unique DNA sequence can be further added to the 
amplicons, to provide a unique ‘barcode-identifier’ to denote the sample of 
origin. This is particularly useful when combining amplicons derived from 
different DNA samples. This project utilized the Ion Amplieq™ library 
preparation method (Figure 2-1). 
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Figure 2-1 Ion Ampliseq™ library preparation workflow. Adapted from the Ion Ampliseq™ Library 
Kit 2.0 User Guide (ThermoFisher Scientific, Publication No. MAN0006735, Revision E.0 24 May 
2017)  
2.4.2 Template Preparation 
 
Each amplicon needs to be joined to a small bead, or ion sphere particle, on 
which the DNA sequencing reaction takes place. Beads containing barcoded 
amplicons undergo a further emulsification polymerase chain reaction, to 
populate each bead with multiple monoclonal copies of the original amplicon. 
The monoclonal ion sphere particles are loaded onto a microchip, which contains 
70 million individual wells. In principle, one monoclonal ion sphere particle will 
occupy an individual well on the microchip. 
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2.4.3 DNA sequencing 
 
The prepared microchips are loaded onto the initialised Ion Proton sequencing 
machine. Single nucleotides (A, T, C or G) are individually passed over the 
microchip sequentially, and when a nucleotide is incorporated into the growing 
DNA template, there is a release of a hydrogen ion, resulting in a change in pH. 
This change in pH, within each individual well, is detected by the micro-
electronic circuitry contained within the microchip. These signals are collated to 
generate raw DNA sequencing data, which is uploaded to an internet based 
sever, in real-time. 
2.4.4 Data Analysis 
 
Raw DNA sequence data is converted to data files. Genetic sequence data can 
then be separated according to each sample unique barcode, and compared with 
reference genome sequence databases (alignment) to determine which genetic 
areas of the sample DNA have been sequenced. Raw DNA sequence data files and 
aligned DNA sequence files, can be analysed using different bioinformatics 
software tools, to determine any genetic sequence changes, and these can be 
further characterised with in-silico analysis. 
2.4.5 Sequencing Coverage and Depth 
 
The degree of target DNA sequencing, ranging from single gene to whole 
genome, is known as sequencing coverage. The number of amplicons that cover a 
specific genetic region will determine sequence depth. As a general principle, the 
capacity of DNA sequencing, per DNA sample, per primer pool, per microchip, is 
limited. This means that NGS panels that cover a wide genomic region eg. whole 
genome, will have reduced sequence depth potential. Conversely, for NGS panels 
that cover a smaller, or more targeted genetic region, eg a panel of genes, a 
greater sequence depth will be possible. In relation to cancer, DNA samples 
contain a mixture of tumour DNA and germline DNA. Therefore the NGS 
sequence depth has to be sufficient, so that amplicons generated in the library 
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preparation step, will represent both tumour and germline DNA contained 
within the sample. Histopathological examination can provide an estimate of the 
number of nucleated tumour cells contained within FFPE tumour tissue sample. 
This can influence the degree of sequencing depth required. For example, a 
sample containing 10% tumour cells, may require at least 1000x sequencing 
depth, so that at least 100 amplicons will be generated from the tumour DNA. 
Samples containing 100% tumour cells, may only require at least 100x sequence 
depth, as all of the amplicons may be generated from tumour DNA. 
 
Circulating cell free tumour DNA (ctDNA), may only account for a very small 
proportion of total circulating cell free DNA (as little as 0.01%), therefore NGS 
sequencing depth would need to be significantly deeper than with DNA derived 
from FFPE tumour tissue, to increase the chances of amplicons being generated 
from tumour DNA. 
2.5 Next Generation Sequencing - Process 
2.5.1 NGS Platform and Gene Panel Choice 
 
The Ion Torrent, Ion Proton (LifeTechnologies, part of ThermoFisher Scientific, 
UK) platform was selected for somatic variant discovery via Next Generation 
Sequencing, since the AmpliSeqTM (118) method of library preparation only 
requires 10ng of input DNA per sample, per primer pool. The amplicon size 
range between 75 and 150 base pairs, which is most appropriate for FFPE 
tumour DNA and ctDNA, where tumour DNA fragments are of the same size 
range. 
2.5.2 Custom Panel for NSCLC 
 
A custom, 22 gene panel for non-small cell lung cancer, was designed for genes 
that are mutated at >1% frequency, that may also convey prognostic 
information, or they provide predictive biomarkers for response to targeted 
therapies. These genes are listed in Table 2-1. Specifically, this panel includes 
genes implicated in the pathogenesis of lung cancer. Genes encoding cell surface 
receptors, mutated at >1% in lung cancer, may provide a target for mono-clonal 
antibodies, or tyrosine kinase inhibitors, include DDR2, MET, FGFR2, ERBB2, 
 45 
FLT3, KIT, PDGFRA and EGFR. Activated RAS/RAF/MEK/ERK and PIC3-K/AKT 
cellular signaling pathways are commonly seen in lung cancer. Many anticancer 
agents that target these aberrant cellular pathways are in development. 
Therefore, genes involved in these pathways, mutated at >1% in lung cancer 
were included in the custom gene panel. There are namely, NRAS, KRAS, BRAF, 
MAP2K1 (MEK1), PIK3CA, MTOR and AKT1. Loss of NF1 (mutated >1% NSCLC) 
also activates the RAS pathway(119). DNA mis-match repair genes BRCA1 and 
BRCA2, may convey sensitivity to PARP-inhibition therapy (120, 121). The 
tumour suppressor genes TP53 and STK11 are also mutated in >1% NSCLC. 
CDKN2A is mutated in >1% of NSCLC. This acts as a tumour suppressor by 
regulating the cell cycle. A new class of anti-cancer drugs, cyclin-dependent 
kinase inhibitors are being explored in various cancer types, eg breast 
cancer(122), and deletion/inactivation of CDKN2A may convey sensitivity to 
these agents(123). 
 
The custom, whole exon, 22-gene panel was designed using the on-line Ion 
Ampliseq Designer tool v3.0 (http://www.ampliseq.com) specifying high 
specificity, for FFPE DNA, with amplicon range of 125 – 175 bp. Three primer 
pools were needed to achieve >90% NGS coverage of the intended target regions. 
Therefore 30ng of input DNA is required for the library preparation step for this 
gene panel. 
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Table 2-1 Genes chosen for the 22-gene custom targeted next generation sequencing for NSCLC 
samples, and the achievable gene sequence coverage with the current design (exonic regions). Gene 
mutational frequencies compiled from Kandoth, et al (2013)(80). 
Genes Included in this 
Panel 
Mutational Frequency in 
Adenocarcinoma of Lung 
(%) 
Mutational 
Frequency in 
Squamous Cell 
Carcinoma of Lung 
(%) 
Coverage with current 
design (%) 
TP53 51.8 79.3 100 
NRAS 1.8 0.6 100 
PGDFRA 6.6 4.0 100 
MTOR 7.5 4.6 99.36 
DDR2 4.0 2.5 – 3.8 100 
KIT 1.8 3.5 100 
EGFR 11.4 2.9 99.93 
MET 25 25 99.87 
BRAF 6.6 4.6 98.59 
FGFR2 3.1 2.3 99.81 
BRCA2 5.7 5.8 98.68 
AKT1 0.0 0.6 95.1 
MAP2K1 1 1 93.11 
BRCA1 5.2 3.5 99.86 
CDKN2A 6.6 14.9 44.47 
PTEN 2.2 8.1 96.77 
KRAS 26.3 1.2 100 
NF1 11.8 10.3 98.15 
STK11 8.8 1.7 72.77 
FLT3 4.0 4.0 97.7 
ERBB2 2-4 2-4 91.97 
PIK3CA 4.4 14.9 97.8 
 
2.5.3 Cancer Hotspot Panel 
 
In addition to the custom 22-gene panel, above, an off-the-shelf, Cancer Hotspot 
Panel (v2) (LifeTechnologies) was also used. This specifically covered 50 cancer 
mutation “hotspot” regions in contained within known oncogenes and tumour 
suppressor genes, and only required one primer pool per DNA sample (a total of 
10ng of input DNA). 
 
2.5.4 Input DNA requirements 
 
At least 10% of the nucleated cells in the FFPE tumour tissue samples had to be 
tumour cells. There was a minimum requirement for a least 10ng of DNA for NGS 
using the Ion Ampliseq library preparation method. 
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2.5.5 Library Preparation 
 
NGS library preparation was performed using the Ion AmpliSeq™ targeted panel 
method, using the manufacturer’s Ion AmpliSeq™ Library Kit 2.0 User Guide 
(LifeTechnologies part of ThermoFisher Scientific, UK)(118). The initial 
polymerase chain reaction (PCR) amplification of the sample DNA was 
performed with the primer poola, with 20-25 cycles of the initial PCR, depending 
on the amount of input DNA. The flanking DNA sequences of the resulting 
amplicons were treated with the restriction endonuclease FuPa, to enable the 
addition of DNA ‘barcode’ sequences and adapter DNA sequences. After this, 
amplicons are bound to Agencourt® AMPure® XP magnetic beads (Beckman 
Coulter) and washed in ethanol, and eluted into a nested PCR for library 
enrichment. The enriched library is again bound to Agencourt® AMPure® XP 
magnetic beads (Beckman Coulter) and washed with ethanol. The resulting 
libraries were eluted in LowTE buffer, and concentrations were determined 
using Qubit (High Sensitivity kit) (Agilent Technologies), as above, with target 
concentrations 300-1500 ng/ml. 
 
Libraries were further diluted in LowTE to obtain a final concentration of ~100 
pM (equivalent to 15ng/ml for amplicons up to 225bp). Diluted, bar-coded 
libraries were then combined together, ready for template preparation and 
sequencing. 
 
The following equation was used to determine the number of DNA samples that 
can be sequenced per microchip, as a function of the number primer pools per 
panel and the desired average sequence depth (per amplicon). To calculate an 
approximate minimum sequencing depth, then the average sequencing depth is 
divided by a factor of 5, as advised by the field application scientist 
(LifeTechnologies part of ThermoFisher Scientific). 
                                                         
a Either the 50-gene cancer hotspot panel primer pool, or the 3 primer pools that 
make up the custom 22-gene NSCLC panel. 
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No. of 
Samples 
   70,000,000b   
 = No. of 
primer 
pools per 
library  
x No. of 
amplicons 
per primer 
pool 
x average 
sequencing 
depth per 
amplicon 
 
 
For this project, minimum sequencing depths were set at 100x for germline DNA, 
1000x FFPE tumour DNA, and an average sequence depth was set at 25000x for 
ctDNA. 
 
2.5.6 Planning the Run 
 
Each sequencing run was planned on the Ion Torrent Server 
(https://www.thermofisher.com/uk/en/home/life-science/sequencing/next-
generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-
torrent-next-generation-sequencing-data-analysis-workflow/ion-torrent-suite-
software.html), whereby each barcode used in the library was attributed to the 
research ID of the DNA sample. 
2.5.7 Template Preparation 
 
Template preparation and Ion Proton microchip loading was performed using 
the Ion Chef, according to manufacturer’s user guide (Ion PI™ Hi-Q™ Chef Kit – 
User Guide (ThermoFisher Scientific), Catalogue No. A27198, Publication No. 
MAN0010967, Revision A.0 27 March 2015). Calibration of chip loading densities 
obtained, demonstrated that, in our hands, greater chip loading densities were 
obtained using a combined loading sample of 75 pM, rather than the 50 pM 
recommended in the user guide, without compromising loading quality. 
 
 
                                                         
b 70 Million is the number of individual sequencing wells on the IonProton 
Sequencing Chip. 
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2.5.8 Sequencing 
 
Sequencing runs were performed on the Ion Proton machine, over 150 minutes 
in line with manufacturer’s recommendations. Resulting data were then 
downloaded from the Ion Torrent Server. 
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2.5.9 NGS In-Silico Variant analysis 
 
For each sample, resulting raw sequence data files (BAM and BAI) files, and data 
files containing sequence depth per amplicon per sample, were downloaded 
from the Ion Torrent Server. 
 
The Ion Torrent Server also provided an Ion Torrent Variant Caller, for each 
sample, and resulting variant called data files (variant caller files (VCF)) were 
downloaded as Microsoft Excel spreadsheets. 
2.6 Bioinformatics 
2.6.1 VarScan 
 
The open access VarScan version 2.4.0 (August 2015)(124), bioinformatics tool 
was used to analyse the raw sequencing data BAM files, to optimise low level 
sequence variants. 
 
To facilitate somatic variant discovery, VarScan was also utilised to compare 
variants detected in genomic DNA, FFPE-embedded tumour DNA and ctDNA 
samples. Resulting variants were then annotated as being germline, somatic or 
loss of heterozygosity, based on comparisons between the 3 DNA populations. 
2.6.2 Annovar 
 
Novel genetic variants were identified within VCF files from the Ion Torrent 
Variant Caller and VarScan. The open access bioinformatics tool ANNOVAR(125) 
was used to characterize genetic sequence variants by comparison of genetic 
changes contained within databases of variants (COSMIC, dbSNP, 1000Genomes 
and Sift).  
2.6.3 Integrative Genomics Viewer (IGV) 
 
Genetic sequence changes contained within an amplicon was visually inspected, 
by loading BAM files into the software Integrative Genomics Viewer (IGV)(126). 
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2.6.4 Alamut 
 
In order to classify genetic sequence changes into pathogenic mutations, single 
nucleotide polymorphisms (SNPs) or sequence changes of unknown significance, 
in silico-analysis was performed using Alamut® Visual software (Interactive 
Biosoftware). This software predicts the nature of the genetic change, reporting 
whether the change is intronic or exonic, mis-sennse, non-sense, and whether it 
effects gene splicing. For any given genetic sequence change, this software also 
searches the on-line databases including COSMIC and dbSNP, to determine 
whether the genetic mutation has been previously described. 
 
2.6.5 Limit of Detection 
 
Tru-Q Reference Standard DNA (HorizonDiscovery), is commercially available 
combined DNA from 10 engineered human cancer cell lines. This contains a 
panel of known pathogenic mutations, at known allelic frequencies determined 
by droplet digital PCR, for example Table 2-1. AKT1 wild type reference standard 
(HorizonDiscovery), is genomic DNA derived from human cell line MCF10A. 
 
AKT1 wild-type human genomic DNA was ‘spiked’ with reference standard DNA 
(TruQ1), containing known pathogenic mutations at known frequencies 
(obtained from HorizonDiscovery), to mimic the presence of ctDNA mutations 
against a background of total circulating cell free DNA. NGS was then performed 
on these samples (in triplicate), using the 50 gene cancer hotspot panel. 
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Table 2-2 Panel of genetic mutations contained within reference standard DNA TruQ1 
(HorizonDiscovery), commercially available at 50 ng/µl. Adapted from 
https://www.horizondiscovery.com/tru-q-1-5-tier-reference-standard-hd728 (accessed 4.2.2018) 
Gene  Variant  Expected Allelic Frequency, % 
BRAF  V600E  8.0% 
BRAF  V600K  4.0% 
EGFR  G719S  16.7% 
EGFR  T790M  4.2% 
FLT3  ΔI836  5.0% 
IDH1  R132C  5.0% 
JAK2  V617F  5.0% 
KRAS  G12A  5.0% 
KRAS  G12R  5.0% 
KRAS  G13D  25.0% 
MEK1  P124L  5.0% 
NOTCH1  L1600P  4.8% 
NRAS  Q61K  5.0% 
PIK3CA  H1047R  30.0% 
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2.7 Droplet Digital Polymerase Chain Reaction (ddPCR) 
2.7.1 ddPCR Reaction 
 
Droplet Digital PCR reaction mixes were set up in a total volume of 25ul in 
ddPCR supermix containing template DNA at 50fg to 100ng plus, primers, and 
fluorescently labelled probes (FAM (carboxyfluorescein) for mutant probe and 
HEX (6-carboxy-2 ,4,4 ,5 ,7,7 -hexachlorofluorescein succinimidyl ester) for wild-
type probes) at final concentrations of 450mM and 250nM, respectively (Table 
2-2). 
 
Table 2-3 Droplet Digital PCR Set-up Protocol. 
Component Volume Per Reaction (μl) Final Concentration 
2x ddPCR supermix for 
probes (no dUTP) 
12.5 1x 
20x target 
primers/probe (FAM) 
1.25 450 nM primers/250 nM 
Probe 
20x wild type 
primers/probe (HEX) 
1.25 450 nM primers/250 nM 
Probe 
DNA sample γ * 
Water 10 - γ  
Final Volume (μl) 25  
*γ = 50 fg to 100 ng 
 
22 μl of each reaction then dispersed into approximately 20,000 droplets, using 
the QX200™ Droplet Generator (BioRad), aiming for an average of 1 copy of DNA 
per droplet, given a range of input DNA (50fg – 100ng), based on a Poisson 
distribution. The reaction mix containing droplets are transferred to a clean 96-
well Eppendorph plate for use in the T100 (BioRad) thermal cycler and later the 
QX200™ Droplet reader (BioRad). 
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Table 2-4 Droplet Digital PCR Cycling Conditions 
Cycling Step Temperature, 
°C 
Time Ramp Rate No. of 
cycles 
Enzyme Activation 95 10 min ~ 2°C/sec 1 
Denaturation 94 30 sec ~ 2°C/sec 40 
Annealing/Extension * 1 min ~ 2°C/sec 
Enzyme Deactivation 98 10 min ~ 2°C/sec 1 
Hold 4 infinite ~ 1°C/sec 1 
Heated lid at 105°C and sample volume set to 45μl. 
* Temperature gradient 65°C to 50°C, or optimal annealing temperature for a 
specific primer/probe set. 
 
The water-oil emulsion based PCR was performed on a T100 (BioRad) thermal 
cycler. PCR was performed as per the protocol in Table 2-3. After PCR, the 96-
well plates were briefly centrifuged, to bring the samples to the bottom of the 
wells, and placed on the QX200™ Droplet reader (BioRad). The template was set-
up using the QuantaSoft software, and resulting data was collected and analysed 
using the same software. 
2.8 Defining the Rain 
 
Droplet digital technology aims to classify individual droplets as positive or 
negative based on the degree of fluorescence signal for each droplet, for 
particular fluorophore (either FAM (mutant probe) or HEX (wild-type probe). 
However, there are still some droplets with intermediate fluorescence values 
which fall between those that are positive and those that are negative, and these 
droplets are known as ‘noise’ or ‘rain’. In order to overcome potential problems 
of data interpretation resulting from ‘rain’, minimum fluoresence amplitude 
thresholds are calculated for each droplet digital PCR data file, using a free, open 
access bioinformatics pipeline called ‘definetherain’ 
(http://www.definetherain.org.uk). After defining fluorescence apliture 
thresholds, Quantasoft was used to determine number and ratio of positive and 
negative droplets per PCR reaction. 
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2.9 Annealing Temperature Optimisation 
 
For each ddPCR primer/probe set, and 10ng of a reference standard DNAc, a 
temperature gradient was performed during the annealing phase, to determine 
the optimum annealing temperature, according to the PCR protocol in table 2-3. 
Fluorescent cut off values were determined for each temperature point using 
‘definetherain’, and the no-template controls (NTCs) were analysed using the 
same cut offs, to ensure that no false positive droplets were detected. For all 
primer and probe sets, the optimum annealing temperatures were between 
53.0°C and 55.7°C. 
                                                         
c Tru-Q tier 1 reference standard DNA (Horizon Discovery) contains a panel of known mutations at know alternate allele 
frequencies. 
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2.10 Other Molecular DNA Techniques 
2.11 Pyrosequencing 
 
An initial PCR mix is made with 12.5µl of 10x MegaMix Goldd, 0.5 µl (at 
10pmol/µl) F&R biotinylated primers for pyrosequencing (Table 2-4), 10µl 
water and 20ng of DNA, in a final reaction volume of 25µl. 
                                                         
d Proprietary reagent (Cambio Ltd. Cambridge, UK) provides a final reaction 
concentration of 2.5 mM MgCl2, 1 unit of Taq polymerase, high purity dNTPs, 
reaction buffer and enzyme stabilizer. 
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Table 2-5 Pyrosequencing PCR Primers. Btn = Biotin 
Gene Exon Primer Name Primer Sequence 
EGFR 
18 
EGFR_18_F ATGGTGAGGGCTGAGGTGAC 
EGFR_18_Btn_R [Btn]TATACACCGTGCCGAACGC 
T790M 
EGFR_T790M_F GTCTTTGTGTTCCCGGACAT 
EGFR_T790M_Btn_R [Btn]GCATCTGCCTCACCTCCAC 
20 
EGFR_20v2_F CGAAGCCACACTGACGTG 
EGFR_20v2_Btn_R [Btn]GGTGGAGGTGAGGCAGATG 
21 EGFR_21_F GAAAACACCGCAGCATGTCAA 
 EGFR_21_Btn_R [Btn]CCTCCTTCTGCATGGTATTCTTTC 
KRAS 
2 
(codons 
12&13) 
KRAS_c12&13 _F GACTGAATATAAACTTGTGGTAGTTGG 
KRAS_c12&13_Btn_R [Btn]TTGGATCATATTCGTCCACAA 
3 
(codon 
61) 
KRAS_c61 _F CAGGAAGCAAGTAGTAATTGATGG 
KRAS_61_Btn_R [Btn]AAGAAAGCCCTCCCCAGTC 
4 
(codon 
146) 
KRAS_c146_F AGGCTCAGGACTTAGCAAGAAGTT 
KRAS_c146_Btn_R [Btn]GATTAAGAAGCAATGCCCTCTC 
PIK3CA 
9v2 
PIK3CA_9v2_F GCACTTACYTGTGACTCCATAGAA 
PIK3CA_9v2_R [Btn]GAAAATGACRAAGAACAGCTCAAA 
9v4 
PIK3CA_9v2_F GCACTTACYTGTGACTCCATAGAA 
PIK3CA_9v2_R [Btn]GAAAATGACRAAGAACAGCTCAAA 
20 
PIK3CA_20B_F GTTCAATGCATGCTGTTTAATTGT 
PIK3CA_20B_R [Btn]CGAAAGACYCTAGCCTTAGATAAA 
 
 58 
The PCR cycle conditions were then as follows: 
Table 2-6 Initial PCR for EGFR/KRAS/PIK3CA pyrosequencing of FFPE tumour DNA 
Cycle Phase Temp. (°C) Time Cycles 
Initial 
Denaturation 
95 10 min 
1 
Denaturation 95 30 Seconds 
35 Annealing 60 30 Seconds 
Synthesis 72 30 Seconds 
Final Synthesis 72 10 min 1 
Hold 4 ∞  
 
40μl of primer/annealing buffer mix is added to each well in a separate clean 
low-well PyroMark Q96 plate. This consists of a final concentration of 0.4μM 
sequencing primer (Table 2-6) in 1x PyroMark Annealing Buffer (Qiagen). 
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Table 2-7 Pyrosequencing Primers 
Gene Exon Primer Name Primer Sequence 
EGFR 
18 EGFR_18_pyro GAATTCAAAAAGATCAAAGT 
T790M EGFR_T790M_pyro CGAAGGGCATGAGC 
20 
EGFR_20Av2_pyro CCCTCCCTCCAGGAA 
EGFR_20Bv2_pyro CAGGAAGCCTACGTGA 
21 EGFR_21A_pyro AAGATCACAGATTTTGG 
 EGFR_21B_pyro ATTTTGGGCTGGCCAAAC 
KRAS 
2 KRAS_c12&13_pyro CTTGTGGTAGTTGGAG 
2* KRAS12&13_seqA3 TGTGGTAGTTGGAGCTG 
3 K-ras_c61_pyro GGATATTCTCGACACAGC 
4 KRAS_c146v2_pyro GGAATTCCTTTTATTGAAAC 
PIK3CA 
9v2 PIK3CA_9v2_pyro CCTGTGACTCCATAGAAAA 
9v4 PIK3CA_9v4_pyro CCATAGAAAATCTTTCTCC 
20 PIK3CA_20B_pyro TTTGTTGTCCAGCCA 
 
PCR products from the initial PCR were immobilized onto streptavidin 
SepharoseTM beads, by adding 55μl buffer/beads master mix (2μl streptavidin 
beads, 40μl 1x PyroMark Binding Buffer, 13μl sterile water) to each PCR product, 
and mixed for 10 minutes at room temperature. Using a vacuum pump manifold 
(Qiagen), the bead-bound DNA is washed in 70% ethanol for 5 seconds, followed 
by the denaturation solution (0.2M NaOH) for 5 seconds, and a further wash 
solution (PyroMark Wash Buffer (Qiagen)) for 10 seconds. The vacuum is 
switched off to release the cleaned/denatured PCR products into the low-well 
PyroMark Q96 plate containing sequencing primer and annealing buffer. 
 
To anneal the sequencing primer, this plate was placed onto a thermocycler and 
heated to 80 °C for 2 mins, removed, and allowed to cool to room temperature 
for 10 minutes. 
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The low-well PyroMark Q96 plate was loaded into a PyroMark Q96 machine 
along with a reagent cartridge containing loaded with dNTPs and the key 
enzymes; DNA polymerase, ATP sulfurase, firefly luciferase and apyrase. The 
sequencing is run using the PyroMark Q96 v2.5.8 software (Qiagen). Raw 
sequencing data files were visualized as pyrograms using the same software. 
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2.12 EGFR Analysis – Fragment Sizing 
 
Fluorescently labeled PCR primers (Table 2-7) amplify exon 19 or exon 20 of 
EGFR. PCR product fragment sizes are analysed with the ABI 3730 genetic 
analyser. A PCR product larger or smaller than the normal allele size indicates 
the presence of an insertion or deletion respectively. Samples are analysed 
alongside a negative control (H2O), a normal control for each exon and positive 
control for each exon, namely an exon 19 deletion and an exon 20 insertion. 
 
The initial PCR reaction mix contains 5µl 10x Megamix Gold, 0.5µl (final 
concentration 10pm/µl) fluorescently labelled forward and reverse primers 
(Table 2-7), 3.5µl dH2O and 10ng DNA, in a final reaction volume of 10µl. The 
PCR thermo-cycle conditions are given in Table 2-8. 
 
Table 2-8 Primer Sequences for the fragment sizing assay [EGFR exon 19 and exon 20] 
 
Table 2-9 Thermo-cycling condition for EGFR fragment length analysis. 
Cycle Phase Temp. (°C) Time Cycles 
Initial 
Denaturation 
95 5 min 
1 
Denaturation 95 30 s 
27 Annealing 60 30 s 
Synthesis 72 45 s 
Final Synthesis 72 5 min 1 
Hold 4 ∞  
 
 
Exon Primer Name Primer Sequence 
19 
EGFR_19v2_FAM_F [6FAM]ACTCTGGATCCCAGAAGGTGA 
EGFR_19v2_GS_R ACACAGCAAAGCAGAAACTCA 
20 
EGFR_20v4_HEX_F [HEX]CGAAGCCACACTGACGTG 
EGFR_20v4_GS_R GGTGGAGGTGAGGCAGATG 
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2.12.1 COLD-PCR 
 
COLD-PCR is a nested PCR. The initial PCR with external primers is set-up 
according to Table 2-9, with cycling conditions Table 2-10. The secondary PCR is 
set-up according to Table 2-12 or 2-13 depending on the downstream 
application, with cycle conditions in Table 2-11. 
 
Table 2-10 Primary COLD-PCR set-up 
Reagent Final Conc. 1x (µl) 
Megamix Gold 1x 12.5 
F + R External 
Primer Mix* 
10 pmol/µl 1.0 
dH2O  9.5 
DNA (10ng/µl)  2.0 
Total  25.0 
* See Tables 2-10 for primer sequences. 
 
Table 2-11 External Primer Sequences for COLD-PCR 
Gene Exon Primer Name Primer Sequence 
EGFR 
18 
EGFR_18_eF GGCACTGCTTTCCAGCAT 
EGFR_18_eR CCCCACCAGACCATGAGA 
19 
EGFR_19v2_eF GCTGGTAACATCCACCCAGA 
EGFR_19v2_eR GGCCAGTGCTGTCTCTAAGG 
20* 
EGFR_20_eF CATTCATGCGTCTTCACCTG 
EGFR_20v2_eR CCGTATCTCCCTTCCCTGAT 
21 
EGFR_21_eF GCAGAGCTTCTTCCCATGAT 
EGFR_21_eR AGGAAAATGCTGGCTGACCT 
KRAS 
2 
KRAS_12&13_eF AAAAGGTACTGGTGGAGTATTTGA 
KRAS_12&13_eR TCATGAAAATGGTCAGAGAAACC 
3 
KRAS_61_eF TTTTTGAAGTAAAAGGTGCACTG 
KRAS_61_eR TTTAAACCCACCTATAATGGTGAA 
PIK3CA 
9 
PI3KCA_9_eF TGAGATCAGCCAAATTCAGTT 
PI3KCA_9_eR GGGAAAAATATGACAAAGAAAGC 
20 
PI3KCA_20_eF GGAATCCAGAGTGAGCTTTCA 
PI3KCA_20_eR TTCTCAATGATGCTTGGCTCT 
* Exon 20 external primers are used as the primary primers for T790M, 20A, 20B 
pyro and exon 20 fragment analysis assays.
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Table 2-12 Primary COLD-PCR Cycle Conditions 
Cycle Phase Temp. (°C) Time Cycles 
Initial 
Denaturation 
95 5 mins 1 
Denaturation 95 30 s 
20 Annealing 60* 30 s 
Synthesis 72 45 s 
Final Synthesis 72 5 mins 1 
*For PIK3CA Exon 9 use 61 °C, and PIK3CA Exon 20 use 63 °C. 
Secondary COLD-PCR Reaction (for use with subsequent pyrosequencing) 
 
Table 2-13 Secondary COLD-PCR Reaction (replaces initial PCR reaction for Pyrosequencing) 
Reagent Final Conc. 1x (µl) 
Megamix Gold 1x 12.5 
F + R Primer Mix* 10 pmol/µl 0.5 
dH2O  11.0 
PCR Products 
from Primary 
COLD-PCR 
Neat 1.0 
Total  25.0 
*Primer sequences as per Table 2-13, unless for EGFR Pyrosequencing (use 
primers in Table 2-6) or EGFR fragment length analysis (use primers in Table 2-
7) 
 
Table 2-14 Pyrosequencing COLD-PCR Internal primers 
Exon Primer Name Primer Sequence 
18 
EGFR_18_F ATGGTGAGGGCTGAGGTGAC 
EGFR_18_Btn_R [Btn]TCCCTCCAGGAAGCCTACG 
T790M 
EGFR_T790M_F TTGCGATCTGCACACACC 
EGFR_T790M_Btn_R [Btn]GCATCTGCCTCACCTCCAC 
20 
EGFR_20v2_F TGCGAAGCCACACTGACG 
EGFR_20v2_Btn_R [Btn] GCACACGTGGGGGTTGTC 
21 
EGFR_21_F GAAAACACCGCAGCATGTCAA 
EGFR_21_Btn_R [Btn]CCTCCTTCTGCATGGTATTCTTTC 
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Table 2-15 Fragment sizing COLD-PCR primers [EGFR exon 19 and exon 20] 
 
Table 2-16 Secondary COLD-PCR Cycle Conditions 
Cycle Phase Temp. (°C) Time Cycles 
Initial 
Denaturation 
95 2 mins 1 
Denaturation 95 15 s 
10 Annealing 60 30 s 
Synthesis 72 1 min 
Denaturation 95 15 s 
25 
Hybridisation 70 8 mins 
Critical 
Denaturation 
(see Table 2-16) 3 s 
Annealing 60 30 s 
Synthesis 72 1 min 
 
Table 2-17 Critical Denaturation Temperatures for Secondary COLD-PCR reaction 
Gene Assay Pyrosequencing 
Critical Temp. (°C) 
Fragment Size 
Critical Temp. (°C) 
EGFR 
Exon 18 85.4 N/A 
Exon 19 N/A 82.0 
Exon 20 85.4 88.3 
Exon 21 81.4 N/A 
T790M 88.3 N/A 
KRAS 
Codon 12/13 80.6 N/A 
Codon 61 81.3 N/A 
PIK3CA 
Exon 9 78.3 N/A 
Exon 20 79.7 N/A 
Exon Primer Name Primer Sequence 
19 
EGFR_19_FAM_F [FAM]CGTCTTCCTTCTCTCTCTGTCA 
EGFR_19_GS_R CCACACAGCAAAGCAGAAAC 
20 
EGFR_20_HEX_F [HEX]CTCCAGGAAGCCTACGTGAT 
EGFR_20_GS_R GTCTTTGTGTTCCCGGACAT 
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2.12.2 Sanger Sequencing 
 
DNA extracted from FFPE tumour tissue was first amplified using a PCR and M13 
tagged primer sequences as per table 2-17. This initial PCR has a final reaction 
volume of 25 µl, and a final concentration of 1x Megamix Gold, 25 pmol/µl 
Forward and Reverse primer mix and 20ng of DNA. In the thermocycler, samples 
are preheated to 95°C for 5 minutes, followed by 30 cycles of denaturation 
(95°C for 1 minute), annealing (60°C for 1 minute) and extension (72°C for 1 
minute). There is a final extension at 72°C for 7 minutes, then hold at 4°C. 
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Table 2-18 Dideoxy-sequencing primer sequences. Underlined sequences = M13 tag sequences. 
Gene Exon Primer Name Primer Sequence 
EGFR 
18 EGFR_18v2_MF tgtaaaacgacggccagtGGCACTGCTTTCCAGCAT 
 EGFR_18v2_MR caggaaacagctatgaccCCCCACCAGACCATGAGA 
19 EGFR_19v2_MR caggaaacagctatgaccCAGGGTCTAGAGCAGAGCAG 
 EGFR_19v2_MF tgtaaaacgacggccagtAGCATGTGGCACCATCTC 
20 EGFR_20v2_MF tgtaaaacgacggccagtCATTCATGCGTCTTCACCTG 
 EGFR_20v2_MR caggaaacagctatgaccCATATCCCCATGGCAAACTC 
21 EGFR_21v2_MF tgtaaaacgacggccagtATTCGGATGCAGAGCTTCTT 
 EGFR_21v2_MR caggaaacagctatgaccTGGCTCACACTACCAGGAGA 
KRAS 
2 (codon 
12&13) 
KRAS_c12&13_MF tgtaaaacgacggccagtCTTAAGCGTCGATGGAGGAG 
KRAS_c12&13_MR caggaaacagctatgaccAGAATGGTCCTGCACCAGTAA 
3 (codon 
61) 
KRAS_61v2_MF tgtaaaacgacggccagtTGTTTCTCCCTTCTCAGGATTCCTA 
KRAS_61v2_MR caggaaacagctatgaccAGAAAGCCCTCCCCAGTCC 
PIK3CA 
1A 
PIK3CA_1A_MF tgtaaaacgacggccagtAGCCTAATTTAGAGCAACAGTCTAGAT 
PIK3CA_1A_MR caggaaacagctatgaccAGGGGGTATTTTCTTGCTTCTTTAAATA 
1B 
PIK3CA_1B_MF tgtaaaacgacggccagtTCCACGACCATCATCAGGTGAACT 
PIK3CA_1B_MR caggaaacagctatgaccAGATTACGAAGGTATTGGTTTAGACAGAAA 
9 
PIK3CA_9_MF tgtaaaacgacggccagtAGAGACAATGAATTAAGGGAAAATGACAA 
PIK3CA_9_MR caggaaacagctatgaccAATCTCCATTTTAGCACTTACCTGTGAC 
20 
PIK3CA_20_MF tgtaaaacgacggccagtTGGTAAGAGAAGTGAGAGAGGAATGCT 
PIK3CA_20_MR caggaaacagctatgaccACAGTGCAGTGTGGAATCCAGAGTG 
 
The PCR products were cleaned to remove excess dNTPs and primers. To do this 
AMPure beadse bound to PCR products were washed in 70% ethanol. DNA was 
then eluted into sterile water, and transferred into a clean PCR plate. 
 
Sanger sequencing of the PCR-derived fragments was performed using the 
BigDye Terminator v1.1 system (ThermoFisher Scientific), setting up forward 
                                                         
e AMPure (Agencourt) Beads (Beckman) 
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and reverse reactions separately. The sequencing reaction is set-up using final 
concentrations of 1x BigDye v1.1f, 100 pmol/µl Forward OR Reverse M13 primer 
(Eurogentec), 1X Sequencing Bufferg and neat, cleaned PCR product. 
 
The samples are placed in the thermocycler at 94°C for 2 minutes, followed by 
25 cycles of denaturation (94°C for 10 seconds), annealing (50°C for 5 seconds) 
and elongation (60°C for 4 minutes). A subsequent clean-up of sequencing 
products was performed to remove excess dye terminators using the 
Agencourt’s paramagnetic bead technology - CleanSEQh method, and washed in a 
higher concentration of ethanol (85%), to prevent loss of the smaller DNA 
fragments. The final cleaned DNA products are eluted into 0.04 mM EDTA 
solution. 
 
Capillary electrophoresis, using POP-7 polymer (Applied Bios. 
(LifeTechnologies)), in a 3730 DNA analyser machine (ThermoFisher Scientific), 
is performed on the cleaned sequencing products to generate 
electropherograms, according to manufacturers protocol. Raw sequence data in 
the form of electropherograms are then visually inspected using Mutation 
Surveyor® software v4.0.8, a DNA variant analysis software from SoftGenetics®. 
 
 
 
                                                         
f Commercially available proprietary reaction mix (ThermoFisher Scientific) 
contains DNA polymerase, dNTPs, fluorescently labelled ddNTPs. 
g Proprietary Buffer - 5X Sequencing Buffer (For use with BigDye® Terminator 
v1.1 & v1.3) (Applied Bios, LifeTechnologies) 
h CleanSEQ (Agencourt) (Beckman) 
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3 Detection of ctDNA in Lung Cancer Patients using NGS and 
ddPCR 
 
3.1 Background 
 
The amount of total cell free DNA available from a blood sample is generally very low, 
for example, previously reported as 24.3 ng/ml in patients with lung cancer(127). 
Circulating tumour DNA (ctDNA) represents only a fraction of total circulating cell free 
DNA. The fraction of ctDNA present in the circulation is dependent on tumour type, 
tumour stage and whether the patient has received any anti-cancer therapies. 
 
It is essential to clearly establish the feasibility of obtaining, and analysing ctDNA in 
patients with advanced lung cancer, so that conclusions relating to the clinical context 
and clinical impact can subsequently be made. To do this, genetic analysis techniques 
must be able to detect a low frequency ctDNA mutation “signal”, against background 
wild-type genomic cell free DNA “noise”. The ratio of mutant DNA to total ‘wild-type’ 
DNA is known as alternate, or variant allele frequency. 
 
It is important to explore the limits of detection in ctDNA analysis, as mutations usually 
occur at low alternate allele frequency, for example between 0.1 – 5%(112). The clinical 
consequences of false negative results could be significant. There is currently a lack of 
data in the literature regarding lower limits of mutation detection in ctDNA in terms of 
the clinical consequences for lung cancer. 
 
Next generation sequencing (NGS), and droplet digital PCR (ddPCR) are two major 
technologies available for DNA sequence analysis. They can be used for DNA derived 
from tumour tissue and ctDNA. Droplet digital PCR is widely considered to be a more 
sensitive and specific approach to analysing mutations contained within ctDNA. 
However, unlike NGS, which can interrogate multiple mutations simultaneously, ddPCR 
can only detect the presence of very specific mutations. However, the amplification 
phase of NGS can generate low-level sequence artifacts. When applied to ctDNA 
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analysis, it is therefore important to be able to differentiate between low level ‘true 
positive’ mutations, and low level ‘false positive’ mutations. 
 
Different software bio-informatics tools exist for the analysis of NGS genetic sequence 
data, and can detect different rare alleles, with different degrees of sensitivity and 
specificity. Technical exploration is needed into better defining the lower limits of 
detection of the Ion Torrent NGS platform, used in this thesis. Specifically, NGS data is 
compared, using a customised open access software analysis and annotation tool 
(VarScan(128) with Annovar(125)), with the software tool available with the Ion 
Torrent NGS platform, namely the Ion Torrent Variant Caller (ITVC). 
 
We have used NGS and ddPCR technologies to investigate mutations in ctDNA from lung 
cancer patients, to see whether we should use either, or both, in subsequent research in 
this thesis. 
3.2 Chapter Aims 
This chapter aims to define some of the biological and technical factors that influence 
the ability to detect low-level mutations using NGS and ddPCR. Specific chapter aims are 
to: 
• Using DNA derived from cancer cell lines: 
o Assess the limit of mutation detection of NGS, using the Ion Proton NGS 
platform, and comparing VarScan(128) with Annovar(125) and ITVC. 
o Assess the level of background sequence changes generated by Ion 
Torrent NGS platform. 
o Assess the limit of mutation detection of ddPCR, as a function of the 
amount of input DNA. 
• Using DNA derived from patient samples, and experience gained from cell line 
DNA:  
o Assess the influence of clinical features of lung cancer, including stage and 
histological subtype of disease, on total cell free DNA levels. 
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3.3 Chapter Results 
3.3.1 Limit of mutation detection using NGS 
 
Comparative sequence data, analysed using two different bioinformatics software, 
revealed a difference in the ability to detect all of the expected mutations, and both 
software tools had different limits of detection (Figure 3-1).  The VarScan(128) with 
Annovar(125) bioinformatics software tools were able to detect all of the expected 
mutations. ITVC invariably failed to detect the FLT3 p.836_837delI mutation, regardless 
of alternate allele frequency of the mutation (Figure 3-1). This FLT3 mutation is 
important in acute myeloid leukaemia(129), so the inability to detect this mutation may 
have important implications for certain clinical applications in this disease(130). 
 
VarScan(128) with Annovar(125) was able to consistently detect mutations at lower 
alternate allele frequency (consistently as low as 0.5% alternate allele frequency), ITVC 
was only able to detect mutations confidently, at a minimum of 5% mutant allele 
frequency - a 10 fold higher limit of detection than VarScan with Annovar. The majority 
of mutations in ctDNA usually exist in the 0.1 – 5% alternate allele frequency 
range(112). Of the two software tools compared here, VarScan with Annovar is 
preferred to ITVC for clinical ctDNA mutations detection, since it offers a lower limit of 
mutation detection. VarScan and Annovar has subsequently been the preferred choice 
for all analysis of other NGS data generated in this thesis. 
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Figure 3-3 Limits of detection of spiked, mutant DNA against a background of wild-type DNA, using NGS and a 50-gene hotspot panel and 2 different software analysis tools (ITVC and 
VarScan), prior to application to ctDNA analysis. 
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3.4 NGS Background levels of noise 
 
50 gene cancer hotspot panel NGS analysis of all of the DNA samples in the previous 
section revealed the presence of many other genetic sequence changes, in addition to 
the mutations known to be present in the DNA samples. The total number of sequence 
changes differed depending on the software used to detect them (Figure 3-2, panel C). 
The total number of variants detected by ITVC ranged from 11 to 42. This reflects that 
this software only identifies sequence changes that are present with an alternate allele 
frequency of >5%. The total number of variants detected using VarScan with Annovar 
were filtered so that only variants with a COSMIC ID were included. Using this method, 
the average number of variants detected ranged from 527 to 645 for SNPs 
(approximately 100 fold greater than ITVC), and 66 to 82 for Insertions/Deletions 
(approximately 10 fold greater). Data generated from VarScan with Annovar revealed 
that the bulk (95%) of the genetic variations, occur at the level of 0.1% alternate allele 
frequency or less. Less than 5% of the total variants occur at an alternate allele 
frequency of greater than 1% (Figure 3-2, panels A & B). It is thought that the vast 
majority of these ‘low level’ sequence changes are due to ‘sequence artefacts’ as a result 
of amplification errors during the NGS process. In terms of using NGS for ctDNA 
analysis, care must be taken when deciding whether a very low level genetic sequence 
variation (for example, an alternate allele frequency of less than 0.1%), represents a 
true somatic mutation contained within ctDNA, or whether it is sequencing artefact. In 
keeping with the literature, it is extremely difficult to differentiate between ‘true-
positive’ changes and ‘false-positive’ changes, though there have been attempts to 
increase confidence in identifying ‘true-positive’ mutations by setting alternate allele 
frequency ‘thresholds’. 
 
To summarise, VarScan with Annovar appears satisfactory in detecting the presence of a 
known genetic mutation, with a 10-fold greater sensitivity of detection, compared to 
ITVC. This appears to be at the expense of a significantly increased number of total 
variants detected, many of which are ‘sequence artifact’. Therefore, for the purposes of 
this thesis, to increase the changes of detecting clinically relevant genetic mutations, the 
NGS data is filtered according to changes occurring in exons, that are likely to result in a 
non-synonymous protein change, and that may have already been previously 
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catalogued in a database such as COSMIC. When a suspected ‘true-postive’ low-level 
mutation is detected by NGS, a second genetic analysis technique will be used to confirm 
the presence of that mutation, mostly in the form of ddPCR. 
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Figure 3-1 Total numbers of genetic sequence changes detected by NGS. Box-and-whisker plots (i) 
and histograms (ii) showing alternate allele frequencies for total variants, for samples containing 
known mutations at an alternate allele frequency of 0.01% (A) and 0.5% (B). The average total 
number of variants detected, at decreasing allele frequencies, with each software, is shown (C). 
Error Bars shown represent 95% CI.  
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3.5 Limit of Detection for Droplet Digital PCR  
 
Droplet digital PCR is able to more confidently detect a specific mutation, against a 
background of wild type DNA, compared with NGS. Mutations occurring as low as 0.01% 
alternate allele frequency can be detected. Increasing, or decreasing the amount of input 
DNA in ddPCR, increases or decreases respectively, the confidence in detecting a ‘true-
positive’ result, compared with a ‘false-positive’ result (Figure 3-3). 
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Figure 3-2 Limit of detection with droplet digital PCR for 6 different tumour-associated mutations. NTC = No 
Template Control. 95% Poisson Error Bars shown. 
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For each of the mutations tested, the resulting minimum level of detection is tabulated 
(Table 3-1), as a function of the amount of input DNA, reflective of the amount of 
circulating cell free DNA that is available from a blood test. 
 
Table 3-1 Minimum level of detection (alternate allele frequency %) for each mutation, using ddPCR 
  Amount of Input DNA 
  5ng 10ng 20ng 
Mutation 
EGFR c.2573T>G p.L858R 1% 0.5% 0.5% 
EGFR c.2369C>T p.T790M 1% 1% 0.5% 
KRAS c.38G>A p.G13D 1% 1% 0.5% 
PIK3CA c.1573G>A 
p.E525K 
0.5% 0.5% 0.1% 
PIK3CA c.1624G>A 
p.E524K 
0.5% 0.5% 0.1% 
PIK3CA c.3140A>G 
p.H1047R 
0.5% 0.5% 0.5% 
 
Comparing data from figure 3-2 with figure 3-3, it is possible to detect mutations at 
lower alternate allele frequencies with ddPCR (0.1% alternate allele frequency for 2 of 6 
tested mutations), compared with NGS using VarScan with Annovar (0.5% alternate 
allele frequency). However, these data confirm that knowledge of the amount of input 
DNA available for ddPCR, crucially relevant when dealing with ctDNA, will impact on the 
sensitivity and specificity of the test, especially when mutations occur at very low 
alternate allele frequencies. It must also be remembered that ddPCR is very specific for 
any given genetic mutation, which is satisfactory if analysing samples for a specific 
mutation (e.g. the EGFR TKi resistance mutation - EGFR c.2369C>T p.T790M) but much 
less satisfactory when screening for a panel of potential mutations, as the amount 
ctDNA is a limiting factor. 
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3.6 Blood sample collection and cell free DNA extraction 
 
In this research project, there were a total of 110 research blood samples taken 
from recruited patients, for total cell free DNA quantitation, and subsequent 
molecular analysis for mutations contained within ctDNA. There are no 
published data regarding factors that influence the total concentration of cell 
free DNA in blood samples from lung cancer patients. Therefore total cell free 
DNA (cfDNA) concentration was compared to tumour stage (III versus IV), 
treatment status (pre-treatment or on-treatment), and duration of blood storage, 
for both SCLC and NSCLC cancer sub-types (Figures 3-4 and 3-5). Concentrations 
of total extracted cell free DNA (ng/ml) was quantified using the Qubit (Agilent 
technologies). Non-parametric comparisons of median values were performed 
using Mann-Whitney-U test. 
 
Statistically significant differences in total cell free DNA concentrations were 
seen in only 2 situations – a comparison of Stage IV SCLC blood samples with 
Stage III SCLC and with Stage IV adenocarcinoma blood samples.  In both cases, 
this may reflect the differing biology of SCLC and NSCLC, with SCLC known to be 
a more aggressive disease, with a higher disease burden. 
 
More specifically, there were 43 blood samples taken from patients with SCLC. A 
statistically significantly higher mean concentration of total cell free DNA was 
seen in patients with stage IV SCLC (n=32, median 20.8 ng/ml, interquartile 
range 12.8 – 37.3 ng/ml)), compared to patients with stage III SCLC (n=11, 
median 11.40 ng/ml, interquartile range 7.56 – 15.34 ng/ml) (p<0.05). This has 
not been previously detected in reports in the literature. This may be a reflection 
of a higher disease volume in patients with stage IV SCLC, compared to stage III. 
 
There was a statistically significantly higher mean concentration of total 
circulating cell free DNA seen, in patients with stage IV SCLC compared to stage 
IV adenocarcinoma of the lung (n=40, median 8.45 ng/ml (interquartile range 
5.96 – 10.13) (p < 0.05) (Figure 5). This may reflect a difference in the biology of 
the two cancer sub-types, or differences in disease volume between the two 
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cancer types, stage-for-stage. For example, there may be more cell free DNA in 
patients with stage IV SCLC, potentially due to a higher disease volume, and/or 
because it is a more aggressive form of lung cancer associated with a poorer 
prognosis. 
  
There were a total of 47 blood samples from EGFRmut+ve lung adenocarcinoma 
patients. There was no apparent difference observed between the 
concentrations of total circulating cell free DNA between the blood samples from 
patients with stage III disease (n=9, median 7.58 ng/ml, (interquartile range 7.02 
– 11.88 ng/ml) and stage IV disease (n=38, median 9.48 ng/ml,  (interquartile 
range 7.47 – 13.82 ng/ml). 
 
Equally, no apparent difference was observed between mean concentrations of 
total cell free DNA between blood samples from EGFRmut+ve lung adenocarcinoma 
patients that were EGFR TKi treatment naïve (n=12, median 8.09 ng/ml, 
(interquartile range 7.46 – 11.68 ng/ml) or receiving EGFR TKi therapy (n=35,  
median 8.02 ng/ml, (interquartile range 7.09 – 12.31 ng/ml). 
 
There is no apparent effect of duration of storage (0 - 4 days) of blood samples 
collected in CellSave blood collection tubes, on the concentration of total cell free 
DNA (Figure 4, panels A iii. & B iii). This is consistent with, and extends previous 
findings for SCLC by Rothwell et al(110). These data are meaningful when 
considering use of ctDNA analyses as biomarkers in routine clinical practice, as 
they suggest that CellSave blood collection tubes represent a feasible method for 
blood collection from lung cancer patients, without reducing the relative 
mutational abundance of ctDNA, compared to ‘wild-type’ genomic cell free DNA.  
This is especially important when there may be a delay in getting the sample to 
the lab, for example the time taken to transport the blood sample from the clinic. 
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Figure 3-3 Potential Factors that may Influence Concentration of total cell free DNA. Box-and-whisker plots shown for patients with Adenocarcinoma of Lung (A) and Small Cell Lung 
Cancer (B), based on stage of disease (i), whether the sample is treatment naïve or not (ii) and the number of days between sample collection and sample processing (iii). * denotes that 
the difference between groups is statistically significant (p<0.05). 
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Figure 3-4 Differences in total cell free DNA (cfDNA) concentrations, between different histological subtypes of lung cancer (A). 
Taking into consideration the effect of stage of disease and the difference between adenocarcinoma and small cell lung cancer 
(B). * denotes that the difference between groups is statistically significant (p<0.05). 
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3.7 Clinical Implications 
 
Detection and molecular characterisation of cancer mutations within ctDNA, 
using NGS or ddPCR, offers the prospect of facilitating personalised cancer 
therapy, using blood samples (“liquid biopsies”) alone, where tumour tissue 
biopsies are unavailable or inadequate for confident diagnosis.  However, it is 
important to define the ability of current technologies to confidently and reliably 
detect low levels of mutations against a background of ‘wild-type’ or genomic 
DNA, since (a) there is often only a small quantity of total circulating cell free 
DNA, and (b) mutations in ctDNA form only a fraction of total cell free DNA, and 
occur mostly between 0.1 – 5% alternate allele frequencies(112). 
 
An advantage of NGS analysis is the ability to detect sequence changes contained 
within a panel of genetic regions, simultaneously, from one sample of DNA. The 
choice of NGS software analysis tool is important in determining the ability to 
detect the presence of mutations, especially at low mutational frequency. 
However, a commonly observed problem with NGS analysis, here and in the 
literature, is the ability to distinguish low level mutations from background ‘NGS 
sequence artefact’, especially where there is a large volume of ‘sequence artefact’ 
at low alternate allele frequencies. 
 
A newer technology, such as third generation sequencing, is where raw DNA is 
sequenced directly, without the need for amplification. This may reduce the 
amount of ‘sequencing artefact’ generated, and this could offer a more sensitive 
technique for confidently detecting low level sequence variants(131). However, 
it is likely to be several years before this technology can be used for assessing 
ctDNA as a biomarker in routine clinical practice, mainly due to accessibility and 
cost issues. 
 
Droplet digital PCR (ddPCR) is a more sensitive molecular technique, compared 
to NGS, both in the literature and in the data presented here. It is currently 
proposed by this thesis, that that the level of mutation detection using ddPCR, is 
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determined by the amount of input DNA, such that, more input DNA is required 
to confidently detect decreasing levels of mutational abundance. This is of direct 
relevance to using ddPCR for ctDNA analysis since the average concentration of 
total circulating cell free DNA in samples from patients with locally 
advanced/metastatic lung cancer is low, in the order of 1 ng/ul. This is 
consistent with the literature for other cancer types(132). A low amount of input 
DNA, may result in ‘false-negative’ test result, with important clinical 
implications. For example, patients with EGFRmut+ve adenocarcinoma of the lung 
may not be treated with an EGFR TKi, if they have a false negative EGFR mutation 
assay result on testing ctDNA. Conversely, the ‘absence’ of a mutation may also 
be important to guide a treatment decision, for example the use of cetuximab for 
KRAS ‘wild-type’ colorectal cancer patients. Caution needs to be taken if the 
presence of a ‘wild-type’ gene is an important predictive biomarker. In this case, 
it is important to reduce the ‘false-negative’ test result, since a false negative 
KRAS mutation test may result in the patient potentially being given a therapy, 
which would then be ineffectual, and associated with increased toxicity for the 
patient. Using ddPCR it would be difficult know whether a ‘negative’ test is due to 
there being not enough input DNA, the level of mutation is lower than the limit of 
detection, or the mutation is truly absent. In conclusion, for patients with 
advanced lung cancer, ddPCR is better suited for clinical applications where a 
‘true-positive’ result is required, i.e. detecting the presence of a mutation, rather 
than a clinical application where a ‘true-negative’ result is required, i.e. to 
confirm the absence of a mutation. 
 
For EGFRmut+ve adenocarcinoma of the lung, there are over 20 recognised 
activating mutations within the EGFR tyrosine kinase domain(36). Given that 
ddPCR is effective for detecting an individual mutation, per reaction, the amount 
of input ctDNA will also limit the number of mutations that can be tested for, per 
sample. Work is ongoing to multi-plex ddPCR reactions to overcome this 
problem. 
 
For successful introduction of NGS/ddPCR mutation analysis into routine clinical  
practice, cancer mutations must be detected reproducibly, even if/where there 
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are significant delays between sample collection and processing/analysis. Data 
presented in this results chapter, demonstrate that the use a specialised blood 
collection tubes, such as CellSave, provide sufficient stability in the quantities of 
total cell free DNA concentration, to allow delays of up to 4 days in transport of 
samples, from any peripheral hospital to a centralised analytical laboratory for 
processing and testing. Therefore, CellSave tubes can facilitate the use of ctDNA 
analyses as biomarkers in routine, individualised clinical management of lung 
cancer patients, many of whom are managed in peripheral clinics without on-site 
genetic facilities.  
 
No statistically significant difference could be detected in cfDNA concentration 
between samples from patients with small cell lung cancer, before or during 
intravenous chemotherapy, nor for adenocarcinoma patients before or during 
oral, EGFR TKi therapy. 
 
Patients with stage IV small cell lung cancer have statistically significant more 
total circulating cell free DNA in their blood compared with patients with stage 
III SCLC and patients with stage IV adenocarcinoma of the lung. Further research 
can address whether this is a phenomenon observed as a result of a larger 
disease volume, as a consequence of more “aggressive” disease than NSCLC by 
correlating total cell free DNA concentration with radiological volume of disease, 
and disease activity, for example with CT-PET scans. 
 
Despite the current limitations, analysis of ctDNA offers the prospect of a useful, 
quantitative and qualitative biomarker for real-time monitoring of disease 
status, prior to or on treatment, via serial blood samples from patients with 
locally advanced or metastatic lung cancer. Using the methods in this thesis, and 
understanding their limitations, it will be interesting to explore in subsequent 
results chapters, the potential utility of ctDNA as biomarker in specific clinical 
settings for patients with locally advanced/metastatic lung cancer. 
 
 
 
 85 
4 Mutation Discovery in Tumour Tissue by Next Generation 
Sequencing  
 
4.1 Chapter Background 
 
Next generation sequencing (NGS) offers the ability to determine simultaneously 
multiple, target genetic regions, from a single DNA sample. There are many genetic 
changes of potential clinical interest and relevance to lung cancer e.g. mutations in 
EGFR, BRAF, PIK3CA, MET, HER2 and ALK. These can be assessed by any one of multiple 
different NGS platforms, using various gene panels. Some gene panels are commercially 
available, but, for most NGS platforms, there is also the option of creating a customised 
gene panel. 
 
It is possible to utilise NGS analysis for tumour DNA, whether this is DNA extracted from 
FFPE tumour tissue, or circulating cell-free tumour DNA (ctDNA). However, the quantity 
and quality of lung cancer tumour DNA is often a limiting factor in NGS analysis. In 
order to detect clinically relevant genetic changes in small quantities of tumour DNA 
from patients with lung cancer, it is important to select an appropriate gene panel and 
NGS platform combination. 
4.2 Chapter Aims 
 
The aim of this chapter is to determine whether it is possible to detect somatic genetic 
variants, in DNA samples obtained from FFPE tumour tissue samples, obtained from 
patients with NSCLC and SCLC, using NGS. Given the small amounts of tumour DNA 
often available, it is of interest whether sufficient NGS sequence ‘depth’ (see section on 
NGS methodology) can be achieved to determine the presence or absence of a somatic 
mutation. 
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4.3 Chapter Objectives 
 
This chapter has the following objectives: 
• To use NGS to assess the mutation status of DNA from tumour tissue samples 
from patients with adenocarcinoma of the lung (including EGFR mutation 
positive (EGFRmut+ve) adenocarcinoma), squamous cell carcinoma of the lung, and 
small cell lung cancer. 
• To assess the correlation between mutations detected via NGS and sequences 
obtained via complementary molecular techniques (Sanger gene sequencing, 
pyrosequencing and droplet digital PCR) confirm the presence of additional 
somatic mutations revealed by NGS. 
• To compare the ability of a novel, custom-designed, in-house 22-gene non-small 
cell lung cancer panel with a commercially-available 50 cancer gene hotspot 
panel to detect the presence of known EGFR mutations, previously detected by 
routine diagnostic gene sequencing. 
• To assess the ability of the 22-gene panel to detect mutations, which cannot be 
assessed, using the 50-gene panel. 
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4.4 Chapter Results 
4.4.1 Mutation Detection in Lung Tumour Samples 
 
A total of 29 patients with lung cancer were recruited to this research project. These 
included 11 patients with EGFRmut+ve adenocarcinoma of the lung, 5 patients with 
adenocarcinoma of lung (EGFR mutational status previously unknown), 3 patients with 
squamous cell carcinoma of the lung, and 10 patients with small cell lung cancer. 
Tumour tissue samples, or cytological ‘cell-block’ samples, were only available for DNA 
extraction and NGS analysis in 26 of the 29 patients (Table 4-1). For 2 patient samples 
(EGFR_2 and EGFR_5), there was insufficient tumour tissue remaining after routine 
histopathological examination. For 1 patient (SCLC_7), NGS was not performed since the 
available tissue sample did not contain any nucleated tumour cells. 
 
Table 4-1 Summary of recruited lung cancer patients. NSCLC = Non Small Cell Lung Cancer, SCC = Squamous 
Cell Carcinoma, SCLC = Small Cell Lung Carcinoma. 
Tumour 
type 
Histology Mutation status Number of 
patients 
Tumour DNA 
available for 
NGS analysis 
NSCLC Adenocarcinoma Known EGFRmut+ve 11 16 9 
Previously unknown 
mutation status 
5 4 
SCC   3 3 
SCLC    10 9 
Total    29 26 
 
 
The result of NGS analysis of the patient tumour DNA samples, using the 50 gene cancer 
hotspot panel, is shown in the heat map in Figure 4-1. In tumour samples from 23 of the 
26 patients (88%), there was sufficient tumour DNA quantity and quality to enable a 
good sequence ‘depth’ (defined as 1000x sequence depth for this research project – see 
Methods and Materials – Next Generation Sequencing – Process – Library Preparation), 
to enable genetic characterisation. This is where mutations were confidently detected, 
or the genetic regions were confidently labelled as wild-type. Adequate sequence 
‘depth’ was not achieved, in more than half of the genetic ‘hotspot’ regions contained 
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within the NGS panel, for tumour samples from 3 patients (EGFR_3, RT_2 and RT_4). 
This was because there was insufficient tumour DNA available for patient RT_2 (the 
sample contained only scanty cellular material). For the other two patients (EGFR_3 and 
RT_4), there was enough tumour DNA (>10ng), but the quality of the DNA may have 
been too poor. For example, it is known that DNA can fragment or otherwise degrade, as 
part of the formalin fixation process.  
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Figure 4-1 Heat map for sequence coverage and somatic genetic alteration using the 50 gene cancer hotspot panel. Genes 
received a ‘pass’ if the minimum required sequence depth was achieved in all gene regions covered by the panel. Partial fail if 
only some of the gene regions achieved the minimum required sequence depth. Complete fail if none of the gene regions 
achieved the minimum required sequence depth. Known pathogenic mutations are indicated by red stippling.
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4.5 Patients with EGFRmut+ve Adenocarcinoma of the Lung 
 
Eleven patients with EGFRmut+ve adenocarcinoma of lung were recruited to this study. 
For each of these patients, the EGFR mutation status of tumour DNA had been 
previously characterised, in routine clinical practice. This had been achieved using 
pyrosequencing for the common point mutations (EGFR Exon 18: c.2155G>A p.G719S, 
c.2155G>T p.G719C, c.2156G>C p.G719A, c.2159C>T p.S720F, Exon 20: c2294T>C 
p.V765A, c.2303G>T p.S768I, c.2305G>T p.V769L, c.2369C>T T790M, Exon 21: 
c.2573T>G p.L858R, c.2582T>A p.L861Q); and fragment length analysis for EGFR Exon 
19 3 – 24 base pair deletions, and EGFR exon 4 – 9 base pair 20 insertions. 
 
Table 4-2 summarises the histopathological characteristics of the tumour tissue sample 
for each of the 11 EGFRmut+ve adenocarcinoma patients, as well as the specific EGFR 
mutation sequence changes discovered by NGS. The most common source of tumour 
tissue for these patients was FFPE tumour tissue obtained from CT guided 
transcutaneous biopsy, confirming that for these patients, there is commonly a limited 
amount of tumour tissue available for genetic analysis.  
 
The most commonly demonstrated EGFR mutations detected were EGFR c.2573T>G, 
p.L858R (44%) and EGFR exon 19 deletions (56%), consistent with reported mutational 
frequencies in the literature(133, 134). Where there was sufficient tumour tissue 
available for EGFR gene analysis, there was 100% concordance for EGFR mutation 
detection, between NGS, determined here, and prior pyrosequencing/fragment length 
analysis. 
An additional benefit of NGS, over fragment length analysis, in the case of EGFR exon 19 
deletions, is that NGS provides specific detail of the deleted sequence.  As a result, it was 
possible to detect a novel, complex deletion/insertion EGFR exon 19 mutation; EGFR 
c.2239_2251del12>CCATTG, p.L747_T751>PL (Patient EGFR_1) which has not been 
previously reported in the literature. Knowledge of the specific deleted sequence is vital 
knowledge in the design of sequence-specific probes for subsequent ddPCR detection of 
the mutation. 
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There appears to be an approximate correlation between the percentage of tumour cells 
contained within the tissue sample (determined by histopathological examination), and 
the mutation alternate allele frequency (%) (The frequency of mutations compared to 
background ‘wild-type’ alleles) (Table 4-2). This is to be expected if all of the nucleated 
tumour cells contained within the tissue sample contain the mutation. 
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Table 4-2 Somatic Variant Discovery by NGS (50 cancer gene hotspot panel) in FFPE tumour tissue with previously characterised somatic mutations in the EGFR gene. The minimum 
required sequence depth is determined by the percentage of nucleated tumour cells seen on a haematoxylin and eosin (H&E) stained FFPE tumour tissue slide.  
     
EGFR Change Detected by NGS 
Patient 
Research ID 
Disease Stage Tumour Sample 
% Tumour Cells 
on H&E 
Known EGFR mutation DNA Change 
Predicted Protein 
Change 
Actual 
Sequencing 
Depth at 
Position 
Alternate 
Allele 
Frequency 
(%) 
EGFR_1 IV 
CT Guided Lung 
Biopsy 
50 EGFR Exon 19, 12 bp del. c.2239_2251del12>CCATTG p.L747_T751>PL 40487 33.7 
EGFR_2 IV NA - EGFR p.G719A Insufficient FFPE Tumour DNA for analysis 
EGFR_3 IV 
CT Guided Lung 
Biopsy 
75 EGFR p.L858R c.2573T>G p.L858R 1156 47.8 
EGFR_4 IV 
Surgical 
Resection of 
Primary Tumour 
30 EGFR p.L858R c.2573T>G p.L858R 30125 17 
EGFR_5 IV NA - EGFR Exon 19, 15 bp del. Insufficient FFPE Tumour DNA for analysis 
EGFR_6 IV 
CT Guided Lung 
Biopsy 
10 EGFR Exon 19, 15 bp del. c.2235_2249del15 p.E746_A750 13071 23.8 
EGFR_7 IV 
EBUS LN 
Cytology 
20 EGFR p.L858R c.2573T>G p.L858R 34448 20.4 
EGFR_8 IV 
CT Guided Lung 
Biopsy 
30 EGFR Exon 19, 15 bp del. c.2235_2249del15 p.E746_A750 5589 42 
EGFR_9 IIIA 
CT Guided Lung 
Biopsy 
60 EGFR Exon 19, 12 bp del. c.2238_2249del15 p.L747_T751>P 22565 18.5 
EGFR_10 IV 
CT Guided Lung 
Biopsy 
60 EGFR Exon 19, 15 bp del. c.2236_2250del15 p.E746_A750 68326 70.6 
RT_5 IIIB 
Surgical 
Resection of 
Primary Tumour 
30 EGFR p.L858R c.2573T>G p.L858R 4877 37.1 
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4.6 Non EGFR Mutation Detection in Adenocarcinoma Samples 
 
In the patients with EGFRmut+ve adenocarcinoma of the lung, 44% had a concurrent 
somatic mutation within the TP53 gene (Table 4-3). This has not been previously 
reported in the literature. It is unknown whether mutant TP53 in EGFRmut+ve 
adenocarcinoma patients has any clinical implications for these patients. 
 
Table 4-3 Concurrent mutations detected in EGFRmut+ve adenocarcinoma samples. AAF = Alternate Allele 
*Frequency (%) determined by NGS 
 
There were 5 patients with adenocarcinoma of the lung where the EGFR mutational 
status was unknown prior to NGS. Samples were available for NGS for 4 of these 
patients. The histopathological characteristics of each sample, and the mutations 
detected are summarised in Table 4-4. In these tumour samples, mutations detected 
were KRAS (c.35G>C, p.G12A and c.35G>T, p.G12V), PTEN (c.494G>A, p.G165E) and 
TP53 (c.1006G>T, p.E336TER). The presence of the KRAS mutations were able to be 
confirmed with pyrosequencing and COLD-PCR followed by pyrosequencing. There was 
insufficient DNA remaining after NGS, to confirm the presence of the other mutations in 
the other samples. No additional EGFR mutations were detected in these samples. 
Patient ID 
% 
Tumour 
Cells 
AAF of 
EGFR 
mutation 
(%)(NGS) 
Gene 
Mutation in 
addition to 
EGFR 
Concurrent Gene Mutation 
AAF of Concurrent 
Mutation (%)* 
EGFR_1 50 33.7 No     
EGFR_3 75 41.1 No     
EGFR_4 30 17.0 Yes TP53 c.655C>T p.P219S 23 
EGFR_6 10 23.8 Yes TP53 c.764T>A p.I255N 7.0 
EGFR_7 20 20.4 Yes TP53 c.259A>G p.W220C 16.2 
EGFR_8 30 42.0 No     
EGFR_9 60 18.5 No     
EGFR_10 60 70.6 Yes TP53 c.844C>T pR282W 36.3 
RT_5 30 37.1 No     
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Table 4-4 Somatic Variant Discovery in previously untested Adenocarcinoma samples of Lung using NGS and the 50 gene, targeted cancer hotspot panel. CT = Computed 
Tomography, EBUS = Endobronchial Ultrasound Scan, LN = Lymph Node. 
Patient 
Research ID 
Stage Tumour Sample 
% 
Tumour 
Cells 
Pre Test 
Pass/Fail 
Somatic 
Mutation 
Detected? 
Gene(s) DNA Change 
Predicted 
Protein 
Change 
Actual 
Sequencing 
Depth Achieved 
at Change 
Position 
Variant 
Allele 
Frequency 
(%) 
Confirmed with 
Alternative 
Method 
RT_1 IIIA 
CT Guided Lung 
Biopsy 
100 Pass Yes TP53 c.1006G>T p.E336TER 2884 25.4 
Insufficient 
DNA 
RT_2 IIIA 
EBUS guided LN 
biopsy/cytology 
<1 Fail 
Insufficient 
sequence 
coverage 
- - - - - - 
RT_3 IIIA 
EBUS guided LN 
biopsy/cytology 
40 Pass Yes KRAS c.35G>C p.G12A 20371 59.7 Pyrosequencing 
RT_4 IIIA 
Thoracoscopic 
Biopsy 
50 Pass Yes PTEN c.494G>A p.G165E 2800 3.2 
Insufficient 
DNA 
RT_8 IIIA 
EBUS guided LN 
biopsy/cytology 
40 Pass Yes KRAS c.35G>T p.G12V 7932 4.8 
COLD PCR & 
Pyrosequencing 
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4.7 Mutation Detection in Squamous Cell Carcinoma 
 
Sequence depth was adequate for all the genetic regions, for all 3 of the squamous cell 
carcinoma samples. It was possible to detect two mutations in the TP53 gene (RT_6 and 
RT_9) and one in the PIK3CA gene (RT_7). There was enough remaining DNA in two 
samples (RT_7 and RT_9), after NGS, to confirm the presence of two of these mutations 
using a second technique. The presence of the PIK3CA mutation was confirmed by 
pyrosequencing, and the TP53 c.713G>T, p.C238F was confirmed by Sanger Sequencing 
(Table 4-5). This was because the DNA for one sample (patient RT_6) was exhausted by 
NGS analysis. The histopathological characteristics of the squamous cell carcinoma 
samples, as well as the specific mutations are also detailed in Table 4-5. 
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Table 4-5 Somatic Variant Discovery in Squamous Cell Carcinoma samples of Lung using NGS and the 50 gene, targeted cancer hotspot panel. CT = Computed Tomography 
Patient 
Research ID 
Stage Tumour Sample 
% 
Tumour 
Cells 
Pre Test 
Pass/Fail 
Somatic 
Mutation 
Detected? 
Gene(s) DNA Change 
Predicted 
Protein 
Change 
Actual 
Sequencing 
Depth Achieved 
at Change 
Position 
Variant 
Allele 
Frequency 
(%) 
Confirmed with 
Alternative 
Method 
RT_6 IIA 
Bronchoscopic 
Biopsy 
40 Pass Yes TP53 c.820G>C p.V274L 6830 43.4 
Insufficient 
DNA 
RT_7 IB 
CT Guided Lung 
Biopsy 
50 Pass Yes PIK3CA c.3140A>G p.H1047R 7906 26.7 Pyrosequencing 
RT_9 IIIB 
Bronchoscopic 
Biopsy 
40 Pass Yes TP53 c.713G>T p.C238F 16013 41.8 
Sanger 
Sequencing 
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4.8 Mutation discovery in patients with SCLC 
 
Table 4-6 summarises the patient characteristics and NGS findings for SCLC patients. 
The sources of tumour tissue were bronchoscopic biopsy (50% of cases) aspiration 
cytology (30%), CT guided lung biopsy (one patient) and a needle core biopsy of an 
axillary tumour (one patient). This re-enforces the commonly encountered problem that 
patients with stage III or stage IV SCLC often only have very small amounts of tumour 
cellular material for genetic analysis. As previously stated, there was enough tumour 
DNA for NGS analysis in 9 of the 10 SCLC patients. One patient (SCLC_7) had a 
bronchoscopic biopsy, but there were no nucleated tumour cells remaining in the tissue 
block, as it is likely that previous histopathological examination had exhausted the area 
of the sample that did contain them.  
 
A total of 10 mutations were found in all tested SCLC samples, 9 of which were 
confirmed with a second technique (Table 4-6). The most commonly found mutations in 
the small cell lung cancer samples were within TP53 (78%), KRAS (22%), and RB1 
(11%). The presence of the RB1 c.1700C>T, p.S567L mutation (patient SCLC_4) could 
not be confirmed, as there was insufficient DNA remaining after prior NGS and Sanger 
Sequencing. These are consistent with reported mutational gene frequencies for TP53 
and KRAS in SCLC, however, mutations within RB1 are potentially under-represented in 
these patients, where they have been reported as high as 58%(135). This is likely due to 
the small sample size of SCLC patients included in the current research project. 
 
For one patient (SCLC_5) no pathogenic mutations were identified. Given the good 
sequence ‘depth’ for all the genetic regions within the 50 gene cancer hotspot panel, 
therefore it can be concluded that the cancer in this patient was ‘wild-type’ for these 
genetic areas. It may be that, for this specific cancer sample, the pathogenic mutations 
exist in areas of these genes, or in other genes, not included by the gene panel. Another 
possibility is that different mutational mechanisms are responsible for the 
tumorigenesis in this patient’s cancer, namely gene translocations or gene copy number 
variations, which cannot be detected by this gene panel and method of NGS analysis. 
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Table 4-6 Somatic Variant Discovery in SCLC samples using NGS and the 50 gene, targeted cancer hotspot panel. CT = Computed Tomography. 
Patient 
Research ID 
Stage Tumour Sample 
% 
Tumour 
Cells 
Pre Test 
Pass/Fail 
Somatic 
Mutation 
Detected? 
Gene(s) DNA Change 
Predicted 
Protein 
Change 
Actual 
Sequencing 
Depth Achieved 
at Change 
Position 
Variant 
Allele 
Frequency 
(%) 
Confirmed with 
Alternative 
Method 
SCLC_1 IV 
CT Guided Lung 
Biopsy 
70 Pass Yes TP53 c.742C>T p.R248W 34402 97.2 
Sanger 
Sequencing 
SCLC_2 IV 
Bronchoscopic 
Biopsy 
50 Pass Yes TP53 c.1001G>T p.G334V 6083 31 
Droplet Digital 
PCR 
SCLC_3 IV 
Pleural Fluid 
Cytology 
75 Pass Yes 
TP53 c.844C>G p.R282G 13681 40.2 
Sanger 
Sequencing 
KRAS c.34G>T p.G12C 29246 18.1 Pyrosequencing 
SCLC_4 IIIB 
Lymph Node 
Aspirate 
Cytology 
40 Pass Yes 
TP53 c.451C>A p.P151T 32671 43.8 
Sanger 
Sequencing 
RB1 c.1700C>T p.S567L 16644 36.4 
Insufficient 
DNA 
SCLC_5 IV 
Bronchoscopic 
Biopsy 
70 Pass No  - -  -  -  -  -  
SCLC_6 IV 
Bronchoscopic 
Biopsy 
60 Pass Yes TP53 c.592G>T p.E198TER 23700 64.4 
Sanger 
Sequencing 
SCLC_7 IV 
Bronchoscopic 
Biopsy 
0 Fail 
NGS not 
performed 
 - -  -  -   -  - 
SCLC_8 IV 
Sub-Cutaneous 
Nodule Aspirate 
Cytology 
95 Pass Yes TP53 c.641A>G p.H214R 39757 98.9 
Droplet Digital 
PCR 
SCLC_9 IV 
Needle Core 
Biopsy Right 
Axilla 
100 Pass Yes KRAS c.437C>T p.A146V 41890 45.2 Pyrosequencing 
SCLC_10 IIIB 
Bronchoscopic 
Biopsy 
60 Pass Yes TP53 c.892G>T p.E298TER 7910 80.7 
Sanger 
Sequencing 
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4.9 Custom 22-Gene Panel for Non-Small Cell Lung Cancer 
 
An important aim of this thesis was to compare the commercially-available 50 cancer 
gene ‘hotspot’ panel, used above, with an in-house, custom, 22-gene, whole exon panel, 
specifically designed for NSCLC. Table 4-7 compares the target genetic regions 
contained within these two panels. The custom panel can target the same intragenic 
mutation hotspot regions for the genes contained within both panels, with the exception 
of STK11. Sub-optimal exon coverage of STK11, meant that two STK11 mutations; STK11 
c.996G>A, p.W332* and STK11 c.1062C>G, p.F354L (Exon 8) are detectable by the 50 
gene hotspot panel, but not the custom 22 gene panel. Despite panel design attempts to 
improve STK11 coverage, it was not possible to include exon 8 within the 22 gene 
custom panel. Some of the genes within the 22 gene custom panel, are not included by 
the 50 gene hotspot panel, namely BRCA1, BRCA2, MAP2K1, MTOR and NF1. 
 
It was only possible to assess tumour tissue samples from 11 of the 29 patients using 
the custom 22-gene panel, specifically 8 of the EGFRmut+ve adenocarcinoma patients, and 
3 of the squamous cell carcinoma patients, due to financial constraints of this research 
project. The custom 22-gene panel uses 3 primer pools per sample (see Methods and 
Materials – NGS Principles), compared with one primer pool used by the cancer hotspot 
panel. Consequently, the custom gene panel required 3 times as much input DNA, and 3 
times more sequencing reagents compared to the 50 gene cancer hotspot panel, and is 
thus 3 times more expensive per sample analysed. 
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Table 4-7 Comparing target genetic regions between the 50 gene panel and the 22 gene panel. The final 
column denotes whether the regions contained within the 50 gene panel, are also included by the 22 gene 
panel. SNV = Single Nucleotide Variant. NA = Not applicable. 
Gene 50 Gene Cancer Hotspot Panel 
 
22 Gene Custom Panel 
SNV 
Overlap 
ABL1 Yes - Hotspots No  
AKT1 Yes - Hotspots Yes – Most Exons Yes 
ALK Yes - Hotspots No  
APC Yes - Hotspots No  
ATM Yes - Hotspots No  
BRAF Yes - Hotspots Yes – All Exons Yes 
BRCA1 No Yes – All Exons NA 
BRCA2 No Yes – Most Exons NA 
CDH1 Yes - Hotspots No  
CDKN2A Yes - Hotspots Yes – Most Exons  
CSF1R Yes - Hotspots No  
CTNNB1 Yes - Hotspots No  
DDR2 No Yes – All Exons NA 
EGFR Yes - Hotspots Yes – All Exons Yes 
ERBB2 Yes - Hotspots Yes – Most Exons Yes 
ERBB4 Yes - Hotspots No  
EZH2 Yes - Hotspots No  
FBXWT Yes - Hotspots No  
FGFR1 Yes - Hotspots No  
FGFR2 Yes - Hotspots Yes – All Exons Yes 
FGFR3 Yes - Hotspots No  
FLT3 Yes - Hotspots Yes – Most Exons Yes 
GNA11 Yes - Hotspots No  
GNAS Yes - Hotspots No  
GNAQ Yes - Hotspots No  
HNF1A Yes - Hotspots No  
HRAS Yes - Hotspots No  
IDH1 Yes - Hotspots No  
JAK2 Yes - Hotspots No  
JAK3 Yes - Hotspots No  
IDH2 Yes - Hotspots No  
KDR Yes - Hotspots No  
KIT Yes - Hotspots Yes – All Exons Yes 
KRAS Yes - Hotspots Yes – All Exons Yes 
MAP2K1 No Yes – Most Exons NA 
MET Yes - Hotspots Yes – Most Exons Yes 
MLH1 Yes - Hotspots No  
MPL Yes - Hotspots No  
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MTOR No Yes – All Exons NA 
NF1 No Yes – Most Exons NA 
NOTCH1 Yes - Hotspots No  
NPM1 Yes - Hotspots No  
NRAS Yes - Hotspots Yes – All Exons Yes 
PDGFRA Yes - Hotspots Yes – All Exons Yes 
PIK3CA Yes - Hotspots Yes – All Exons Yes 
PTEN Yes - Hotspots Yes – All Exons Yes 
PTPN11 Yes - Hotspots No  
RB1 Yes - Hotspots No  
RET Yes - Hotspots No  
SMAD4 Yes - Hotspots No  
SMARCB1 Yes - Hotspots No  
SMO Yes - Hotspots No  
SRC Yes - Hotspots No  
STK11 Yes - Hotspots Yes – Most Exons No 
TP53 Yes - Hotspots Yes – All Exons Yes 
VHL Yes - Hotspots No  
 
 
Adequate sequence depth (>1000x) was achieved in 100% of the target gene regions of 
the 50 gene cancer hotspot panel for 23 of the 26 tumour tissue samples analysed with 
this gene panel. Conversely, adequate sequence depth could only be achieved for 39% of 
the target gene regions contained within the custom panel. Where sufficient sequence 
depth was achieved for accurate assessment of mutation status, there was some 
concordance between using the 22-gene custom and 50 gene hotspot panels, on the 
same patient tumour DNA samples (Figure 4-2). In Figure 4-2, all of the exons for most 
of the genes within the 22 custom panel failed to achieve 1000x sequence depth, due to 
individual amplicons repeatedly failing. These are summarized in Table 4-8. All of the 
other amplicons covering the exons for these genes did achieve 1000x sequence depth. 
This problem is commonly encountered with NGS gene panel design, and further work 
to optimize amplicon design to achieve the minimum required sequence depth, if that 
genomic region is of interest or relevance. This was not pursued within this thesis, as 
the individual amplicons that ‘failed’ were not considered to cover ‘critical’ mutation 
regions for the genes of interest for many of the genes. For BRCA2 and NF1, there were 
12 and 13 amplicons, respectively that consistently failed. Optimizing panel design to 
provide a greater sequence depth for these genetic regions would have utilized a further 
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‘primer pool’. This increases the cost of the NGS pane/per sample, and increases the 
DNA requirement, which is a limiting factor from the samples utilized in this project. 
 
The 50 gene cancer hotspot panel was able to detect 100% of the EGFR gene mutations 
in the 8 patient tumour DNA samples that were known to contain an EGFR mutation (as 
they had previously been characterised with pyrosequencing). In contrast, although an 
adequate sequence depth of the EGFR gene was consistently achieved with the 22-gene 
custom panel, it was only possible to the EGFR mutation in 1 one of the 8 EGFRmut+ve 
samples – specifically the EGFR p.L858R mutation in the tumour sample from patient 
EGFR_7. The custom panel failed to detect all of the EGFR exon 19 deletions. A 
retrospective, visual inspection of the NGS DNA sequence data revealed that this was 
due to a design fault of the gene panel. Therefore, in its current stage of development, 
the custom 22-gene panel is not suitable for clinical use in analysis of NSCLC patients’ 
tumour DNA and subsequent treatment decision-making and/or determining eligibility 
for stratified clinical trials. Further work needs to be done so that it can detect EGFR 
exon 19 deletions, and achieve better sequence depth for many of the genetic regions 
included by the panel. Specifically, the custom 22 gene panel needs to be re-designed, so 
that EGFR exon 19 is covered by one amplicon (as with the 50 gene hotspot panel), 
rather than two adjacent ones (as with the current 22 gene custom panel). This further 
development was not possible in this project, owing to financial and time constraints. 
 
The exact 3 pathogenic mutations discovered in the squamous cell tumour samples, 
were detected using both gene panels. Of note, the custom 22-gene panel was also able 
to detect an additional, concurrent somatic genetic alteration of unknown significance 
in BRCA2 (BRCA2 c.G8716C, p.E2906Q), in one patient with squamous cell carcinoma 
(patient RT_9). The BRCA2 gene is not included in the 50 gene cancer hotspot panel, but 
may be of potential clinical relevance in lung cancer. Specifically, mutated BRCA1/2 may 
act as a predictive biomarker of response to therapies, such as PARP inhibitors, for 
example, olaparib.  
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Figure 4-2 Heat map of sequencing coverage achieved, and somatic mutations identified, using the custom 
designed 22 gene panel for NSCLC. Genes received a ‘pass’ if the required minimum sequencing depth was 
achieved in all gene regions covered by the panel. Partial fail if only some of the gene regions achieved the 
minimum sequence depth. Complete fail if none of the gene regions achieved the required minimum 
sequence depth. Pathogenic mutations are indicated by red stippling, and genetic sequence changes of 
uncertain significance are indicated by orange stippling 
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Table 4-8. 22 gene custom panel amplicons regions that consistently failed to achieve the minimum 
1000x sequence depth. The resulting ‘missed genetic regions’ are chromosomal location using 
genome hg19. 
Gene Number of 
‘failed’ 
Amplicons 
Missed Genetic Regions 
MTOR 2 chr1:11182041-11182216, chr1:11199484-11199658 
 
DDR2 2 chr1:162741866-162742017, chr1:162743266-162743439 
 
PIK3CA 4 chr3:178916624-178916782, chr3:178937778-178937953 
chr3:178937462-178937629, chr3:178947888-178948051 
 
KIT 4 chr4:55561831-55561983, chr4:55592101-55592271 
chr4:55569772-55569925, chr4:55594187-55594341 
 
MET 2 chr7:116409589-116409760, chr7:116421907-116422072 
 
BRAF 2 chr7:140439703-140439854, chr7:140549940-140550103 
 
AKT1 1   chr14:105241881-105242055 
TP53 2 chr17:7577130-7577279, chr17:7579486-7579631 
 
ERBB2 2 chr17:37879658-37879823, chr17:37880211-37880374 
 
BRCA1 1   chr17:41245638-41245813 
PTEN 2 chr10:89653788-89653948, chr10:89725092-89725267 
 
BRCA2 12 chr13:32899276-32899430, chr13:32953607-32953773 
chr13:32903580-23903755, chr13:32953495-32953670 
chr13:23912243-23912411, chr13:32945110-32945284 
chr13:32912273-32912438, chr13:32937250-32937412 
chr13:32913590-32913744, chr13:32920842-32921012 
chr13:23913665-32913819, chr13:32918675-32918838 
 
NF1 13 chr17:29508689-29508861, chr17:29679375-29679539 
chr17:29527586-29527739, chr17:29676158-29676327 
chr17:29528330-29528484, chr17:29670092-29670266 
chr17:29548884-29549059, chr17:29665699-29665861 
chr17:29559032-29559203, chr17:29661809-29661984 
chr17:29585914-29586089, chr17:29657458-29657611 
chr17:29592192-29592366 
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4.10 Clinical Implications 
 
Increasingly, new treatments are being developed, which target specific aberrant 
tumour proteins that arise from tumour genetic alterations, such as the use of 
EGFR TKi in lung tumours that harbour EGFR mutations. Clinical trials of these 
new agents increasingly stratify patients on the basis of tumour molecular 
genetics profiles.  Therefore it is crucially important to be confident in the ability 
of NGS, to achieve significant depth of sequence coverage, so that important 
genetic mutations can be accurately, reliably and reproducibly detected for 
clinical decision-making. 
 
The results presented in this chapter demonstrate that it is possible to detect 
somatic mutations using NGS, in small lung cancer samples, using a 
commercially-available, targeted 50 gene cancer hotspot panel. In 88% of lung 
tumour samples, it was possible to perform NGS analysis, even on DNA derived 
from very small tumour tissue biopsy samples, or FFPE blocks made from 
cytological samples, where the tumour content may be very low, or the DNA is 
prone to significant degradation as a result of the fixation process. However, 
despite this, it has to be remembered that this gene panel only focuses on the 
pathogenic hot-spot regions within genes, and could potentially miss genetic 
sequence changes contained within exonic regions outside of the hotspots. Also, 
this panel does not include some genes that may become clinically relevant to 
lung cancer in the future, such as BRCA1 and BRCA2 mutations. 
 
For these reasons, it is sometimes desirable to design a custom targeted panel, in 
attempt to include whole exonic regions of genes of interest, or to tailor a gene 
panel to a specific disease.  The advantage of such a ‘custom’ gene panel 
approach is that it permits careful selection of genes and genetic regions to be 
included on the panel. We designed a custom panel to assay 22 genes which are 
implicated in non-small cell lung cancer, that each have a mutational frequency 
of >1% in NSCLC, and the mutational status of which may be potentially clinically 
relevant i.e. they predict response to targeted therapeutics currently in routine 
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clinical use, or in development in early phase clinical trials. In this results 
chapter, we have demonstrated the ability of a custom panel to detect somatic 
sequence changes in genes such as BRCA2 that would otherwise have been 
missed using a generic, commercially panel. However, technical difficulties were 
encountered with the custom panel, whereby we did not achieve the required 
sequencing ‘depth’ in order to adequately detect, or confidently exclude, the 
presence of clinically-relevant somatic mutations. A further limitation of the 
custom gene panel is that it is more expensive. With the custom gene panel 
approach, it has been demonstrated that careful attention has to be given to 
panel design, as this was the main reason why EGFR exon 19 deletions could not 
be identified. Therefore it is recommended that a significant amount of time 
should be devoted to optimising the design of any custom targeted gene panel, to 
ensure it is robust and has practical clinical utility. 
 
Compared with whole genome sequencing, targeted NGS sequencing method of 
molecular characterisation, allows sufficient ‘depth’ of sequencing to detect 
mutations within cancer DNA, that is often mixed with germline DNA derived 
from normal cells in the same sample. This can be at the expense of the inability 
to determine the presence or absence of other tumorigenic mutations observed 
in lung cancer, particularly larger-scale genetic changes, such as ALK, ROS1 and 
RET translocations, and gene copy number changes, for example MET 
amplification. Therefore, there is still a requirement for the tumour tissue 
analysis using complementary methods such as FISH. Unfortunately, this may 
not always be possible, given the limited amount of tumour tissue available from 
biopsies from patients with advanced or metastatic lung cancer. Therefore, to 
increase the utility of a NGS platform for molecular characterisation of tumour 
tissue, future research is needed to be able to develop NGS assays that can 
simultaneously assess for point mutations, small insertions/deletions, gene copy 
number changes and gene translocations. 
 
The results presented in this chapter also reflect that tumour tissue DNA is not 
always available or adequate. With routine genetic analysis of tumour tissue, 
there is a NGS failure rate, even when tumour DNA appears to be available, and 
 107 
this can be due to DNA degradation resulting from the formalin fixation 
processing of tumour tissue samples. All of the samples in this project were FFPE 
tumour tissue or cytological samples. Future research into the molecular 
characterisation of tumour tissue may be improved by the use of fresh tumour 
tissue samples, but the research must include the feasibility of obtaining this 
tissue within the routine clinical setting, and whether it could subsequently be 
implemented as standard clinical care. 
 
With conventional tumour sampling, it is not possible to fully characterise intra-
tumour or intra-patient heterogeneity, especially where there is multi-focal 
metastatic disease, owing to sampling error/bias, unless a biopsy is potentially 
obtained from each tumour site. This is often either unacceptable to the patient 
or not clinically feasible. Likewise, monitoring clonal evolution of the tumour 
would require repeated, serial biopsies at different time points during a patient’s 
cancer journey. New, or emerging sites of metastatic disease that have developed 
during anti-cancer therapy, may represent resistant sub-clones of tumour, and 
unless these can specifically be biopsied, a repeat biopsy of the original tumour 
may not capture this intra-patient tumour heterogeneity. Therefore, alternative 
sources of tumour DNA, such as circulating cell free tumour DNA (ctDNA) may 
provide DNA for analysis, to help to overcome the limitations of analysis of FFPE 
tumour tissue DNA. NGS of ctDNA in patients with lung cancer, alongside other 
molecular techniques, such as ddPCR, is the focus of the next results chapters. 
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5 Monitoring Disease Progression and Response to Therapy 
using Circulating Tumour DNA in Patients with Metastatic 
EGFRmut+ve Adenocarcinoma of the Lung 
 
5.1 Chapter Overview 
 
There is a pressing need to clarify the potential value of ctDNA, as a circulating, 
surrogate biomarker, in EGFRmut+ve adenocarcinoma of the lung, in different 
clinical settings. These include response to treatment, disease monitoring in 
periods of minimal residual disease, detecting disease progression and 
determining molecular mechanisms of therapeutic resistance. In this chapter we 
will explore the utility of ctDNA in the particular clinical circumstance of patients 
with EGFRmut+ve adenocarcinoma of the lung. 
5.1.1 Chapter aims 
 
For patients with locally advanced and metastatic EGFRmut+ve adenocarcinoma of 
the lung, this chapter aims to: 
• Compare the sensitivity of NGS and ddPCR in assessing EGFR mutations in 
ctDNA 
• Assess the capacity of ctDNA analysis to measure the kinetics of EGFR 
mutations in ctDNA, as the patient receives EGFR TKi therapy 
• Investigate the use of ctDNA to monitor disease status/tumour burden 
and response to treatment, in patients with and without CNS metastases 
• Assess whether NGS analysis of ctDNA can detect mutations not detected 
in the original diagnostic tissue biopsy 
• Assess whether NGS analysis of ctDNA can detect mutations additional to 
mutant EGFR when the patient develops progressive cancer. 
• Determine whether ddPCR can be used to detect the acquired EGFR 
c.2369C>T, p.T790M mutation, when a patient develops therapeutic 
resistance to EGFR TKi 
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5.2 Chapter Results 
5.2.1 Patient and sample collection 
 
The clinical course of the same eleven patients with locally advanced and/or 
metastatic, EGFRmut+ve adenocarcinoma of the lung (first identified in Chapter 4) 
were monitored. Blood samples for EGFR mutational analysis of ctDNA were 
taken at 3 month intervals, as each patient underwent therapy with an EGFR TKi.  
 
Table 5-1 summarises the clinical characteristics for each patient, including stage 
of disease at the time of patient consent, sites of metastases, any prior anti-
cancer therapies, and the type of EGFR TKi used. Relevant clinical parameters 
included the duration of EGFR TKi therapy, and whether the disease was 
progressing or responding at the end of the follow-up period for each patient. 
 
At total of 39 blood samples were drawn for these patients for ctDNA analysis, 
over the research period, with a median of 4 blood samples per patient (range 2 
to 6 blood samples). The median follow-up period, from the time of consent, was 
375 days (range 173 to 697 days).  
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Patient 
Research ID 
Sex TNM Stage 
Sites of 
Metastases 
Prior Treatment EGFR TKI 
Duration of TKI 
(Days) 
Disease status 
at end of 
follow-up 
period 
EGFR_1  
 
T2aN2M1b IV Lung, Bone 
1. Chemotherapy 
Afatinib 373 
Progressive 
disease 
F 2. EGFR TKI 
  
EGFR_2 F T2aN1M1b IV Bone, Liver 
1. Chemotherapy 
2. EGFR TKI 
Gefitinib 326 
Progressive 
disease 
EGFR_3 F T2bN0M1b IV Liver 1. EGFR TKI Gefitinib 634* Partial Response 
EGFR_4 M T2aN0M1a IV Pleura 
1. Surgical 
Resection of 
Primary Tumour 
2. EGFR TKI 
Gefitinib 697* Partial Response 
EGFR_5  F T4N3M1b IV Liver, Lung 1. EGFR TKI Gefitinib 497 
Progressive 
disease  
(with brain 
metastases) 
EGFR_6  F T4N1M1b IV Bone, 
Meningeal 
1. EGFR TKI Afatinib 505* Partial Response 
EGFR_7 M T2aN2M1b IV Bone, Liver 
1. Palliative RT to 
Spine 
2. EGFR TKI 
Gefitinib 173 
Progressive 
disease 
EGFR_8 M TxN2M1b IV Lung, Pleura 1. EGFR TKI Afatinib 321 
Progressive 
disease  
(with brain 
metastases) 
EGFR_9 M T4N0M0 IIIA NA 
1. RT to Primary 
Tumour 
2. EGFR TKI 
Afatinib 485* Partial Response 
EGFR_10 F T1bN2M1b IV Bone 
1. Palliative RT to 
Spine 
2. EGFR TKI 
Afatinib then 
gefitinib 
375* Partial Response 
RT_5 F T4N2M0 IIIB NA 
1. Incomplete 
surgical resection 
2. Chemotherapy 
3. RT to chest  
4. EGFR TKI 
Gefitinib then 
erlotinib 
147* Partial Response 
Table 5-1 Summary of clinical characteristics for patients with EGFR mutation positive adenocarcinoma of the lung. Stage of disease based on International Association for the Study of 
Lung Cancer (IASLC) 7th Edition. * Patient still receiving EGFR TKI at time of final research blood sample. M = Male. F = Female.
 111 
5.2.2 Base-line mutational load 
 
5.2.3 Comparison of NGS and ddPCR quantitative assessments 
 
At the time of consent, the base-line levels of mutant EGFR in ctDNA, for the 11 
patients described in Table 5-1 are summarised in Table 5-2. Using NGS with 
ITVC software, and ddPCR, it was possible to detect mutant EGFR in ctDNA in the 
blood samples from two of the 11 patients. It must be noted that these two 
samples contained the highest level of mutant EGFR within ctDNA (41.6 and 
57.8% alternate allele frequency by ddPCR). Therefore it is expected that both 
techniques will detect mutant EGFR in ctDNA, since the alternate allele 
frequencies are well above the limits of detection of NGS and ddPCR.  
 
In contrast, ddPCR, was able to detect mutant EGFR in an additional three 
patients, in whom the mutational abundance was significantly lower (0.42 – 
0.57% alternate allele frequency). These alternate allele frequencies are below 
the lower limit of detection of NGS. This confirms the suggestion, from results 
chapter 2, that ddPCR is a more sensitive assay than NGS, when assessing for a 
limited number of specific mutations, at low mutational abundance. 
 
The EGFR mutation was not detected in ctDNA in the baseline blood sample for 6 
of the patients, using either methodology. Failure to detect mutant EGFR in 
ctDNA may be due to the use of anti-cancer therapies, prior to the first blood 
sample. At the time of consent and ‘base-line’ blood sample, two of these patients 
had received systemic chemotherapy within the preceding 3-week period. Two 
other patients were already taking EGFR TKi therapy, with responding disease 
based on radiology. One patient had prior surgical resection of the primary lung 
cancer with only microscopic residual disease within the pleura. One patient had 
prior chemotherapy and radiotherapy to the thorax. Even though patient 
numbers are small, it would not be unreasonable to suggest that a reason for 
failure to detect mutant EGFR within the baseline blood sample, is that successful 
therapy may have reduced the burden of disease to an extent that levels of 
mutant EGFR in ctDNA were below the level of detection of NGS and ddPCR, 
 112 
described in Chapter 3.  However, this does not mean that all anti-cancer 
treatments reduce the level of mutant EGFR in ctDNA to ‘undetectable’ levels. 
Patient EGFR_7 had received prior palliative radiotherapy to the spine, and it 
was still possible to detect mutant EGFR within the baseline blood sample. 
  
Even though the proportion of mutant EGFR detection in baseline ctDNA samples 
may be low (18.2% positivity using NGS and 45.5% positivity using ddPCR), it 
may be that there was too little ctDNA to detect using the current technologies as 
a result of prior therapies. I.e. for the patients included in these results, the 
baseline blood samples did not represent patients that were truly treatment 
naive. Therefore a clinician must bear in mind that prior anti-cancer therapies 
received by a patient, will have a significant impact on the amount of ctDNA, and 
the chances of a positive result, if a diagnostic EGFR mutation test on ctDNA is 
required. 
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FFPE Base-line cfDNA sample 
 
Pyrosequencing/Fragment 
Length Analysis NGS 
  
Mutation 
detection by 
NGS 
 
Mutation 
detection by ddPCR 
Patient 
Research 
ID 
EGFR deletion or predicted 
protein change  
DNA Change 
Predicted 
Protein Change 
Variant 
Allele 
Frequency 
(%) 
Any prior anti-
cancer 
treatment? 
Ion Torrent 
Variant Caller 
Software 
Alternate Allele Frequency (%) 
(95% Poisson Interval) 
EGFR_1 EGFR Exon 19, 12 bp del. 
EGFR Exon 19 
c.2239_2251del12>CCATTG 
EGFR 
p.L747_T751>PL 
33.7 No No 
- 
 
EGFR_2 EGFR p.G719A 
Insufficient FFPE Tumour 
DNA for NGS analysis 
- - No No - 
EGFR_3 EGFR p.L858R EGFR c.2573T>G EGFR p.L858R 47.8 Yes Yes 
41.6 
(38.1 - 45.1) 
EGFR_4 EGFR p.L858R EGFR c.2573T>G EGFR p.L858R 17 No No - 
EGFR_5 EGFR Exon 19, 15 bp del. 
Insufficient FFPE Tumour 
DNA for NGS analysis 
 -  - No No 
0.57 
(0.0 - 1.91) 
EGFR_6 EGFR Exon 19, 15 bp del. 
EGFR Exon 19 
c.2235_2249del15 
EGFR 
p.E746_A750 
23.8 No No - 
EGFR_7 EGFR p.L858R EGFR c.2573T>G EGFR p.L858R 20.4 No Yes 
57.8 
(55.2 - 60.3) 
EGFR_8 EGFR Exon 19, 15 bp del. 
EGFR Exon 19 
c.2235_2249del15 
EGFR 
p.E746_A750 
42 Yes No 
0.42 
(0.0 - 0.93) 
EGFR_9 EGFR Exon 19, 12 bp del. 
EGFR Exon 19 
c.2238_2249del15 
EGFR 
p.L747_T751>P 
18.5 No No - 
EGFR_10 EGFR Exon 19, 15 bp del. 
EGFR Exon 19 
c.2236_2250del15 
EGFR 
p.E746_A750 
70.6 No No 
0.53 
(0.0 - 1.79) 
RT_5 EGFR p.L858R EGFR c.2573T>G EGFR p.L858R 37.1 No No 
- 
 
Table 5-2 Summary of EGFR mutations in FFPE tumour tissue samples and in cfDNA from base-line, pre-treatment blood samples.
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5.2.4 Clinical factors in patients with mutant EGFR detected in baseline ctDNA 
 
Two patients (EGFR_3 and EGFR_8) had not received any prior systemic 
anticancer therapies. Mutant EGFR was detected in ctDNA, by ddPCR and NGS, in 
the baseline blood sample of patient EGFR_3. This patient had liver metastases 
and there was much higher mutation abundance (41.6% alternate allele 
frequency). However, for the other patient (EGFR_8), with pulmonary and 
pleural metastases, but no extra-thoracic disease, there was a much lower 
abundance (0.42% alternate allele frequency, detected by ddPCR). NGS was not 
sufficiently sensitive to detect the mutation in ctDNA. 
 
Two cases had received palliative radiotherapy to the spine, to treat vertebral 
body metastasis (EGFR_7 and EGFR_10). Mutant EGFR within ctDNA was 
detectable by ddPCR in the baseline blood sample (57.8% and 0.53% alternate 
allele frequency, respectively). Patient EGFR_10 had metastatic disease only in 
bones, whereas EGFR_7 also had liver metastases. It is impossible to conclude 
whether the differences in mutational abundance between these two patients 
are due to different sites of metastatic disease. For example, it is unknown 
whether more ctDNA is shed by liver metastases, compared to bone metastases. 
 
One patient (EGFR_5) had their base-line blood sample taken, after the 
commencement of systemic therapy with gefitinib. The patient had been taking 
this therapy for over 420 days, and there was a clinical query at the time 
whether the patient was developing clinical progression of their cancer. The 
baseline alternate allele frequency for mutant EGFR in ctDNA for this patient was 
0.57% alternate allele frequency, using ddPCR. Therefore it is unknown whether 
this represented a nadir of ctDNA during treatment, or whether this was 
increasing or decreasing as a result of disease response to therapy. 
 
5.2.5 Clinical factors in patients with EGFR mutations in tumour biopsies which 
were not detected in baseline ctDNA 
 
Mutant EGFR was not detected, using NGS or ddPCR, in the first blood sample in 
6 patients. Two of these (patients EGFR_1 and EGFR_2) had received 
chemotherapy within 6 weeks, prior to base-line blood sampling. It may be fair 
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to argue that systemic chemotherapy can result in a decrease in ctDNA, though 
further research is needed to confirm this, and determine how long for. This is 
important, since a negative ctDNA test result should be interpreted with caution, 
in patients who have recently received chemotherapy. 
 
Patient EGFR_4 had a baseline blood sample, for ctDNA analysis, after surgical 
resection of the primary lung cancer. At the time of surgery, biopsies were taken 
of the pleura, which confirmed microscopic adenocarcinoma. There was no 
detectable metastatic disease on pre- and post-operative CT scans. It is entirely 
possible that it was not possible to detect mutant EGFR within the baseline 
ctDNA sample due to a small volume of (microscopic) residual disease. 
 
Patient EGFR_6 had leptomeningeal EGFRmut+ve adenocarcinoma of the lung, and 
had already commenced TKi (afatinib) therapy for 4 weeks by the time of their 
first research blood draw. Decreases in the amount of ctDNA in response to EGFR 
TKi are reported in the literature, and this may offer the explanation for why 
mutant EGFR was not detected in the first blood sample. However, little is known 
about whether leptomeningeal or CNS metastatic disease shed tumour DNA that 
can be detected and analysed in ctDNA in the peripheral circulation. 
 
Patient RT_5, had lung surgery, followed by a course of post-operative 
chemotherapy, but despite this, developed malignant mediastinal 
lymphadenopathy. The first research blood draw was taken at this time point. 
The inability to detect mutant EGFR in ctDNA could be a reflection of the prior 
treatments received, or due to low volume of metastatic disease, or both. 
 
Further studies will need to address the question of the duration of persistence, 
and rate of decline, of ctDNA after a course of chemotherapy. However, there is 
nothing in the literature about the effect of radiotherapy on ctDNA levels in 
EGFRmut+ve lung cancer patients. The results from these case studies suggest that 
it is possible to detect mutant EGFR within ctDNA, in a blood sample taken after a 
course of palliative radiotherapy to the spine. This will information will help the 
clinician to decide when it may be clinically appropriate to request a blood 
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sample for EGFR analysis on ctDNA. For example, to maximise the chances of 
detecting mutant EGFR in ctDNA, is when the patient has not received any recent 
anti-cancer therapies, apart from say, palliative radiotherapy to the spine. 
 
5.2.6 Circulating Tumour DNA Kinetics During Treatment with EGFR TKi 
 
5.2.6.1 Quantitative ctDNA and radiological responses to therapy 
 
In the 5 patients with ddPCR-detectable EGFR mutations in ctDNA at base-line, 
we investigated the quantitative changes in alternate allele frequency of EGFR 
mutation, in ctDNA, over time. 
 
Patient EGFR_3 had metastatic EGFRmut+ve adenocarcinoma of the lung, with 
detectable levels of mutant EGFR in the baseline ctDNA sample, as assessed by 
NGS (40.15% alternate allele frequency) and by ddPCR (41.6% alternate allele 
frequency). The patient was treated with gefitinib therapy and experienced a 
radiological response to therapy by the time of the CT scan at 70 days into 
treatment. This coincided with a reduction of mutant EGFR DNA in the blood, to 
undetectable levels (0% alternate allele frequency), using both NGS and ddPCR 
(Figure 5-1).  
 
This patient (EGFR_3) had a durable radiological response to treatment with 
gefitinib, as demonstrated by the appearances of stable disease on a CT scan at 
day 254 compared with the CT scan at day 70. During this period, circulating 
mutant EGFR in ctDNA remained undetectable, suggesting a good correlation 
between ctDNA levels and radiological assessment and a potential role as a 
surrogate marker for response assessment.  
 
Using NGS and the 50-gene hotspot panel, this patient’s tumour also harboured 
base-line mutations in genes other than EGFR i.e. in exon 6 of TP53 c.A583T, 
p.I195F, and in exon 12 of NPM1 c.T877C, p.S293P. The remaining gene 
sequences assessed by the gene panel were wild-type. The mutational frequency 
of the TP53 and the NPM1 mutations occurred at lower levels (1.9% and 0.5% 
alternate allele frequencies, respectively), compared with the EGFR mutation. 
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These mutations may present in lower abundance in ctDNA as it is possible that 
these mutations are contained within sub-clones of the cancer, and represent a 
sub-population of cancer cells (intra-tumour heterogeneity). However, In order 
to confirm, or deny this hypothesis, biopsies from different parts of the primary 
tumour, and different metastatic sites would need to be assessed with NGS. This 
is the research strategy of some lab groups investigating tumour intra-patient 
tumour heterogeneity(136). 
 
For this same patient (EGFR_3), NGS of serial ctDNA samples revealed that levels 
of mutant TP53 and NPM1 also decreased during treatment. Mutant TP53 
decreased to 0% alternate allele frequency by day 60 of treatment.  Mutational 
levels of NPM1 decreased from 0.5% to 0.24% alternate allele frequency by day 
60 of treatment, and remained at that level by the time of the next blood test at 
218 days. In the first instance, the changes in NPM1 mutation level in ctDNA need 
to be confirmed with ddPCR, which was not performed due to lack of resources. 
 
Each serial ctDNA sample was also assessed by ddPCR, for the emergence of the 
acquired resistance mutation EGFR c.2369C>T, p.T790M, as this accounts for 
therapeutic resistance in approximately 50% of EGFRmut+ve patients. In keeping 
with a continuing radiological response to therapy, EGFR c.2369C>T, p.T790M, 
was not detected in this patient, at any point during the assessment period. 
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Figure 5-1 Patient ID EGFR_3. A patient with EGFR mutation positive adenocarcinoma of the lung 
responding to gefitinib. Changes in mutational EGFR load in ctDNA, using ddPCR (1.) and NGS (2.). 
The NGS data also show changes in mutant TP53 and NPM1 in ctDNA. 95% Poisson Error bars shown 
in (1.). CT scans are shown of primary tumour (A.i., Bi, Ci), and liver metastasis (A.ii., Bii and Cii) at 
base-line, day 105 and day 273).  Blue circles identify baseline tumours. Green circles identify 
improving tumours. 
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Similar correlation between ctDNA kinetics and radiological response to 
treatment were also seen in patient EGFR_10 (Figure 5-2). This patient had 
metastatic EGFRmut+ve adenocarcinoma of lung with bone metastases. They 
received initial radiotherapy to a metastatic lesion in the spine to treat 
impending spinal cord compression, prior to systemic therapy with afatinib, 
subsequently converted to gefitinib due to hepato-toxicity. The base-line ctDNA 
sample was taken after radiotherapy and before the commencement of systemic 
therapy, when the abundance of mutated EGFR was 0.53% alternate allele 
frequency, assessed by ddPCR. The first CT scan to assess response to TKi 
treatment was performed at day 105 (relative to the start of radiotherapy). This 
revealed a partial radiological response to therapy, and coincided with a fall in 
levels of mutant EGFR in the blood, decreasing to undetectable levels (0% 
alternate allele frequency). A subsequent CT scan, performed at day 273, 
confirmed a sustained radiological response to therapy. The abundance of 
mutant EGFR in blood at the same time also remained at undetectable levels (0% 
alternate allele frequency by ddPCR). As with patient EGFR_3, the EGFR 
c.2369C>T, p.T790M mutation was assessed as a potential marker of therapeutic 
resistance, but this remained undetectable in this patient (0% alternate allele 
frequency, determined by ddPCR). 
 
At the end of the follow-up period, 6 of the 11 EGFRmut+ve lung cancer patients 
(patients EGFR_3, EGFR_4, EGFR_6, EGFR_9, EGFR_10 & RT_5), were still 
receiving EGFR TKi, and still had undetectable levels of the original activating 
EGFR mutation in ctDNA, determined by ddPCR (“swimmer plot” in Figure 5-4), 
which corresponded with a period of responding or stable disease. 
 
These findings are consistent with the potential utility of ctDNA as a surrogate 
marker of both response to EGFR TKi, and monitoring a period of sustained 
disease response, before the development of therapeutic resistance and disease 
progression. 
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Figure 5-2 CtDNA and response to treatment. Patient EGFR_10 has T1bN2M1b (Bone) metastatic 
EGFRmut+ve adenocarcinoma of lung. CT scans show lung primary  and spine lesion at diagnosis (A.i 
and A.ii.), after 105 days (B.i and B.ii.) and after 273 days (C.i and C.ii). Quantitative decreases in 
mutant EGFR load are shown by ddPCR (1.) and NGS (2.). Error bars represent 95% poisson error. 
Blue circles identify tumours at baseline. Green circles identify improving or stable tumours. 
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5.2.7 Quantitative changes in ctDNA and disease progression 
 
By the end of the follow-up period, four of the patients (patients EGFR_1, 2 5 and 
8) had undergone radiological or clinical progression of their lung cancer, while 
receiving EGFR TKi therapy. The mean duration of EGFR TKi treatment was 323 
days (range 283 to 373 days), which is in keeping with the median progression 
free survival data published by the EGFR TKi clinical trials. Figure 5-3 is a “spider 
plot”, illustrating over time, changes in abundance of the original activating EGFR 
mutations in ctDNA, for each of these 4 patients. In all but one of the four 
patients, it is possible to observe increasing levels of mutant EGFR in ctDNA 
earlier than the diagnosis of radiological or clinical disease progression. This 
raises the potential that it may be possible to detect lung cancer disease 
progression earlier, through increases in ctDNA, rather than waiting for 
scheduled radiological assessment of disease status. This has clear potential 
benefits for patients – this could give patients confidence to continue with 
therapy or give them the opportunity to discontinue treatment earlier, avoiding 
potential cumulative toxicities, and switch to alternative therapies that might be 
more effective. 
 
To date, there are no established systemic biomarkers in routine clinical use in 
lung cancer. There is nothing in the literature about changes in therapy for lung 
cancer disease progression defined by ctDNA increases. This has huge potential 
for a clinical trial, of whether earlier intervention for patients developing disease 
progression, defined by increasing ctDNA levels, can improve clinical outcomes. 
This would be comparable disease monitoring using other systemic surrogate 
biomarkers, such as alpha feto-protein (AFP)/human chorionic gonadotrophin 
(hCG) for germ cell tumours, carcinoembryonic antigen (CEA) for colo-rectal 
cancer and Ca125 for ovarian cancer.  
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Figure 5-3 ‘Spider’ plot showing changes with time (days), from first ctDNA sample, in mutational 
EGFR load in ctDNA from 4 EGFRmut+ve adenocarcinoma patients, assessed by ddPCR. The squares 
represent the time of the diagnosis of clinical or radiological disease progression. AAF = Alternate 
Allele Frequency.
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Figure 5-4 Swimmer plot showing ctDNA kinetics and radiological responses in 10 patients with EGFRmut+ve adenocarcinoma of the lung, receiving therapy with EGFR TKi. Radiological 
response to treatment, at the end of the follow-up period is indicated by different coloured bars. The triangles represent each blood test taken for ctDNA analysis, and the trend of 
abundance of mutational EGFR by ddPCR. Squares indicate the diagnosis of clinical or radiological disease progression while taking EGFR TKi therapy.
Patient ID 
 
EGFR_4 
 
EGFR_5 
 
EGFR_3 
 
EGFR_1 
 
EGFR_2 
 
EGFR_6 
 
EGFR_8 
 
EGFR_9 
 
EGFR_10 
 
EGFR_7 
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5.2.8 Qualitative analysis of ctDNA on disease progression 
 
Patient EGFR_1 was treated with afatinib, and achieved a partial radiological 
response by the time of a CT scan on day 150 of therapy (arrow A in Figure 5-5).  
The base-line ctDNA blood sample, taken after the start of afatinib therapy, did 
not show detectable levels of the EGFR mutation in ctDNA, by ddPCR or NGS.  
Radiological disease progression was seen on a CT scan on day 350 (arrow B in 
Figure 5-5), which correlated with a quantitative increase in the abundance of 
the original EGFR mutation in ctDNA, as assessed using ddPCR reaching 4.72% 
alternate allele frequency, by day 373. At this time, the patient discontinued 
afatinib therapy, and received palliative radiotherapy to the left hemi-thorax. 
Interestingly, the level of the original EGFR mutation in ctDNA, determined by 
ddPCR, fell to 1.73% alternate allele frequency, after completion of radiotherapy, 
but had further increased to 14% alternate allele frequency, on repeat testing 84 
days later, without any treatment in that period, suggesting a response to 
radiotherapy, followed by further disease progression. 
 
Analysis of ctDNA using NGS and the 50 gene cancer hotspot panel, 
demonstrated an increasing abundance of a CDKN2A mutation on disease 
progression, as well as the EGFR mutation.  The same CDKN2A mutation was 
present in the diagnostic biopsy, but not on the base-line ctDNA sample, taken 
during afatinib therapy (Figure 5-5). This mutation may have been present in 
ctDNA at the start of afatinib therapy, but levels declined to 0% prior to the time 
of the first blood sample for ctDNA analysis. NGS also demonstrated the 
appearance of a mutation that was not present in either the original tumour 
tissue biopsy or in base-line ctDNA sample, specifically a TP53 c.637C>T, 
p.R213Stop, mutation (Figure 5-5.2 and 5-5.3). Therefore, in addition to tracking 
quantitative changes in levels of mutations in ctDNA, in response to different 
anticancer therapies, it is also possible to assess for the emergence of previously 
undetected mutations within ctDNA. These mutations may have been missed in 
the original tumour biopsy, due to tumour intra-heterogeneity, or they could 
develop during therapy, due to clonal evolution. 
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Detecting ‘emerging’ mutations in serial ctDNA samples, can offer insights into 
potential mechanisms of acquired resistance to therapy. Mutated TP53 is not 
currently a ‘clinically actionable’ target, since, unlike EGFR, there are no drugs 
which are effective against the aberrant protein derived from mutated forms of 
the gene. Therefore, TP53 mutations are not currently assessed in routine lung 
cancer clinical practice. However, there are increasing numbers of molecularly-
agents that are active against mutations which confer acquired resistance on 
tumours.  For example, osimertinib is effective in the treatment of the acquired 
EGFR c.2369C>T, p.T790M mutation commonly seen in EGFR TKi resistance. 
Therefore, routine assessment, for the emergence of this EGFR mutation, by 
serial ctDNA analysis, could easily be incorporated into routine patient 
monitoring. 
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Figure 5-5 Patient EGFR_1. Molecular vs radiological assessments of disease progression during 
EGFR TKi therapy. Changes in levels of mutations in ctDNA are shown by ddPCR (1.) and NGS (2.), 
and a heatmap (3.).CT scan at day 150 of therapy (arrow A) revealing the lung primary (A.i) and the 
right hilar lymphadenopathy (A.ii). CT scan at day 350 (arrow B) revealing disease progression in 
both sites (B.i and B.ii). Blue circles highlight tumours after response to EGFR TKi therapy and red 
circles highlight growing tumours.  
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5.2.9 Screening for emergence of T790M using ddPCR 
 
The presence of the EGFR c.2369C>T, p.T790M mutation, using NGS and ddPCR, 
was assessed in all 39 serial plasma samples from 10 patients. By the end of the 
follow-up period, six of the 10 patients had developed drug 
resistance/progressive disease on EGFR TKi therapy. In two of the patients who 
had progressive disease (33%), it was possible to detect the EGFR c.2369C>T, 
p.T790M acquired resistance mutation, using ddPCR, at alternate allele 
frequencies of 1%. It is expected that acquired EGFR c.2369C>T, p.T790M 
mutations emerge in approximately 50% of patients with EGFRmut+ve 
adenocarcinoma of the lung who develop resistance to EGFR TKi therapy. 
 
For the other 4 patients with disease progression, it was not possible to 
demonstrate the EGFR c.2369C>T, p.T790M mutation. Obtaining a negative 
result for this mutation may be due to several reasons. Firstly, there may 
different mechanism of acquired resistance (expected in approximately 50% of 
EGFRmut+ve lung cancer patients). Secondly, a false negative result may also result 
from technical limitations, such as the limit of detection of current technologies, 
including droplet digital PCR (see Chapter 3). Thirdly, the progressive metastatic 
disease may not shed DNA into the peripheral venous circulation, and therefore 
cannot be assessed via ctDNA. 
 
5.2.10 Disease progression within the CNS 
 
Three EGFRmut+ve patients (EGFR_5,6 and 8) had CNS metastases.  Patient EGFR_6 
had meningeal disease at the time of diagnosis, while brain metastases were 
detected in patients EBFR_5 and 8, at the time of clinical/radiological 
progression of their lung cancer. It is impossible to exclude the presence of 
cerebral metastatic disease at diagnosis in these latter 2 patients, because 
baseline radiological imaging of the brain is not standard practice in the UK, 
unless there is a clinical indication, such as focal neurological signs. 
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At diagnosis, Patient (EGFR_5) had liver and lung metastases. A partial 
radiological response to primary palliative gefitinib therapy was seen in the 
primary lung tumour on CT scan at day 168 of therapy. At this time, it was also 
possible to detect mutant EGFR mutation (Exon 19, c.2236_2250del15, 
p.E746_A750) in ctDNA by ddPCR, at an alternate allele frequency of 0.57% 
(95% Poisson Error 0 – 1.91%), but not by NGS (Figure 5-6). The patient 
continued therapy with gefitinib for a further 259 days, at which time, the 
patient was admitted to hospital and treated for pneumonia. Neurological 
decline in this patient prompted a MRI scan of the head, shortly afterwards, (day 
451) which revealed the presence of metastatic disease within the brain. 
 
NGS and ddPCR analysis of ctDNA at the time of the MRI, revealed a low level of 
the original activating EGFR mutation. In addition, there may have been a 
concurrent low level EGFR c.2369C>T, p.T790M mutation detected in ctDNA by 
ddPCR (<0.5% alternate allele frequency). However, the Poisson error included 
0%, which means this could represent a false-positive result. It is not known 
whether this patient had cerebro-metastatic disease at the time of diagnosis, and 
therefore, it is unknown whether this had progressed or responded during 
afatinib therapy. There is too little data from this patient to determine whether 
changes in levels of EGFR mutation or the potential appearance of EGFR 
c.2369C>T, p.T790M, in ctDNA represents tumour progression within the CNS. 
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Figure 5-6 Molecular and radiological assessments of response to gefitinib therapy in a patient 
(EGFR_5) with metastatic CNS disease. Changes in mutant EGFR level in ctDNA, using ddPCR (1.) with 
95% Poisson error bars, and NGS (2.).Baseline CT scan showing the primary lung tumour (A.). CT 
scan on day 168 (B.). CT scan at day 427 of therapy (C). Sagittal section from MRI head on day 451 
(D.). Blue circles show lung tumour. Yellow circle show lung tumour and possible disease 
progression. Red circle shows brain metastasis. 
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A decrease in the level of the original activating EGFR mutation in ctDNA (Exon 
19, c.2235_2249del15, p.E746_A750) was observed in one patient (EGFR_8), by 
day 56 of afatinib therapy (from 0.44% to 0% alternate allele frequency 
determined by ddPCR). Levels remained undetectable by ddPCR at the time of a 
CT scan (day 185), which also confirmed radiological response to treatment. This 
patient developed neurological deterioration prompting MRI imaging of the 
patient’s brain on day 316.  Radiological images showed a lesion in the left 
posterior occipital lobe, suspicious of a metastatic lesion, and hydrocephalus, 
consistent with malinant CNS disease. At this time, comparing ctDNA analysis 
using ddPCR and NGS, the abundance of the original EGFR mutation in ctDNA 
remained at 0% alternate allele frequency, utilising ddPCR, but there was an 
increase observed using NGS (from 0% to 0.3% alternate allele frequency) 
(Figure 5-7). This patient experienced clinical progression of their CNS disease, 
yet the increase in mutational level of the EGFR mutation in ctDNA was not 
consistent between the two platforms. Therefore there is not enough evidence 
with this case study, that changes in mutation level in ctDNA reflect CNS disease 
progression. 
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Figure 5-7 Patient EGFR_8. Molecular and radiological assessments of response to afatinib therapy in 
a second patient with metastatic CNS disease. Changes in mutant EGFR load in the blood are shown 
by ddPCR with 95% Poisson error bars (1.) and by NGS (2.).Baseline CT scan of lung tumour (blue 
circle) (A.). CT scan at day 185 (B.) showing radiological response to therapy (green circle). The two 
axial MRI images of the patient’s brain on day 316 (arrow C), show hydrocephalus (C.i.) and a 
suspicious metastatic lesion  in the left posterior occipital lobe (red circle) (C.ii.). 
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To help to further assess whether tumour-derived DNA may be able to cross the 
blood:brain barrier, permitting detection in blood samples as ctDNA, we 
investigated whether ctDNA is present in cerebro-spinal fluid (CSF) of  a patient 
with CNS metastases. Patient EGFR_6 had leptomeningeal disease and bone 
metastases present at diagnosis. During the period of disease control with 
afatinib, the abundance of the original activating EGFR mutation contained 
within ctDNA remained at 0% alternate allele frequency, determined by ddPCR. 
Comparison of blood ctDNA and cell free DNA within CSF at the time of disease 
progression (day 420 of therapy) revealed the presence of the original activating 
EGFR mutation within CSF, but not within ctDNA. Both cell free DNA CSF, and 
ctDNA analysis were negative for the EGFR c.2369C>T, p.T790M resistance 
mutation, using ddPCR. This data provides a proof of principle that it is possible 
to identify EGFR mutations within cell free DNA contained within CSF, in an 
EGFRmut+ve lung cancer patient with CNS disease. It also raises the query of 
whether tumour DNA derived from CNS disease, fails to reach the peripheral 
venous circulation. 
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5.3 Clinical Implications 
 
Data presented here demonstrate that it is possible to detect various EGFR mutations in 
ctDNA in patients with locally advanced and metastatic EGFRmut+ve adenocarcinoma of 
the lung. This has important implications for monitoring disease during therapy, and at 
disease progression, as well as in the diagnostic setting, where there is often little or no 
tumour tissue available for EGFR mutational analysis.  
 
In this results chapter, patients with mutant EGFR detected in ctDNA experienced a 
clinical response to EGFR TKi. A blood test for ctDNA analysis is an attractive way to 
detect the presence of an EGFR mutation, especially due to the high failure rate of EGFR 
mutational analysis on a patient’s original tumour biopsy, or lack of biopsy of the 
primary tissue altogether. Therefore, detecting EGFR mutations in ctDNA, could have 
the potential to increase the successful detection of EGFRmut+ve adenocarcinoma of the 
lung, and thereby supporting the use of EGFR TKi as a therapeutic option for these 
patients. 
 
Understanding the clinical factors that influence the chances of detecting mutant EGFR 
within ctDNA is very important. The clinician needs to know the best time to take a 
blood sample from a patient, to optimise the chances of detecting mutant EGFR if it is 
present. The results in this chapter would suggest that it is possible to detect mutant 
EGFR within ctDNA when the patient is treatment naive, or when the patient has 
received prior palliative radiotherapy to the spine. If the patient has received recent 
radical radiotherapy, lung surgery or systemic chemotherapy, then the chances of 
detecting mutant EGFR in ctDNA could be less. Even though this is useful information 
for the clinician requesting EGFR mutation testing on ctDNA, these findings would need 
further validation in a larger study. 
 
Data presented in this chapter also support the hypothesis that the kinetics of EGFR 
mutation load in serial ctDNA samples can be useful in monitoring therapy, both in 
assessing response and detecting progression, in conjunction with (and perhaps 
preferentially over) classical radiological assessment and may provide a means for 
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earlier and more sensitive detection of response to treatment and/or progressive 
disease/emergence of resistance to therapy. 
 
These quantitative changes have been shown to correlate with radiological response to 
therapy with serial scans. An interesting future research question is to determine 
whether ctDNA kinetics could be a valid predictive biomarker for expected duration of 
response to EGFR TKi. This may influence clinical management and follow-up of these 
patients in that patients who are predicted to have a shorter duration of disease 
response may require closer monitoring for signs of disease progression. 
 
Patients often undergo a period of effective disease control on EGFR TKi therapy. For 
the majority of the patients in this cohort, the duration of radiological stable disease 
was reflected in the consistent low level, or inability to detect, the mutant EGFR load in 
the blood.  It would be interesting to investigate further whether consistently 
undetectable mutant EGFR levels, during a period of EGFR TKi therapy, may accurately 
reflect the period of disease control, and may help to potentially reduce the need for 
repeated CT scanning during this period. 
 
We have also discovered that this is possible to detect increasing levels of mutated 
ctDNA up to 2 months before clinical disease progression. These finding have been 
confirmed by a larger study(137) (Zheng et al, 2016), who monitored mutant EGFR in 
ctDNA, in 117 patients with acquired resistance to EGFR TKi therapy. The authors 
reported that 47% of 117 EGFRmut+ve patients treated with EGFR TKi, developed the 
acquired EGFR c.2369C>T, p.T790M mutation, up to a median 2.2 months prior to 
clinical progression of their cancer(137). This has important implications for patient 
care. There may be the opportunity for an earlier change in therapeutic strategy, before 
the patient deteriorates clinically, as a result of disease progression. This interesting 
clinical question could be answered by a prospective clinical trial. Specifically whether 
an earlier change in therapeutic strategy, based on ctDNA progression, may offer 
superior patient outcomes, compared to those for whom therapy is changed upon 
radiological or clinical disease progression. 
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Previous research by Siravegna et al (2015) demonstrated that it is possible to observe 
the emergence of a KRAS mutation (a negative predictor of response) in ctDNA, in 
colorectal cancer patients treated with anti-EGFR (cetuximab) therapy. These mutations 
then become undetectable in ctDNA when cetuximab is stopped, and re-appear when 
treatment is recommenced(138). In line with this, the results in this chapter confirm 
that it is possible to observe the appearance of the EGFR TKi resistance mutation EGFR 
c.2369C>T, p.T790M, in patients with EGFRmut+ve adenocarcinoma of the lung. However, 
more research is required to determine whether the level of EGFR c.2369C>T, p.T790M 
mutation in ctDNA, decreases on cessation of EGFR TKi therapy.  It is possible that 
ctDNA kinetics could be used in the assessment of continuous versus intermittent EFGR 
TKi therapy, and whether intermittent therapy may improve the duration of disease 
control. 
 
NGS of ctDNA using the 50-gene cancer hotspot panel can reveal the emergence of new 
mutations, associated with disease progression, during or following EGFR TKi therapy. 
Detecting the acquired EGFR c.2369C>T p.T790M ‘TKi resistance’ mutation, in ctDNA 
has the advantage of avoiding the need for a repeat biopsy of the tumour tissue, with 
associated complications, and means that patients can be switched to osimertinib 
therapy. At present, a few diagnostic laboratories in the UK are implementing ctDNA 
analysis in routine clinical practice for some specific indications, namely screening for 
EGFR mutations in ctDNA at the time of diagnosis, for patients that either do not have a 
biopsy, or EGFR analysis of tumour tissue DNA has failed. These laboratories are also 
able to offer screening for the acquired EGFR c.2369C>T, p.T790M resistance 
mechanism, as this may more precisely define the therapeutic options for patients e.g. 
to direct the clinician towards recommending osimertinib, rather than gefitinib. 
 
As more ‘targeted therapies’ become available for patients with locally advanced or 
metastatic lung cancer, detecting multiple potential genetic mutations in ctDNA, to 
direct these therapies, is of increasing importance. This can be achieved using NGS with 
a gene panel, provided the mutational level within ctDNA is above the limit of detection 
of NGS. 
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5.3.1 Progression of metastatic CNS disease 
 
It has been possible to detect mutant EGFR in cell free DNA in CSF from a patient with 
progressing leptomeningeal disease, but not in ctDNA in peripheral venous blood. 
Subsequently, when a patient develops progressive disease within the CNS during 
therapy with an EGFR TKi, and it is not possible to detect the resistance conveying EGFR 
c.2369C>T, p.T790M mutation in ctDNA, it is worth considering testing cell free DNA 
within the CSF, provided a lumbar puncture is not contra-indicated. However, even 
though it is possible to detect mutant EGFR within cell free DNA within CSF, clinical 
response to osimertinib must be validated in a greater number of patients with CNS 
disease harbouring this mutation. 
 
The inability to detect mutant EGFR in ctDNA in patients with CNS disease may be 
explained if the tumour DNA does not cross the blood-brain-barrier.  However, for two 
patients in this results chapter (EGFR_5 and EGFR8) who had confirmed CNS metastatic 
disease at the time of clinical disease progression, there is not enough data to contribute 
to this hypothesis, and is the subject of ongoing research. 
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6 Circulating tumour DNA as a Prognostic Biomarker in Patients 
with Small Cell Lung Cancer 
 
6.1 Chapter Overview 
 
There is an important, unmet clinical need for valid surrogate biomarkers, which could 
offer prognostic information, and help to stratify SCLC patients between existing 
anticancer therapies, and in trials of new therapeutic approaches. In aiding careful 
patient selection and decision-making for individual patients, they may increase efficacy 
and simultaneously help to avoid potentially toxic treatment, especially as this type of 
lung cancer carries a very poor prognosis. We set out to determine the feasibility of 
ctDNA as a biomarker in patients with advanced small cell lung cancer (SCLC), as there 
is little in the literature on this topic. 
 
6.2 Chapter Aims 
 
1. To determine the feasibility of detecting and quantifying mutations contained 
within ctDNA, in patients with small cell lung cancer. 
2. To monitor quantitative changes in ctDNA with time, as patients undergo anti-
cancer therapies. 
3. To compare base-line levels of ctDNA mutations with survival, and determine 
potential utility as a prognostic biomarker. 
4. To determine feasibility of using base-line ctDNA levels as a basis for individual 
patient treatment stratification. 
6.2.1 Chapter Objectives 
 
1. Tumour tissue obtained from the diagnostic tumour biopsy of SCLC patients, will 
be analysed using NGS to detect somatic mutations. 
2. Analysis of ctDNA, using ddPCR and NGS is performed on serial blood samples 
collected from patients with small cell lung cancer, as they undergo 
chemotherapy. 
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3. Levels of ctDNA are correlated with survival of the patients, and a cut-off ctDNA 
level can be determined using Receiver Operator Curves (ROC). 
4. It is considered whether baseline levels of ctDNA can be used as a prognostic 
biomarker, and whether this information can be used to stratify patient 
treatments, in the case of small cell lung cancer, this can include whether 
patients should receive prophylactic cranial irradiation (PCI). 
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6.3 Chapter Results 
 
6.3.1 Patient recruitment and clinical data 
 
Ten patients with SCLC were recruited to this part of the study. Patients’ clinical 
characteristics, including stage of disease, sites of metastases, therapeutic 
strategy and clinical outcome are summarised in Table 6-1. Eight of the 10 
patients had stage IV disease and two had stage IIIB. One of the stage IV patients 
died before receiving any palliative chemotherapy (SCLC_3), but all of the other 9 
patients underwent primary palliative chemotherapy. Carboplatin and Etoposide 
was the most common regimen used, with an average of 4 cycles (range 3 to 6 
cycles). There is a 85-89% response rate to first-line treatment of SCLC(139), 
and all of the 9 patients who received chemotherapy, had an initial radiological 
response to treatment. In 8 of these 9 patients, initial radiological responses to 
chemotherapy were sustained at the time of repeat staging CT scan on 
completion of treatment. 
 
At the end of chemotherapy, the most common subsequent treatment was 
consolidation radiotherapy to the thorax. Two patients with confirmed brain 
metastases at diagnosis also received therapeutic cranial irradiation, after 
completion of first line palliative chemotherapy. Prophylactic cranial irradiation 
(PCI) was a potential therapeutic option for the other 7 patients, but only 3 were 
treated in this way. 
 
Although all of the treated patients achieved an initial radiological response to 
chemotherapy, the survival times were very variable (range 86 – 477 days). As is 
often the case in SCLC, the diagnosis of progressive or relapsed disease usually 
occurred shortly before death, therefore progression-free and overall survival 
are very similar, in these patients. Overall survival data were calculated from 
date of consent to this study (i.e. pre-treatment) to death. 
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Patient Research ID TNM Stage Sites of Metastases Treatment Intent Chemotherapy 
Initial Radiological 
Response 
Subsequent Therapy 
Cranial 
Irradiation 
OS 
(Days) 
SCLC_1 T2aN2M1b IV Brain Palliative Carboplatin/Etoposide PR Palliative RT to Brain TCI 242 
SCLC_2 T3N2M1b IV Bone, Liver Palliative Carboplatin/Etoposide PR 
Consolidation RT to 
chest, palliative RT to 
spine 
PCI 165 
SCLC_3 T2bN3M1b IV LN, Lung, Liver, Adrenal 
Best Supportive 
Care 
Nil NA NA NA 2 
SCLC_4 
T4N2M0 
(Oesophageal 
Encroachment) 
IIIB No Distant Metastases Palliative Cisplatin/Etoposide PR 
Consolidation RT to 
chest 
PCI 477* 
SCLC_5 T2aN3M1b IV Liver Palliative Carboplatin/Etoposide PR 
Consolidation RT to 
chest 
PCI 201 
SCLC_6 T2aN3M1b IV Adrenal Palliative Carboplatin/Etoposide PR RT for SVCO NO 163 
SCLC_7 T4N3M1b IV Bone, Liver, Possible Brain Palliative Carboplatin/Etoposide PR Nil NO 171 
SCLC_8 T4N3M1b IV Bone, Liver, Adrenal Palliative Carboplatin/Etoposide PR Nil NO 86 
SCLC_9 T3N1M1b IV Brain, Adrenal, Axillary LN Palliative Carboplatin/Etoposide PR 
Consolidation RT to 
chest 
TCI 246* 
SCLC_10 T4N2M0 IIIB No Distant Metastases Palliative Carboplatin/Etoposide PR 
Consolidation RT to 
chest 
NO 201* 
Table 6-1 Summary of clinical characteristics for patients with Small Cell Lung Cancer. *Patients still alive at time of final data collection. LN = Lymph Nodes. NA = Not 
Applicable. OS = Overall Survival (Days). PCI = Prophylactic Cranial Irradiation. PD = Progressive disease. PFS = Progression Free Survival (Days).  PR = Partial Response. 
RT= Radiotherapy. SVCO = Superior Vena Cava Obstruction. TCI = Therapeutic Cranial Irradiation. 
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6.3.2 Molecular Characterisation of Tumour DNA 
 
Nine of the 10 patients had sufficient tumour tissue available for NGS analysis 
using the 50 gene cancer hotspot panel, used in previous chapters. The likely 
pathogenic mutations revealed are listed in Table 6-2. The most common 
somatic mutations observed were in the TP53 gene, observed in 8 of 9 tumour 
samples. This is consistent with the previous literature(135). Pathogenic 
mutations in KRAS were observed in 2 patients, and one point mutation each of 
RB1 and SMAD4.  
 142 
Patient Research ID Pathogenic Mutations 
Alternate Allele 
Frequency in Tumour 
Tissue (%) 
Potential Clinical Significance 
SCLC_1 TP53 c.742C>T, p.R248W 97.2 1,2 
SCLC_2 TP53 c.1001G>T, p.G334V 31.0 1,2 
SCLC_3 
TP53 c.844C>G, p.R282G 40.2 1,2 
KRAS c.34G>T, p.G12C 18.1 3 
SCLC_4 
TP53 c.451C>A, p.P151T 43.8 1 
2 RB1 c.1700C>T, p.S567L 36.4 
SCLC_5 No Mutations Detected - 4 
SCLC_6 TP53 c.592G>T, p.E198TER 64.4 1,2 
SCLC_7 
*TP53 c.814G>T, p.V272L 
*SMAD4 c.1081C>T, p.R361C 
40.6* 
53.5* 
1,2 
SCLC_8 TP53 c.641A>G, p.H214R 98.9 1,2 
SCLC_9 KRAS c.437C>T, p.A146V 45.2 3 
SCLC_10 TP53 c.892G>T, p.E298TER 80.7 1,2 
Table 6-2 Summary of pathogenic mutations identified in tumour samples/ctDNA from patients with 
Small Cell Lung Cancer, identified by NGS. * Mutations detected in ctDNA, due to insufficient tumour 
tissue. 1. Sensitivity to PARP/WEE1 inhibitors. 2. Potential target for immunotherapy. 3. Clinical 
response to CDK4/6 inhibitor. 4. Not Determined. 
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For one patient (research ID SCLC_7) there was insufficient FFPE tumour tissue 
for DNA extraction and analysis.  However, 2 pathogenic mutations were 
detected, using NGS, in a base-line ctDNA sample from this patient, one in TP53 
c.814G>T, p.V272L (alternate allele frequency of 40.6%), and another mutation 
in SMAD4 c.1081C>T, p.R361C (alternate allele frequency 41.1%). This specific 
SMAD4 mutation has not been previously documented in SCLC, but loss of 
function of the tumour suppressor gene, SMAD4, has previously been reported in 
non-small lung cancer, and this may be linked to increases in chemo-sensitivity 
to DNA topoisomerase inhibitors(140), such as etoposide. It is impossible to 
draw conclusions from a single patient, but it would be interesting to identify 
other patients whose tumours or ctDNA contain this mutation and determine 
whether this mutation may convey increased sensitivity to etoposide and have 
potential use as a predictive biomarker. 
 
SCLC_7 had an initial tumour response to chemotherapy, based on initial plain 
chest radiograph imaging, rather than cross-sectional CT scans. However, a 
subsequent CT scan, on completion of treatment, demonstrated that, although 
the primary lung tumour had increased in size compared with the baseline CT 
scan, the liver metastasis had almost completely resolved. This is a prime 
example of intra-patient tumour heterogeneity. The best way to characterise 
whether there were different ‘branch’ mutations contained within the lung 
tumour, compared to the liver metastases, would be to perform NGS of tumour 
tissue samples from the lung and the liver. It is widely accepted that ctDNA could 
represent tumour DNA from all tumour sub-clones contained within the body. 
Had there been tumour tissue available for NGS analysis for SCLC_7, it may have 
been possible to determine whether any of the mutations, contained within 
ctDNA, were derived from different tumour sub-clones, and whether this may 
account for the differences in radiological response observed between the lung 
and liver tumours.  
 
For one patient (patient ID SCLC_5), despite adequate NGS sequence analysis of 
the FFPE tumour tissue DNA, and baseline ctDNA, no pathogenic mutations were 
discovered, using the targeted 50 gene cancer hotspot panel. It is therefore 
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highly likely that the mechanism of tumorigenesis is the result of a ‘driver’ 
mutation that is not contained within this NGS gene panel. 
 
6.3.3 Analysis of circulating tumour DNA 
 
In addition to the FFPE tumour tissue samples, above, a total of 38 research 
blood samples were obtained, including a base-line blood sample from each of 
the 10 patients. Serial samples were also collected from 9 of these 10, during the 
course of treatment, for comparison with clinical data (radiological response and 
overall survival).  There were between 1 and 7 serial blood tests per patient 
(median 4 samples per patient). 
 
It was not always possible to obtain a research blood sample following the 
clinical or radiological diagnosis of disease progression, as patients were 
sometimes too unwell, or hospitalised, and blood sampling for research was 
either not appropriate or not feasible. 
6.3.3.1 Comparison between NGS and ddPCR detection of mutations in ctDNA 
 
NGS was useful to detect pathogenic mutations, but once known, it was more 
cost effective to track ctDNA kinetics using ddPCR rather than NGS. This was 
deemed acceptable as there was good correlation in alternate allele frequency 
between the two molecular platforms, as assessed by Bland-Altman plots (Figure 
6-1), for both FFPE tumour tissue DNA and ctDNA. 
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Figure 6-1 Correlation of alternate allele frequency (AAF) (%) of mutated DNA in FFPE tumour tissue (A) and ctDNA samples (B), as assessed by both ddPCR (i) and NGS 
(ii) approaches. Each data point represents one sample analysed.    
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6.3.4 Concordance between FFPE and baseline cfDNA 
 
There was enough tumour tissue for NGS analysis for 9 of the 10 patients. There 
was not enough tumour tissue for NGS analysis for one patient (SCLC_7), since 
the FFPE tumour tissue had been exhausted by prior histopathological 
examination.  Using NGS, mutations were detected with the 50 gene cancer 
hotspot panel in FFPE tumour tissue in 8 patients, and of these the same NGS 
detected the same mutations in baseline ctDNA in 6 patients. In one patient 
(SCLC_5), it was not possible to detect any mutations in the tumour tissue, or 
baseline ctDNA, using NGS. However, for the patient with no available tumour 
tissue (SCLC_7), it was possible to detect mutations in baseline ctDNA using NGS, 
as previously stated. Therefore, concordance for mutation detection between 
tumour tissue and baseline ctDNA, using NGS is 77.8%. 
 
It was possible to detect the mutations in 7 of 8 patients where mutations could 
be assessed by ddPCR in the baseline ctDNA sample. This gives a concordance for 
mutation detection between tumour tissue and baseline ctDNA, using ddPCR, of 
87.5%. The main difference between NGS and ddPCR, is that ddPCR was able to 
detect a mutation in baseline ctDNA in a patient that NGS was not able to.  
6.3.5 Concordance between ddPCR and NGS for mutation detection in ctDNA 
 
NGS analysis of FFPE tumour tissue, revealed 12 mutations that were assessable 
within the baseline ctDNA samples, using NGS and ddPCR. It was not possible to 
set up a ddPCR assay to assess for 2 of the mutations, owing to time and financial 
constraints of this research project. Of the 10 remaining mutations, ddPCR 
detected 9 of them, and NGS detected 8 of them. 
 
For these 10 mutations, overall concordance in mutation detection in ctDNA, 
between ddPCR and NGS was 90% (Table 6-3). It was possible to detect 8 of the 
mutations, in baseline ctDNA, using ddPCR and NGS. For one patient SCLC_1 the 
TP53 mutation was not detectable in base-line ctDNA either by NGS or by ddPCR. 
This patient had stage IV SCLC with brain as the only site of metastases. It is 
possible that the absence of the mutation in the ctDNA, by both NGS and ddPCR 
 147 
may be due to an absence of ctDNA in the blood sample - the only site of 
metastatic disease in this patient was the brain and ctDNA may not be able to 
cross the blood: brain barrier into the peripheral circulation, as discussed in 
Chapter 5.  
 
For one patient (SCLC_4) there was discordance in baseline ctDNA detection, 
between NGS and ddPCR. The TP53 mutation was able to be detected using 
ddPCR, but not with NGS. The most likely explanation is that this TP53 mutation 
occurred at an alternate allele frequency (0.69%) below the limit of detection of 
the ITVC software used for NGS (see Chapter 3). The reason for the low alternate 
allele frequency is that this patient had stage IIIB disease, where there may be 
lower levels of ctDNA compared to patients with stage IV disease. 
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FFPE Tumour Tissue Baseline ctDNA Sample 
   
Next Generation Sequencing Next Generation Sequencing Droplet Digital PCR 
Patient 
ID Stage Gene 
Mutation 
Detected 
Coverage 
(x) 
AAF 
(%) ITVC 
Coverage 
(x) AAF (%) 
Mutation 
Detected AAF (%) 95% Poisson Error 
SCLC_1 IV TP53 Yes 34402 97.2 No 100414 0.13 No  0.0   
SCLC_2 IV TP53 Yes 6083 31 Yes 62914 60.10 Yes 67.9 64.7 - 71.1 
SCLC_3 
IV KRAS Yes 29246 18.1 Yes 8473 32.30 Yes 36.7 35.6 - 37.9 
IV TP53 Yes 13681 40.2 Yes 12437 71.10 Yes 86.3 85.8 - 86.8 
SCLC_4 IIIB 
TP53 Yes 32671 43.8 No 63381 0.54 Yes 0.69 0.0 - 1.73 
RB1 Yes 16644 36.4 No 22970 0.62 
Not 
Tested - - 
SCLC_5 IV Nil 
Detected 
Nil 
Detected  
  -  - 
Nil 
Detected  - -  NA - - 
SCLC_6 IV TP53 Yes 23700 64.4 Yes 25436 33.40 Yes 48.1 44.9 - 51.2 
SCLC_7 IV 
TP53 
Not Available for Testing 
Yes 23402 40.60 Yes 53.5 51.0 - 56.0 
SMAD4 Yes 30870 41.10 Not Tested  -  - 
SCLC_8 IV TP53 Yes 39757 98.9 Yes 18508 49.20 Yes 69.7 65.8 - 73.6 
SCLC_9 IV KRAS Yes 41890 45.2 Yes 8735 8.20 Yes 8.73 11.1 - 12.8 
SCLC_10 IIIB TP53 Yes 7910 80.7 Yes 24113 3.20  Yes 0.783  0.0 – 2.63 
Table 6-3 Comparing mutation detection between in FFPE tumour tissue DNA and baseline cfDNA by NGS and ddPCR. AAF = Alternate allele frequency. ITVC = Ion Torrent 
Variant Caller. 
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6.3.6 Baseline cfDNA mutational load as a Prognostic Biomarker 
 
Receiver operating characteristic (ROC) analyses were performed to generate a 
cut-off value for baseline ctDNA level (alternate allele frequency (%)), to predict 
a prognosis of greater than, or less than 4 months, from the time of consent to 
enter the study (Table 6-4).  The time-point of 4 months was chosen because this 
is the average time taken to complete a course of palliative chemotherapy, 
followed by a course of radiotherapy. Since it is preferable to correctly identify 
patients with a truly poor prognosis, the cut-off ctDNA level was chosen that 
gave the highest specificity while maintaining the optimum sensitivity. On the 
basis of these data, a ctDNA fraction of 44.3% can be suggested as a possible 
prognostic biomarker, with patients having a base-line ctDNA mutation load of 
less than 44.3% alternate allele frequency, belonging to a better prognostic. It 
would be important to validate this prospectively, in a larger group of patients. 
 
 
ROC Curve Analysis 
Stage of 
Disease 
Area 
Under the 
Curve 
(AUC) 
Indication of 
Test 
Suitability 
95 % 
Confidence 
Interval (AUC) 
Significance 
Cut-off 
Baseline 
ctDNA AAF 
Sensitivity 
(Optimum) 
Specificity 
IIIB and IV 0.929 Excellent 0.741 - 1.00 p = 0.079 44.30% 1.00 0.87 
Only IV 0.900 Excellent 0.644 - 1.00 p = 0.121 44.30% 1.00 0.80 
Table 6-4 Receiver Operating Characteristics (ROC) Curve analysis to determine a baseline ctDNA 
fractional abundance (%) to predict prognostic group for patients with Small Cell Lung Cancer. 
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Prognosis is poor in locally advanced and metastatic SCLC. If patients have more 
favourable prognoses, then more aggressive anticancer therapies can be 
considered, where clinically appropriate, as the benefits of treatments may 
outweigh the risks.  However, it is desirable to be able to identify SCLC patients 
with a worse prognosis, to help to avoid the inappropriate use of toxic anti-
cancer therapies, such as chemotherapy and cranial irradiation, where the risks 
may outweigh the benefits. The novel data presented here, suggest baseline 
ctDNA level may act as an independent prognostic biomarker in patients with 
stage IIIB and stage IV small cell lung cancer. 
 
6.3.7 Treatment stratification according to baseline level of ctDNA 
 
The base-line ctDNA level was compared to whether patients received PCI (Table 
6-5). Using the proposed cut-off of 44.3% AAF in the base-line ctDNA, as a 
prognostic biomarker, could have potentially influenced the clinical management 
for two (patients SCLC_2 and 10) of the 7 patients that could have been 
considered for PCI. One patient (SCLC_2) received PCI, but using the 44.3% cut-
off would have put them into a poorer prognostic group. In fact, this patient had 
an initial good clinical and radiological response to chemotherapy, and 
subsequently received consolidation thoracic radiotherapy (20 Grey in 5 
fractions), palliative radiotherapy to a site of spinal metastatic disease (L2-5)(20 
Grey in 5 fractions) and PCI (20 Grey in 5 fractions), but only survived 5.5 
months from the time of consent. This was approximately 2.5 months following 
completion of treatment. Despite the initial radiological and clinical response to 
palliative chemotherapy, it is interesting to speculate whether the use of the 
44.3% cut-off for this patient could have been spared the time burden and 
toxicities of the PCI, especially when pain control, such as the spinal metastatic 
disease, would have taken precedence. However, as mentioned, it would be 
vitally important to validate this biomarker in larger cohorts of prospective 
patients. 
 
Conversely, the other patient (ID SCLC_10) would have been placed in the ‘better 
prognostic’ group, on the basis of base-line ctDNA level cut-off of 44.3%. They 
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also experienced a good radiological response to chemotherapy. This patient was 
living at 6.7 months from the time of consent (at the time of the last follow-up for 
this patient), and subsequent treatment modalities, such consolidation thoracic 
radiotherapy and PCI could be considered if clinically appropriate. 
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Patient 
Research ID 
Did patient 
receive PCI? 
Was 
ctDNA 
detected 
in 
baseline 
sample? 
AAF 
(%) 
Prognostic 
Group 
using 
baseline 
ctDNA 
AAF cut-
off 
Should PCI be considered based 
on baseline ctDNA cutoff 
Potential Change to 
Clinical 
Management 
SCLC_2 Yes Yes 67.9 Poorer PCI may not offer clinical benefit Yes 
SCLC_4 Yes 
Yes 0.69 Better PCI should be considered as 
clinically appropriate 
No 
SCLC_5 Yes Unable to quantitate ctDNA Unable to advise No 
SCLC_6 No Yes 48.1 Poorer PCI may not offer clinical benefit No 
SCLC_7 No Yes 53.5 Poorer PCI may not offer clinical benefit No 
SCLC_8 No Yes 69.7 Poorer PCI may not offer clinical benefit No 
SCLC_10 No 
Yes 0.783 Better PCI should be considered as 
clinically appropriate 
Yes 
Table 6-5 Comparing whether baseline ctDNA level, as a prognostic biomarker, would have 
potentially influenced clinical decision making regarding PCI. 
 
6.3.8 Mutation detection in ctDNA as a surrogate for tumour tissue analysis 
 
There was insufficient FFPE tumour tissue NGS anaylsis in one patient (research 
ID SCLC_7). NGS analysis was performed on baseline ctDNA, and the pathogenic 
mutations in TP53 c.814G>T, p.V272L and in SMAD4  c.1081C>T, p. R361C, were 
discovered with alternate allele frequencies of 40.6% and 41.1% respectively. 
Patients with treatment-naïve stage IIIB and stage IV SCLC had relatively high 
amounts of ctDNA in the blood (median alternate allele frequency of 32.85%, 
range 0.13% - 71.1%), therefore increasing the chances of mutation detection, 
compared to metastatic NSCLC (Chapter 3). Thus illustrating that ctDNA analysis 
is an exciting, alternative source of easily accessible tumour DNA for molecular 
analysis in patients with SCLC. It is therefore also an attractive surrogate for 
analysing tumour tissue samples.  
 
6.3.8.1 Kinetics of ctDNA in SCLC patients treated with chemotherapy 
 
Although decreases in ctDNA during chemotherapy have been observed in 
patients in various cancer types, there is little in the literature about the 
dynamics of ctDNA in patients with small cell lung cancer. We therefore 
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investigated the possibility of using NGS and ddPCR assessments of changes in 
levels of mutations in ctDNA, to monitor response/resistance to therapy in our 
SCLC patients. 
A somatic KRAS c.437C>T, p.A146V mutation was discovered in the tumour 
tissue DNA from Patient ID SCLC_9. Changes in abundance of this mutation were 
monitored, using both NGS and droplet digital PCR methodologies, in serial 
ctDNA samples, taken at various time-points during palliative chemotherapy, 
and subsequent consolidation radiotherapy to the chest (Figure 6-2). Findings 
were similar to those observed in EGFRmut+ve NSCLC, in Chaper 5 – after 
commencing chemotherapy, ctDNA levels fell to undetectable levels, as assessed 
by both methods.  This compared well with radiological assessment of response 
to treatment, as assessed by plain film radiography (chest X-ray), and confirmed 
by a CT scan on completion of treatment. Using ddPCR, KRAS mutation levels in 
ctDNA levels remained undetectable, until the end of the period of follow-up.  
However, there was a slight increase in mutant KRAS level using NGS, not 
observed by ddPCR, towards the end of therapy. 
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Figure 6-2 ctDNA kinetics and correlation with radiological response in a chemotherapy-sensitive, 
metastatic small cell lung cancer (Patient ID SCLC_9). Changes in mutant KRAS levels in serial ctDNA 
samples using ddPCR (95% Poisson error bars shown)(1.), and NGS (2.). A(i) Baseline chest 
radiograph (A(i)) and baseline CT scan (A(ii)), showing the primary lung tumour (yellow circles). 
Plain chest radiograph  at 112 days (B). Post-treatment CT scan of chest (day 168) (C). Green circles 
highlight responding disease. 
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Quantitative changes in ctDNA abundance with time were also assessed in a 
patient (SCLC_7) who achieved an initial radiological response to palliative 
chemotherapy (Figure 6-3). Similar patterns of decline in a TP53 mutation in 
ctDNA were observed with both ddPCR and NGS, during chemotherapy, with a 
plateau being reached at approximately 10-15% variant allele frequency, after 
cycle 1 of chemotherapy. NGS also showed a similar pattern for a second, SMAD4 
mutation, in this same patient. Towards the end of the course of 6 cycles of 
chemotherapy, there was a slight increase in levels of both mutations in ctDNA 
as assessed by NGS and, in the TP53 mutation, by both methods. Although a CT 
scan after completion of chemotherapy demonstrated that the liver metastases 
had almost completely resolved, the rise in ctDNA mutation levels may be 
explained by an increase in size of the primary lung lesion, compared to the 
baseline CT scan.  Unfortunately, a corresponding ctDNA sample was not taken at 
the same time as the CT scan.  However, it is tempting to speculate that, by 
analogy with our results for NSCLC patients in Chapter 5, the slight rises in 
ctDNA mutations seen in the midst of the course of chemotherapy may have been 
an indication of early, sub-clinical disease progression in the primary tumour, 
outweighing a reduction in the burden of disease in the liver, which would not 
manifest itself, until later radiological investigations. 
 
 156 
 
 
Figure 6-3 ctDNA kinetics and correlation with radiological response in a second patient with 
metastatic small cell lung cancer (Patient ID SCLC_7). Changes in mutational frequency in ctDNA 
determined by (1) ddPCR and (2) NGS. Baseline chest x-ray (A(iii)), and baseline CT scan illustrating 
the primary lung tumour (A(i)), and hepatic metastases (A(ii)) (tumours highlighted by yellow 
circles). The primary lung tumour on a chest x-ray at day 91 (B) (green circle highlights responding 
tumour). CT scan at 149 days with responding tumour in the lung (red circle)(C.i) and responding 
tumour in the liver (green circle) (C.ii.).  
 157 
All of the patients who received chemotherapy obtained an initial radiological 
response to treatment. This compared with initial decreases in the mutational 
levels in ctDNA, compared to baseline levels (Figure 6-4), though the degree of 
the initial decrease was variable. For all patients, the greatest and most rapid 
decrease in ctDNA is seen during the first cycle of chemotherapy, between day 0 
(baseline) and day 21. As for EGFRmut+ve adenocarcinoma patients treated with 
EGFR TKi (Chapter 5 above), ctDNA decline preceded radiological response to 
chemotherapy, suggesting that it may be possible to utilise ctDNA as a predictive 
biomarker of response to treatment, and to assess response/resistance both 
earlier and more frequently than by radiological imaging. This might inform 
individual patient treatment choices, such as the optimum number of cycles of 
chemotherapy before discontinuing or switching to subsequent anti-cancer 
treatments. 
One interesting phenomenon observed, also illustrated on Figure 6-4, is that 
patients appear to cluster in 2 groups, based on the extent of ctDNA decrease.  
Patients with overall survival greater than 6 months all showed a smaller 
absolute decline in ctDNA mutation levels. No such clustering was seen when 
considering relative decreases in ctDNA mutation levels. Although this finding 
needs to be validated in a much larger series, this could be of great clinical 
significance in determining a SCLC patients’ disease response to chemotherapy, 
and prognosis. This is especially interesting since radiological response to 
treatment is not of prognostic value in itself. Therefore, provided this finding 
could be validated, ctDNA mutation kinetics could be an important development 
as a prognostic biomarker. 
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Figure 6-4 Quantitative changes in ctDNA fraction over time in patients with SCLC, treated with palliative chemotherapy. OS = Overall Survival 
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6.4 Clinical Implications 
 
In this chapter, we have shown that it is possible to use NGS with a targeted gene 
panel to detect somatic mutations in tumour tissue DNA, from patients with 
locally advanced and metastatic SCLC, provided there is enough tumour tissue 
available for analysis. Furthermore, the same approach can reliably identify and 
quantitate the level of these mutations in ctDNA. Concordance between NGS and 
ddPCR for mutation detection in ctDNA analysis was high, at 90%. This supports 
the hypothesis that ctDNA can be used as an easily-accessible alternative to 
tumour DNA, for molecular analysis of SCLC and NSCLC patients, using NGS and 
ddPCR. In one patient (SCLC_7), where no tumour tissue was available for 
analysis, it was possible to detect pathogenic mutations in ctDNA from a baseline 
blood sample. 
 
There is little in the way of SCLC prognostic scoring, and treatment stratification, 
in routine clinical practice in the UK. One previously reported prognostic 
indicator is the Manchester score(141), which groups patients into ‘good’, 
‘medium’ and ‘poor’ prognostic groups, based on a two-year overall survival 
statistic. Since the vast majority of patients with advanced SCLC do not survive 
for 2 years, there is a need to develop improved biomarkers that may help 
facilitate earlier clinical decisions. In this chapter we chose 4 months as an 
appropriate prognostic ‘milestone’ for patients with locally advanced or 
metastatic small cell lung cancer, because this is the time taken to complete a 
course of 4 cycles of palliative chemotherapy and subsequent thoracic and/or 
cranial irradiation. These treatments involve multiple hospital visits and are 
associated with significant toxicities. It is therefore crucial to patients’ quality of 
life to consider only anti-cancer therapies for which potential benefits can be 
expected to outweigh the potential risks. This means that although patients 
should be considered for any available palliative anti-cancer therapies, accurate 
prognostic biomarkers may help to avoid any toxic therapies, from which the 
patient may gain limited clinical benefit. Equally, patients with a prognosis of 
less than 4 months and who are not demonstrating an appropriate response to 
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therapy, on the basis of mutational ctDNA decline, may also have the option of 
discontinuing chemotherapy earlier than the planned four cycles of 
chemotherapy, if the toxicities are too great, and/or if the patient is not gaining 
any symptomatic improvement despite receiving chemotherapy.  
 
It is proposed, on the basis of data presented here, that the baseline level of 
ctDNA could serve as a prognostic biomarker, when a poorer prognosis is 
defined as an overall survival of less than 4 months following baseline ctDNA 
testing. The baseline ctDNA level of 44.3% alternate allele frequency is suggested 
as a cut-off level for determining a patient’s prognostic group (greater or less 
than 4 months overall survival). This would have to be validated as part of a 
larger, prospective clinical study, in which it could also be assessed whether it 
could be used to stratify patients to routine treatments such as whether patients 
should receive PCI, following a course of palliative chemotherapy, or clinical 
trials, such as shorter versus standard courses of chemotherapy. It would also be 
valuable to prospectively compare this prognostic biomarker to prognostic 
scores already in use for patients with SCLC, such as the Manchester Prognostic 
Index. 
 
One potential limitation of the putative use of quantitative baseline ctDNA data 
as a prognostic indicator in SCLC is the ability to detect a pathogenic mutation in 
ctDNA. Previous studies show that approximately 10% of cases of small cell lung 
cancer will have mutational mechanisms other than point mutations in TP53 or 
RB1 genes(142). Using a targeted gene panel and NGS analysis of ctDNA may 
therefore not detect mutations in all cases of SCLC, and may miss other 
mutational mechanism such as translocations and gene copy number 
aberrations. This may have been the situation for one patient in this chapter, 
(patient ID SCLC_5). For the purposes of future clinical research, further 
molecular genetic analysis should be performed on the tumour tissue from these 
patients, to elucidate novel pathogenic mechanisms, and to determine whether 
these mechanisms can be detected in ctDNA. 
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It could be argued that the level of ctDNA may be a surrogate for volume of 
disease, which in itself could be a prognostic indicator. However, volume of 
disease is not routinely measured in clinical practice. There are problems with 
radiological inter-interpreter variability, and there remain practical problems 
such as how can diffuse disease be measured. There may also be clinically 
significant differences in patients with the same apparent total volume of 
disease, but differently distributed e.g. one has a large primary tumour and the 
other has several small metastases. Therefore ctDNA could offer a measureable 
surrogate for active disease volume, which may be more clinically relevant than 
absolute radiological disease volume.  Future research should therefore address 
the correlation between ctDNA levels and absolute disease volume (with 
standard radiology such as CT), and metabolically active disease volume (such as 
with PET scanning).  
 
An additional benefit of quantitative monitoring of mutations in ctDNA, is that it 
can be achieved via serial, minimally invasive blood tests, without requiring 
repeat radiology, and consequent exposure to ionising radiation, to assess 
disease progress. As demonstrated here, a fall in ctDNA to undetectable levels 
commonly correlates well with a radiological response.  It may be that patients 
who do not achieve undetectable levels of ctDNA despite chemotherapy, may 
have minimal residual disease that harbours an underlying resistant sub-clone of 
the cancer. 
  
The absolute decrease in mutational alternate allele frequency (%) in ctDNA, 
during chemotherapy, may be another prognostic indicator, though this also 
needs to be validated in a larger group of SCLC patients. An interesting clinical 
question is whether the number of chemotherapy cycles can be individualised 
for these patients based, on initial changes in ctDNA levels on therapy plus 
objective assessments of toxicity. 
 
None of the patients in this results chapter received second line palliative 
therapies (as is often the case, in advanced SCLC clinical practice). One area for 
significantly more research is to determine the optimal timing of repeat blood 
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samples during the minimal residual disease phase, and whether it is possible to 
detect disease relapse earlier (as is the case with patients with EGFRmut+ve 
adenocarcinoma of the lung in Chapter 5, above). Clinical studies could be 
designed to determine whether patients with advanced SCLC survive longer, if 
they receive earlier intervention with second line palliative therapies, compared 
to waiting for patients to develop clinical or radiological disease progression. 
Also, much more work is needed to determine molecular mechanisms of 
therapeutic resistance in small cell lung cancer, to enable to development of 
therapies that could overcome these. 
 
Therefore ctDNA analysis in small cell lung cancer, as with NSCLC, certainly 
provides an exciting, and easily accessible, alternative source of tumour DNA for 
analysis. Kinetics of ctDNA in response to systemic anticancer therapies may 
provide new prognostic and predictive biomarkers for lung cancer patients that 
help the clinician to optimise the benefits of anti-cancer treatments, while 
minimising the risks. 
 
 
 
163 
 
7 Discussion and Future Research 
 
Lung cancer has been the focus of this thesis since it remains the most common 
cause of cancer death. Patients are commonly diagnosed at advanced stages of 
disease, where prognosis is poor. There is an urgent need for developing 
biomarkers for lung cancer, for use in routine clinical practice and clinical trials. 
Biomarkers would be particularly helpful in lung cancer for earlier diagnosis, 
prognosis, and patient stratification to different anti-cancer treatments, and for 
monitoring response and resistance to treatment. 
 
There is often a very limited amount of tumour tissue available from patients 
with locally advanced or metastatic lung cancer. Thus, other sources of tumour 
DNA are attractive alternatives to permit genetic analyses, such as circulating, 
cell-free tumour DNA (ctDNA).  The last decade, has seen the development of 
important new genetic technologies, such as next generation sequencing (NGS) 
and droplet digital PCR (ddPCR), which can be, applied to tumour DNA analysis.   
This thesis set out to apply these genetic technologies to ‘real-life’ tumour tissue 
samples and ctDNA from patients with EGFRmut+ve adenocarcinoma of the lung 
and advanced small cell lung cancer (SCLC). 
7.1 Summary of Key Conclusions 
 
In Chapter 3, we assessed the ability of a targeted 50-gene panel to detect known 
cancer mutations, in DNA from cell lines and patients, using the Ion Proton NGS 
platform and two different bioinformatics tools (Ion Torrent Variant Caller 
(ITVC), and VarScan with Annovar). Cancer mutations were successfully 
identified in patients’ ctDNA, against a background of wild-type cell free DNA 
(expressed as an alternate allele frequency, AAF). VarScan with Annovar was 
able to identify the presence of mutations at a 10-fold lower AAF than ITVC, but 
at the expense of a 10-fold increase in the total number of genetic variants, many 
of which are likely to represent false-positive genetic sequence changes or 
‘sequence artifacts’. 
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We also confirmed that the lower limit of mutation detection, using ddPCR (in 
the order of 0.1% alternate allele frequency), was much lower than NGS (5%). 
However, a limitation of ddPCR is that it can only detect sequence-specific 
mutations, whereas NGS can provide sequence data for multiple genetic regions 
simultaneously. Furthermore, the lower limit of mutation detection in ddPCR 
was determined by the amount of DNA available for analysis, quite often a 
limiting factor of total cell free DNA. 
 
In assessing factors which can influence the amount of DNA available for ddPCR 
and NGS, and in keeping with the results from Rothwell et al (2016)(110), we 
found no statistically significant difference between total cell free DNA yields 
from SCLC patients’ plasma samples extracted at different time-points, up to 4 
days  after collection collected in CellSave Tubes (Janssen).  In these SCLC 
patients, significantly more total cell free DNA was observed in patients with 
stage IV small cell lung cancer, compared with stage III SCLC, and stage IV NSCLC. 
 
In Chapter 4, NGS and the 50 gene cancer hotspot panel were successful in 
identifying mutations in lung tumour tissue samples, despite there often being 
only a very small amount of tumour material present from the currently used 
tumour sampling methods used for patients with advanced lung cancer. Two 
different NGS panels (the 50 gene commercial panel, and an, in-house custom 22-
gene panel) were compared mutations in FFPE tumor tissue from patients with 
Adenocarcinoma of lung, Squamous Cell Carcinoma of lung and Small Cell Lung 
Cancer (SCLC). The 50-gene panel demonstrated a superior ability to detect 
EGFR mutations, specifically EGFR exon 19 deletions, and fewer ‘gene fails’ were 
observed. However, the 50 gene hotspot panel is a much more focused panel, and 
did not identify mutations genes that were detected with the 22 gene panel, 
suggesting a value for custom gene panels.  However, more validation work on a 
custom design panel is required to reduce false negative results seen here. 
 
In Chapter 5, we were able to detect and monitor real-time changes in 
mutational level of mutant EGFR in ctDNA, in patients with EGFRmut+ve 
adenocarcinoma of the lung, throughout their clinical course. We detected a 
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novel EGFR mutation sequence change. It was possible to detect emergence of 
mutations in ctDNA, as the tumour developed treatment resistance.   
Quantitative increases in mutations in ctDNA were detected, several weeks 
before the diagnosis of clinical and/or radiological disease progression, 
suggesting a potential opportunity to detect therapeutic resistance at an earlier 
stage. This raises the question of whether an earlier change in therapeutic 
strategy, based on ctDNA changes, may improve lung cancer patient outcomes. 
This would have to be the topic for a clinical trial.  
 
Similarly, in Chapter 6, we were able to monitor changes in mutation levels in 
ctDNA from patients with advanced small cell lung cancer, during systemic anti-
cancer therapy. It is proposed that the base-line mutational ‘load’ of ctDNA may 
be valuable as a prognostic biomarker for these patients, and this may have 
important clinical implications, such as facilitating patient selection for 
potentially toxic treatments, such as prophylactic cranial irradiation (PCI).  
Further work will be required to validate baseline mutation level in ctDNA as a 
prognostic biomarker. 
7.2 Molecular Characterisation of Lung Tumour DNA 
7.2.1 Tumour Tissue 
 
Genetic characterisation of tumour DNA is vitally important in defeating cancer. 
Many somatic genetic changes in lung cancer have practical clinical implications, 
such as guiding the use of EGFR tyrosine kinase inhibitor (EGFR TKi) drugs 
against lung tumours that harbour sensitising EGFR mutations. Therefore it is 
vitally important to ensure that modern technologies, such as NGS and ddPCR, 
can be translated into a clinically robust, and meaningful, genetic analysis 
platform. To be useful, it is crucial that NGS can detect clinically relevant or 
important genetic mutations. 
 
We have confirmed that the commercially available, off-the-shelf, 50-gene cancer 
hotspot panel (LifeTechnologies), can be used reliably to detect clinically 
important genetic point mutations and small insertions or deletions (INDELs) 
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relevant to lung cancer. However, this gene panel only focuses on known 
pathogenic hot-spot regions within genes, and could potentially miss other, 
disease-causing genetic sequence changes, outside of these hotspot regions. Also, 
this panel does not include some genes that may become clinically relevant to 
lung cancer in the future, for example, with the potential use of PARP inhibitors 
for BRCA1 and BRCA2 mutant lung cancers(143). Hence, a need for custom gene 
panels for the various types of lung cancer. 
 
When selecting mutations for inclusion in a custom lung cancer gene panel, 
clinical relevance must be paramount.  The SMP-2-MATRIX clinical trial(144) has 
developed a 28-gene panel for NSCLC which includes mutations which are 
considered ‘potentially clinically actionable’. In a similar fashion, a custom 22 
gene panel for NSCLC cancer was designed specifically for use in this research 
project (Chapter 4). Technical difficulties were encountered with this panel, for 
example, the 22-gene panel was unable to detect a key lung cancer mutation, 
namely EGFR exon 19 deletions, and there was a high ‘genetic sequencing failure 
rate’ for other genes within the panel. Therefore it is recommended that a 
significant amount of additional research time has to be devoted to validating 
any custom targeted gene panel to ensure it is robust and able to detect all of the 
clinically relevant genetic mutations, before it can be applied to clinical samples. 
 
The lung cancer tissue samples obtained from patients in this thesis reflect 
availability of tumour tissue in advanced lung cancer in ‘real-life’. Often, the 
amount of tumour tissue is very small, resulting in small amounts of extractable 
DNA. This is provided the tumour sample is not exhausted by prior 
histopathological examination. Furthermore the DNA is often degraded by the 
sample formalin fixation process, further reducing the success of NGS analysis. 
Despite these limitations, the results in this thesis have shown that it is possible 
to achieve successful NGS analysis of FFPE tumour tissue, largely owing to the 
relatively small amount of input DNA required for the NGS technique used. To 
improve successful NGS analysis, DNA from fresh tissue samples could be used, 
but this is not always possible in patients with advanced lung cancer. Also, NGS 
of ctDNA can also overcome some of the limitations of tumour tissue DNA 
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analysis, especially since this thesis shows it is possible to demonstrate 
mutations in ctDNA, where no tumour tissue is available. 
 
Another concern with molecular characterisation of FFPE tumour tissue, is that 
small biopsy samples acquired from locally advanced, or metastatic lung cancers, 
only represent a small proportion of any one tumour site, at any one moment in 
time. It is not, therefore, possible to fully characterise intra-patient tumour 
heterogeneity, especially when metastatic disease exists. Likewise, when a 
tumour progresses, a repeat biopsy of a lung cancer, or a site of metastatic 
disease, is not often clinically feasible. This thesis proposes that, despite low 
levels of total cell free DNA in the peripheral circulation; it is possible to detect 
mutations contained within ctDNA using techniques such as NGS and ddPCR. 
Results in this thesis have shown that analysis of ctDNA may reveal mutations 
contained by different tumour sub-clones, which will help to characterise intra-
patient tumour heterogeneity. In conjunction with the TRACERx study, NGS of 
differential tumoural regions has better delineated phylogenetic tumour sub-
clonal evolution. Longitudinal ctDNA profiling in patients with treated early 
stage NSCLC who relapse, can determine the phylogenetic evolution of relapsed 
and metastatic tumour sub-clones(145). While molecularly characterizing 
tumour sub-clones with relapse/metastatic potential, it can also facilitate earlier 
detection of relapse, and research into future therapeutic strategies based on 
individual sub-clones. 
7.2.2 Circulating Cell Free Tumour DNA 
 
Despite detection and molecular characterisation of ctDNA promising to 
facilitate personalised cancer therapy, current limitations to analytical sensitivity 
include low quantities of circulating cell free DNA (cfDNA), and technical and 
clinical factors. 
 
Several NGS methods and bioinformatics applications have been assessed in the 
literature to address this problem of large numbers of sequencing artefacts 
generated by NGS, in order to increase the confidence in detecting true, low-level 
NGS sequence variants. However, there are no widely accepted consensus 
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technology and analysis protocols that are ready for use in widespread clinical 
practice, amongst the many different, currently-available NGS technologies, and 
analysis platforms. 
 
Droplet digital PCR (ddPCR) is a molecular technique that currently offers the 
ability to detect low levels of mutant alleles, for a specific genetic variant. In 
Chapter 3, the amount of input DNA alters the confidence of detecting low level 
variants.  For example, if 5ng input DNA is used, then it may only be possible to 
detect mutant alleles as low as 1% abundance, but if 20ng of input DNA is used, 
then it may be possible to detect mutant alleles as low as 0.5% or even 0.1% 
allelic frequency. This is important, given that the amount of total cell free DNA 
available from a plasma sample is usually very low, for example 1ng/µl. This has 
to be taken into account when writing clinical reports which will be used in 
treatment decision-making for individual patients, since it is important to 
establish a threshold, or limit of detection, as a factor of the amount of input 
DNA. 
 
In keeping with previously published data(110), data in Chapter 3 show that if 
blood is collected in specialized blood collections tubes (CellSave tubes) there is 
no detrimental increase in the amount of total cell free DNA, if the sample takes 
up to 96 hours to be processed.  This is important to maximize the chances of 
detecting cancer mutations within ctDNA. We can therefore advise that these 
specialised blood collection tubes can facilitate blood samples to be collected 
from patients in any clinic within the UK, and sent to a central lab for processing. 
 
The absolute concentrations of total cell free DNA that can be extracted from 
plasma samples for these lung cancer patients in this thesis is low. At the time of 
the research conducted in this project, there were few platforms available for 
extracting circulating nucleic acids. It may be that more platforms are developed 
that are able to obtain better yields of circulating cell free DNA from a patient 
sample, but these need to be evaluated in future research. 
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Results in this thesis suggest that patients with stage IV small cell lung cancer 
generally have a much higher amount of cell free DNA, and a greater chance of 
detecting cancer mutations in ctDNA, compared to stage IV adenocacinoma. This 
could reflect a higher volume of ‘more active’ disease, PET FDG avidity can 
predict ctDNA detection in NSCLC(145). A clinical study correlating baseline 
ctDNA level with baseline PET-FDG avidity in SCLC could be designed.In this 
thesis, the number of patient samples with squamous cell carcinoma of the lung 
were too small to enable a meaningful comparison of availability of cell free DNA. 
Therefore, future work is required to determine whether there is more or less 
total cell free DNA in patients with advanced squamous cell cancer of the lung. 
This can further inform whether there is a greater or lesser chance of detecting 
cancer mutations in ctDNA, in lung cancer patients with a squamous histology. 
Subsequently, it has been reported that there is ctDNA detection is associated 
with histological subtype. This is where there is more chance of finding ctDNA in 
lung squamous cell cancers (97%), compared to lung adenocarcinomas (71%). 
94% of stage I squamous cancers were positive for ctDNA, and only 13% of stage 
I lung adenocarcinomas were positive for ctDNA. This has been suggested that 
squamous cell cancers are more necrotic, and shed more tumour DNA into the 
circulation(145). 
 
The greatest impact on longer term survival for lung cancer patients may come 
from developments in biomarkers for lung cancer screening and management of 
earlier stages of disease. The role of ctDNA as a biomarker in earlier stages of 
lung cancer must be further investigated, to see if it can facilitate earlier 
diagnosis and improve outcomes for lung cancer patients. Given the current 
technical limitations, it may be extremely difficult to detect and characterize 
ctDNA in early-stage lung cancers, assuming that there will be lower levels of 
ctDNA. Indeed, in NSCLC, ctDNA levels correlated to tumour size, such that a 
tumour volume of 10 cm3 will yield a ctDNA variant allele frequency of 
0.1%(145). To overcome this, increasingly more sensitive technologies are 
needed, which can identify mutations in ctDNA present at significantly lower 
level, in a background of wild-type/genomic DNA. 
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Despite the current limitations, analysis of ctDNA still offers the advantage of 
being a minimally invasive investigation (namely a blood tests), and serial 
samples that can be taken, and analysed in real-time, as a patient undergoes 
various anti-cancer therapies. The feasibility of serial blood sampling for ctDNA 
analysis has been clearly demonstrated with the several case studies presented 
in this thesis. As with these case studies, blood sampling ctDNA testing could 
easily be adopted in the routine clinic. 
7.3 Role of ctDNA in stratified medicine 
 
There are numerous clinical trials, and more anticipated, which utilize molecular 
characterization of tumour tissue to stratify lung cancer patients for treatment 
with molecularly targeted anti-cancer agents. This is in an effort to increase 
clinical efficacy of treatment and to reduce unnecessary treatment toxicity, 
especially if a particular anti-cancer treatment has no clinical efficacy. 
 
We are fortunate, in UK lung cancer research, to have access to the Stratified 
Medicine Project 2 (SMP2) - the largest molecular characterization project of this 
sort, to date, funded by CRUK. SMP2 aims to molecularly profile tumour tissue 
from patients with non-small cell lung cancer, using NGS sequencing technology. 
On the back of this, there exists the UK MATRIX trial, an umbrella trial, 
examining the clinical efficacy of several targeted anticancer therapies, given to 
lung cancer patients harbouring specific somatic mutations in specific 
genes(144). 
 
Nevertheless, SMP2 is prone to the same problems as those reported in this 
thesis. Conventional CT guided biopsy and/or bronchoscopic biopsies yield very 
small quantities of tumour tissue, which are often depleted or exhausted during 
histological diagnosis, severely limiting tumour DNA extraction and analysis 
from tissue samples.   As a result, many samples fail the pre-NGS quality control 
(QC) test. Even if there is apparently sufficient tumour DNA, there is still a failure 
rate for comprehensive gene profiling using the targeted NGS platform. At the 
time of writing, the resulting fraction of patients that therefore have a 
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satisfactory NGS test result, that enables them the option of entry into clinical 
trials such as the MATRIX trial, is approximately 25%(146). 
 
Sequencing of DNA obtained from Fresh Frozen tumour tissue samples is 
advised in the Genomics England, 100,000 genomes project, in order to yield 
better quality DNA, and improve the success of sequencing, and minimising the 
problems with DNA degradation which result from the FFPE fixation process. 
However, this is not routine practice in the NHS, and other limitations remain – 
particularly those arising from small biopsies, or small proportions of tumour 
cells within a biopsy sample(147). 
 
A current limitation of ctDNA analysis is the risk of a false negative result when 
assessing for the presence of a somatic mutation, especially if the mutation is 
present at a level below the limit of detection of the technology used. This is even 
more problematic when trying to be confident that a particular gene is ‘wild-
type’, which is required by some of the current proposed therapeutic strategies 
in the MATRIX trial. 
7.4 Applications of ctDNA in Lung Cancer Clinical Practice 
7.4.1 CtDNA in Patients with EGFRmut+ve Adenocarcinoma of the Lung 
 
We have demonstrated, in this thesis, that for patients with EGFRmut+ve 
adenocarcinoma of the lung, whether locally advanced or metastatic, it is 
possible to detect the EGFR mutation in ctDNA. It is known that mutant EGFR 
detected in ctDNA can act as a predictive biomarker for response to targeted, 
systemic EGFR TKi therapy, and this is especially important where it is not 
possible to obtain this information from a tumour tissue sample. 
 
Data presented in this thesis show that increases and decreases in mutant EGFR 
levels in ctDNA can be observed during systemic anti-cancer therapy with EGFR 
TKi therapy. We observed decreases, down to undetectable levels, within 2 
months of starting therapy. Levels then remain low, or undetectable, while the 
patient often experiences a sustained, on-going [radiological] response to 
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treatment.  A quantitative increase in ctDNA was also observed, at the time of 
disease progression, due to acquired resistance to EGFR TKi therapy. In fact, it 
seems reasonable to conclude that levels of ctDNA may increase several weeks 
before the diagnosis of clinical or radiological progression of lung cancer 
(Chapter 5). A subsequent, recent publication has also reported a lead time of 
ctDNA detection in NSCLC of 70 days (range 10-346 days), before radiological 
confirmation of disease (CT or plain chest radiograph)(145). This may represent 
a potential window of opportunity to switch therapeutic strategies in these 
patients, earlier in their treatment course, and in a period before patients 
clinically deteriorate and when they are still able to tolerate subsequent 
therapies. This is an interesting area of future clinical research. For example, a 
randomised controlled trial, involving early (e.g. on ctDNA progression) versus 
delayed (e.g. on clinical disease progression) switch in therapeutic strategy. 
Clinical trial such as this, could further address the feasibility of ctDNA mutation 
analysis replacing radiological disease monitoring as the ‘gold-standard’ for 
monitoring response to therapy. 
 
In relation to targeted therapies, it is possible to analyse ctDNA to detect known 
molecular mechanisms of acquired resistance to therapy. A prime example of 
this is the example of the acquired secondary EGFR c.2369C>T p.T790M 
resistance mutation, seen in patient case studies presented here. This is the 
expected resistance mechanism expected in approximately 50% of patients with 
EGFRmut+ve adenocarcinoma, treated with first line EGFR TKi. Osimertinib is a 
third generation oral EGFR TKi which can inhibit both the original activating 
EGFR mutation and the EGFR c.2369C>T p.T790M mutation. Clinical efficacy has 
been demonstrated for this drug, and the license of the drug allows it to be 
prescribed for patients who have an EGFR c.2369C>T p.T790M mutation 
demonstrated via ctDNA analysis. This has the advantage of negating the need 
for an invasive repeat biopsy at the time of disease progression. However, is 
understood that other resistance mechanisms include secondary mutations in 
other genes, and increase in gene copy number. Further work is needed to 
investigate whether ctDNA can be used to detect other molecular mechanisms of 
acquired therapeutic resistance. For example, research into whether increases in 
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gene copy number can be detected within ctDNA, compared to gene copy 
number changes in tumour samples from the same patients. Some research 
groups have started to explore whether it is possible to detect gene copy number 
changes in ctDNA, in a variety of clinical settings. These include: Taqman copy 
number assessment of androgen receptor (AR) and CYP17A1 genes and response 
to abiraterone therapy in prostate cancer patients(148); OncoScan® platform 
for gene copy number profiling in cfDNA in patients with neuroblastoma(149); 
and massively multiplexed PCR for gene copy number variations in patients with 
breast cancer(150). Future research might similarly examine the possibility to 
detect gene copy number variation in ctDNA in patients with lung cancer. 
 
7.4.2 Limitations of ctDNA as a biomarker for patients with EGFRmut+ve 
adenocarcinoma of lung 
 
Despite these exciting new applications of ctDNA testing, with a potential direct 
impact on patient care, it is not possible to detect EGFR mutations in ctDNA, in all 
patients harbouring an EGFR mutation. There are clinical factors that may 
influence the ability to detect EGFR mutations in ctDNA. These include stage of 
disease, volume of disease, and whether the patient is treatment naïve. From 
data presented in Chapter 5, it is possible to detect mutant EGFR in ctDNA, when 
patients are treatment naïve, or have received only minimal treatments, such as 
palliative radiotherapy to focal lesions in the spine. It was not possible to detect 
mutant EGFR in ctDNA in lung cancer patients who have recently received 
surgical resection, radical radiotherapy, or systemic chemotherapy. Undetectable 
levels of mutations in ctDNA in these situations may have resulted from the 
effects of these treatments on the cancer. If serial levels subsequently remain 
undetectable, then this may represent a period of disease stability or ‘minimal 
residual disease’. This phenomenon was also demonstrated in the case studies 
presented in Chapter 5. 
 
From data presented in Results Chapter 4, it remains to be seen whether it is 
possible to capture tumour DNA from cerebral metastasis in the peripheral 
blood circulation. For patients with EGFRmut+ve adenocarcinoma of the lung who 
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develop brain metastases, EGFR mutational analysis can be considered on cell 
free DNA from cerebro-spinal fluid (CSF). Further research is needed to 
determine whether or not mutations in ctDNA are derived from CNS metastases, 
including the potential comparison with mutational analysis of cell free DNA in 
CSF. 
 
7.4.3 NHS clinical testing service for ctDNA 
 
Our data, presented here, and the data of others, raise the prospect that NHS 
molecular genetics diagnostic laboratories might implement EGFR analysis of 
ctDNA, as a diagnostic service for patients with lung cancer.   A routine service of 
this sort will be facilitated by blood collection tubes containing preservative, 
such as CellSave, in which ctDNA remains stable in blood samples stored at room 
temperature for an acceptable period (4 days).  This would allow blood samples 
taken from patients in clinics at distant locations to be transported, without the 
need for specialised transportation requirements, to a central lab for processing 
and testing, without diminishing the reliability of data obtained. 
 
Indeed, at the time of writing this thesis, the NHS All Wales Molecular Genetics 
Laboratory, Cardiff, has recently been able to successfully establish a national 
diagnostic test for EGFR mutations on ctDNA from peripheral blood samples, 
effective since April 2016. It currently accepts samples for testing from Wales 
and South-West England. An EGFR mutation array which includes the EGFR 
p.L858R mutation, the top 20 EGFR exon 19 deletions (together covering 85 % of 
the most common EGFR sensitizing mutations), and the EGFR c.2369C>T 
p.T790M resistance mutation, is assessed using ddPCR platform. 
 
There are currently two main testing routes for this service. The first is a ctDNA 
EGFR analysis at diagnosis, when no tumour tissue is available for genetic 
testing, or EGFR testing on DNA extracted from tumour tissue has failed. If a test 
is positive, then a clinical report can be given to the clinician, who may consider 
EGFR TKi therapy, such as gefitinib. If the test is negative, a clinical report can be 
issued, stating that this may be a false negative result, and/or that the presence 
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of other, rarer EGFR sensitizing mutations cannot be excluded. In this situation, 
the clinician may wish to consider a new or repeat biopsy for the patient to 
obtain more definitive assessment of mutation status. 
 
The second route is for patients that have developed clinical or radiological 
disease progression while taking EGFR TKi therapy. The EGFR c.2369C>T 
p.T790M resistance mutation can be tested for, along with the original 
sensitizing EGFR mutation, as an internal control, thus helping to confirm the 
presence of ctDNA. If an EGFR c.2369C>T p.T790M mutation is detected on 
ctDNA, this can be reported to the clinician, who may wish to consider 3rd 
generation EGFR TKi therapy, such as osimertinib. If EGFR c.2369C>T p.T790M 
mutation is not detected on ctDNA, it is recognized that this may be due to a false 
negative result. Again, the clinician may wish to consider repeat blood sampling 
and repeat ctDNA EGFR testing, or a new or repeat tumor biopsy for mutation 
analysis, if clinically appropriate. 
 
This service through the All Wales Molecular Genetics Laboratory is ISO 
accredited, and subject to a new NEQAS programme for ctDNA testing. It seems 
likely to be the forerunner of similar ctDNA-based regional or national mutation 
testing services for routine clinical use.  Such services will be relatively cheap, 
and a relatively quick turnaround time, of within 5 working days from receipt of 
the blood sample, making this testing pathway applicable in a clinically 
meaningful timeframe. This is especially important for patients with lung cancer, 
where clinical management decisions have to be made on an urgent basis, due to 
the relatively advanced stage of their disease, their relatively poor performance 
status and high incidence of co-morbidity, at presentation. 
 
One current limitation to a testing service of this sort is that it is not a 
comprehensive EGFR mutational panel. An NGS platform could be adopted to 
assess for mutant EGFR in ctDNA in the NHS diagnostic labs, but this technology 
is currently limited by a poorer lower limit level of detection. Therefore, it may 
be more clinically appropriate to assay for specific mutations, with a much more 
sensitive molecular technique. It is not currently possible to increase the number 
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of EGFR assays beyond the current 85% most common EGFR mutations, using 
ddPCR, since the small amount of available total cell free DNA, after extraction, is 
often a limiting factor. It is hoped that, as technologies advance, reduced 
amounts of input DNA will be required for expanded, reliable mutation detection 
in ctDNA. 
 
When establishing a clinical diagnostic service, another consideration is that of 
which technology to use. There are increasing number of ctDNA testing 
platforms, one study compares two amplification refractory mutation detection 
systems (Cobas-ARMS and ADx-ARMS), droplet digital PCR and NGS. It reports 
that the Cobas-ARMS, droplet digital PCR and NGS are more sensitive, but the 
ADx-ARMS gives better quantification of alternate allele frequency when 
>1%(151). Globally, there is currently no consensus technology to use. 
Challenges in platform choice have to include the context of treatment evaluation 
and offer the best chance of drug resistance detection.  
 
7.4.4 CtDNA in patients with Small Cell Lung Cancer 
 
In this thesis, it has been demonstrated that ctDNA can be detected, and 
quantitatively and qualitatively analysed in patients with locally advanced and 
metastatic small cell lung cancer. Quantitative decreases mutations in ctDNA 
were observed when a patient with small cell lung cancer received standard 
palliative chemotherapy. However, there remains a need to predict the course of 
disease, in order to influence decision-making on additional therapeutic 
interventions. For example, one current therapeutic strategy for patients with 
small cell lung cancer is prophylactic cranial irradiation, after initial systemic 
anti-cancer therapy. However, PCI has potential significant toxicities. Selection 
for PCI is currently based on individual clinical assessment, and there are no 
established biomarkers that help the clinician to stratify patients to PCI, to 
optimize clinical benefit from this intervention, and minimize exposure of 
patients to unnecessary treatment toxicity. 
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Data presented here suggest that baseline ctDNA load may be an independent 
prognostic indicator, for shorter term prognosis of SCLC patients, which could 
help decide on whether PCI or other treatments is/are in the best interests of the 
patient. In this thesis, a suggested cut-off level for poorer (<4 months) prognosis 
is a ctDNA burden of 44.3% alternate allele frequency. Patients who are 
predicted to have a poorer prognosis, despite a radiological or clinical response 
to chemotherapy, could be spared the potential inconvenience and treatment 
toxicity of PCI. 
 
It is vitally important that future research should validate baseline ctDNA load as 
a prognostic biomarker, in a larger group of patients, prospectively, using the 
same methodology as in Chapter 6. At the same time, baseline ctDNA load could 
also be correlated with radiological volume of disease, and other prognostic 
indicators, such as the Manchester Prognostic Score, even though this provides 
an estimate of prognosis at the 2 year time point. 
 
Clinical trials have shown an improvement in outcome for SCLC patients, with 
newer treatment strategies, such as concurrent chemo-radiotherapy, in earlier 
stages of disease. It would be useful to explore the use of ctDNA as a biomarker 
in earlier stages of disease, especially for patient stratification to more 
aggressive treatment regimes, or subsequent toxic therapies such as PCI. 
 
As with most cancers, earlier disease detection and treatment may help to 
improve patient survival outcomes. Eventually, ctDNA may help as a biomarker 
to help screen and detect small cell lung cancer at an earlier stage. In order to do 
so, however, newer, more sensitive genetic technologies will need to be 
developed to detect lower levels of ctDNA in earlier stages of disease. 
7.4.5 Areas for future research and development 
 
As technologies advance, it may be possible in the future to detect ever-
decreasing amounts of ctDNA from a blood sample. Therefore it is of increasing 
important to try to place low-level mutation detection in ctDNA in clinical 
context. For example, what constitutes minimal residual disease (MRD), or 
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response to a particular anticancer therapy? The topic of MRD after initial anti-
cancer therapy has attracted much interest, for example tracking MRD in acute 
myeloid leukaemia, in order to help evaluate treatment efficiency, patient risk 
stratification and long-term outcome prediction(152). Methods commonly 
employed in monitoring MRD in AML include multi-colour flow cytometry and 
PCR based methods, but this has to be constantly re-evaluated in light of 
technologies delivering improved levels of detection(153). 
 
In addition to ctDNA, there exist other exciting circulating biomarkers, including 
circulating exosomes (which contain both tumour derived DNA and RNA), micro-
RNAs and platelet-associated circulating tumour RNA. Research into these as 
circulating biomarkers are in their infancy in lung cancer research, but an 
example includes circulating exosomal micro-RNA as prognostic biomarkers in 
lung cancer(154), and the micro-RNA, miR-126 in exosomes and serum in lung 
cancer patients(155). 
 
Circualting Tumour Cells (CTCs) may also provide an interesting source of liquid 
tumour sample. Global gene expression analysis of CTCs in lung cancer is 
possible, and may provide clues into the mechanisms for metastasis, and provide 
potential therapeutic targets. For example NOTCH1 overexpression as a driver in 
lung cancer CTCs(156). It is possible to take CTCs from lung cancer patients and 
introduce them into mice models, which develop metastatic lung cancer tin 
which therapeutic response and resistance can be investigated. These mice 
models could also facilitate pre-clinical drug development(157). The clinical 
context of CTCs in lung cancer has been investigated by authors such as 
Chudasama, for example, the presence of CTCs after lung surgery is not 
necessarily linked with a worse prognosis(158). 
 
As biomarkers, including ctDNA, in lung cancer emerge, and their clinical utility 
is better understood, offers the potential of an era of earlier and more 
personalised treatment regimens for individual lung cancer patients, with better 
outcomes. 
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Feasibility Study 
to Obtain and Analyse Circulating Cell Free Tumour DNA 
in Patients with Lung Cancer, 
in South Wales 
INFORMATION SHEET FOR POTENTIAL PARTICIPANTS WHO HAVE LUNG 
CANCER 
 
You are being invited to take part in a Cardiff University research project.  Before you decide 
it is important for you to understand why the research is being done and what it will involve.  
Please take time to read the following information carefully and discuss it with others if you 
wish.  Please ask if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. Thank you for reading this. 
1 What is the purpose of the study? 
Increasingly, we are discovering more and more genes that are implicated in lung cancer. A 
future goal is to tailor each patient’s treatments, based on which genes are altered within each 
individual patient’s tumour. These may be slightly different, for different patients. However, 
until recently, we have only been able to look for changes in these genes by analysing DNA 
taken from tumour samples that have be acquired by a biopsy, or a surgical resection 
specimen. It may now possible to do this with a simple blood test. We wish to see if we can 
isolate cancer DNA from blood samples, in Cardiff, from patients in South Wales, and 
analyse it to detect the different changes, within the different genes that are causing the 
cancer to grow. It may also be possible to monitor changes in cancer DNA in a blood test, as 
a patient undergoes any type of anti-cancer treatment. In the future, this may provide us with 
invaluable information, for example, by allowing us to predict how useful a specific 
treatment may be, or whether any other treatments may be more effective in treating the 
cancer. 
2 Why am I suitable for this research? 
We are looking to take blood samples from patients with a diagnosis of lung cancer, that has 
been confirmed with a biopsy. This research project requires extra blood samples, which can 
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conveniently be taken in addition to any routine blood tests that you may need as part of your 
treatment plan. Where possible, we are looking for blood samples before you start any 
treatment for your lung cancer. We are also interested in taking further blood tests during any 
treatment you may have, and after the treatment has finished. 
3 Do I have to take part? 
No, it is entirely up to you to decide whether or not to take part, and giving extra blood 
samples for research, is purely voluntary.  If you do decide to take part you should keep this 
information sheet and you will be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to withdraw at 
any time, or a decision not to take part, will not affect your future medical care in any way. 
4 What samples are required from me for the research? 
Each time you are happy for us to take extra blood for this research, we would require up to 
two 10 mls vials of venous blood, which can be taken at the same time as a routine blood test.  
We would also request a small section of your tumour tissue that is already stored in the 
pathology lab. This is provided that there is enough remaining after all of the required routine 
tests, that may be required by your clinical team, have been performed adequately. 
Therefore we do not require additional biopsies, or surgery, for the purposes of this study. 
Once obtained, the cancer DNA from the tumour can also be analysed. This helps us to 
identify the any cancer DNA that may be present in the blood. 
5 How long am I involved in the study? 
Your treating clinical team will provide you with the opportunity to allow us to take further 
blood samples at different time points, during your treatment, and after any treatment has 
completed, provided you remain happy to do so. You will only be asked at routine clinic 
appointments. The frequency of research blood tests may vary, between every few weeks to 
every few months, depending on the type of treatment you receive. 
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6 Will I get any results? 
As the samples are being used solely for the purposes of research within Cardiff University, 
you will not be directly informed of any results. The genetic tests that we perform are using 
techniques that are not yet validated NHS diagnostic techniques. The results will not have 
any impact on your treatment. 
7 What are the benefits for me taking part? 
Giving a blood sample for research is relatively physically easy, and the research sample can 
be taken alongside a routine blood test, for your convenience. 
All the necessary tests that will influence your treatment, will be performed by your NHS 
team. We must stress that this research project is using experimental lab techniques, and they 
are not validated, diagnostic NHS tests. We are also analysing several genes, for which we 
currently do not fully understand the implications of changes in them on your treatment, 
which is why they need to be researched. Therefore the results of this research study will not 
influence the best treatment of your cancer. 
8 Are there any risks? 
When allowing a blood sample to be taken for research, there are no additional physical risks 
than a routine blood test. 
9 How many patients are we hoping to involved? 
As a feasibility study, we only require at approximately 10-20 patients. Once we have 
recruited enough patients, we can then develop future research projects that look at how this 
information can be used in the future to further help patients with lung cancer. 
10 What happens if I am happy to take part in this research? 
If you are interested in participating in this research study, then we will ask you to sign a 
consent form. You can keep a copy of the consent form, and a copy of the consent form will 
be kept with your NHS case-notes. We will then arrange the best time to take the blood 
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samples, taking into account if you are due a routine blood test and co-ordinate with any 
planned treatments that you may receive. 
The blood sample taken for research will be processed in a laboratory, so that we can extract 
any DNA that is present. This DNA will consist of ‘normal’ DNA, and may also consist of 
DNA that has come from the cancer. Likewise, tumour DNA will be extracted in the same 
laboratory, from a small sample of your tumour that we will request from the pathology 
laboratory. 
Once extracted, only the DNA will remain for the purposes of research by the Cardiff 
University research team. The DNA samples will be stored in the Institute of Medical 
Genetics, at the University Hospital of Wales, Cardiff, for the duration of the research 
project. Here, the Cardiff University research team can use different lab techniques to 
identify whether specific lung cancer gene mutations can be detected. 
11 What happens when the research project finishes? 
The project aims to collect samples from patients over the next 2 – 3 years. When we extract 
DNA, it is usually all used up by the different lab techniques that we will use for this 
research. Any unused or residual research DNA samples, after all research test have been 
performed, will be disposed of in accordance with standard protocol within the Institute of 
Medical Genetics, UHW, Cardiff, within 12 months of completion of this research project. 
12 Will the identity of my samples be kept confidential? 
If you consent to take part in the research the investigators may look at your medical records 
to aid with analysing the results. Your records may also be looked at by regulatory authorities 
to check that the study is being carried out correctly.  Your name, however, will not be 
disclosed outside the participating hospitals or health professionals. 
Once within the Institute of Medical Genetics laboratory, the extracted DNA from your 
samples will be allocated a unique identification number. The DNA will be analysed within 
Cardiff University using the unique identification numbers, rather than any patient 
identifiable information. 
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13 What will happen to the results of the research? 
The results of this research will be published in a medical or scientific journal. You will not 
be identified in any publications, nor will any patient identifiable information be used. 
14 Who is organising and funding the research? 
This research project is jointly funded by Stepping Stones Appeal – Velindre Fundraising, 
which specifically aims to support lung cancer research in South Wales, and Cancer Research 
UK (CRUK). 
15 Who Do I Contact if I have any concerns? 
You can discuss your concerns at any time, by contacting your treating clinical team, namely 
your consultant, or their registrar, or one of the specialist nurses who will usually have 
provided you with their contact details. You can also use the contacts listed below. We will 
consider all concerns seriously, and we can provide you with opportunities to discuss any 
concerns further, in clinic, so that we can adequately address them. 
Cardiff and Vale University Health Board also have a formal complaints procedure, should 
you feel that you wish to make a formal complaint about your care, including if you are 
taking part in any research studies. A letter of complaint can be sent to the complaints 
department via fax (02920 336365), or e-mail to concerns@wales.nhs.uk , or they can be 
telephoned on (02920) 744095 for advice about how to proceed with a complaint. More 
information can be found at www.cardiffandvalehb.wales.nhs.uk/complaints  
16 What do I do if I no longer want to participate in this research 
study? 
Even if you give consent to take part in this research study, you can withdraw your consent 
and participation at any time, without giving any reason. This will not detract from your 
clinical care in any way. To no longer take part, then just inform your treating consultant, or a 
member of their team including any of the specialist nurses that you have the contact 
information for. Or you can contact the contacts listed below. After which, no further 
samples, or clinical information, will be taken or used for research purposes.
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17 What happens if I can no longer give consent to provide 
research blood samples? 
In any event that you are unable to provide consent, for any reason, no research samples will 
be taken. However, any samples that you have donated, while you were consenting, will have 
been anonymised, and as a result they can continue to be processed and analysed for research 
purposes. All research DNA samples will also continue to be stored for the duration of this 
research project, after which time, they will be appropriately destroyed.
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18 Further information 
If you have any further questions or queries about this research project, then this can be 
obtained from myself or; 
 
Dr Jason Lester 
Velindre Cancer Centre 
Whitchurch, Cardiff. CF14 2TL 
Tel :02920 615 888 
 
Or 
 
Dr Rachel Butler 
Institute of Medical Genetics 
UHW, Cardiff. CF14 4XW 
Tel: 02920 742 641 
 
Thank you for taking time to read this information sheet, and considering taking part in 
research. 
 
Dr Daniel Nelmes 
Clinical Research Fellow, Institute of Medical Genetics, Cardiff.
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9 Appendix - Patient Consent Sheet 
Consent form date of issue:    28.01.2015 
Consent form version number: C&V 2.5  Page 1 of 1 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: 
 
Feasibility	Study	to	Obtain	and	Analyse	Circulating	Cell	Free	Tumour	DNA	
in	Patients	with	Lung	Cancer,	in	South	Wales.	
 
Name of Main Researcher: Dr	Daniel	Nelmes 
Please initial all boxes  
1. I confirm that I have read and understand the information sheet dated 28.01.2015 (version 
C&V 2.5) for the above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes will be consulted, and data collected 
during the study, by Cardiff University study investigators, where it is relevant to my taking part in 
this research. Clinical data used for this research purposes will be anonymised. I give permission 
for these individuals to have access to my records. 
 
4. I understand that DNA extracted from my samples will be stored in the institute of Medical 
Genetics, UHW, Cardiff, only for the duration of this research project. They will only be accessed 
by the Cardiff University Research team, for the purposes of this research only. 
 
5.  Results obtained from analysing the samples are for research purposes only. I understand 
that no results will be fed back to myself, or my treating clinical team. 
 
6. I understand that results from this research may be published in medical or scientific journals, 
but they will not contain any patient identifiable information. 
 
7. I agree to take part in the above study.   
 
 
            
Name of Participant   Date    Signature 
                                
            
Name of Person   Date    Signature  
taking consent.  
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